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ABSTRACT 
 Viral protein R (Vpr) is an evolutionarily conserved but poorly understood protein 
encoded by all primate lentiviruses, including the lineages that gave rise to both human 
immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), the causative agents of AIDS 
in humans. In this work, I sought to define the contribution of primate lentiviral Vpr to 
viral replication and evasion from cell-intrinsic antiviral defenses. I found that HIV-1 
infection of human dendritic cells (MDDCs) is substantially attenuated upon infection 
with Vpr-deficient (HIV-1/ΔVpr) virus compared to wild-type (WT) infection. This 
replication defect to HIV-1/ΔVpr is evident in a single round of infection, results in 
reduced levels of viral transcription, and is relieved upon complementation by virion-
associated Vpr. The block to transcription is alleviated through Vpr-engagement with the 
Cul4A/DCAF/DDB1 (DCAFCRL4) ubiquitin ligase complex and a yet-to-be identified 
host factor, hypothesized to induce the DNA damage response (DDR) in infected cells. 
MDDCs are critical immune cells that are poised to detect invading viruses through a 
variety of cell-intrinsic antiviral sensors, resulting in the production of type I interferon 
(IFN) and restriction of virus replication. Surprisingly, infection of MDDCs with Vpr-
  viii 
deficient lentiviruses (HIV-2 or SIVmac) resulted in production of type I IFN indicating 
that this pathway is targeted by Vpr. I determined that signaling cascades that induce NF-
κB-dependent type I IFN production are triggered in response to lentiviral integration, an 
obligatory process in lentivirus life cycle that results in host DNA lesions and subsequent 
repair by cellular DNA repair machinery. I also demonstrated that mutations in SIVmac 
Vpr that ablate the ability to initiate DDR are unable to counteract the antiviral type I IFN 
response. Together, our work suggests the existence of a novel host factor that detects 
lentiviral integration in MDDCs to trigger an innate immune response that blocks virus 
dissemination. I hypothesize that Vpr by overcoming this cell intrinsic block to 
integration would be a critical viral adaptation to facilitate cross-species transmission that 
resulted in the HIV pandemic. 
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INTRODUCTION 
History 
The first reported cases of HIV infection occurred in the US in Los Angeles, San 
Francisco and New York in mid-1981 (1, 2). The unusual disease was characterized as a 
severe immunodeficiency that resulted in death from normally non-pathogenic bacteria 
and fungi or rare forms of cancer like Kaposi’s Sarcoma (2–5). At the time, HIV had only 
been observed in gay men, resulting in it initially being called “gay cancer” and later that 
year GRID or gay-related immunodeficiency (2). It wasn’t until the fall of 1982 that the 
CDC renamed the disease acquired immunodeficiency syndrome, or AIDS (2, 6). At the 
time, it had also been documented in female sexual partners of AIDS patients, injection 
drug users, recipients of blood transfusions and hemophiliacs and was suggested to be the 
result of an unidentified infectious agent (1, 2). The virus itself was isolated by two 
separate labs, one by Dr. Françoise Barré-Sinoussi and colleagues at the Pasteur Institute 
and another at the US National Cancer Institute by Dr. Robert Gallo in spring of 1983 (7–
9). Dr. Gallo’s group also developed the first diagnostic blood test for the virus which 
allowed for screening for infected individuals (10). By the end of 1985, AIDS cases had 
been reported in every region of the world, totaling to over 20,000 reported cases (1, 2). 
The first treatment for HIV infection, a reverse transcription inhibitor called zidovudine 
(AZT) was released in the US in March of 1987 (11). While AZT is able to help control 
infection, it is not a cure and resistance mutations occur rapidly in infected individuals 
(12, 13). Combination therapy, in which several inhibitors are used in a cocktail that 
target at least two different steps of the viral life cycle was not developed for another 8 
  
2 
years (11). In 1995, highly active antiretroviral therapy (HAART) was released, which 
resulted in a 60-80% reduction in AIDS-related deaths in the coming years in countries 
that could afford the medication (1, 11). At this time, close to 5 million people worldwide 
had been diagnosed with the virus (1). Despite continued drug development, by the end 
of the 1990s, 33 million people had become infected with HIV and 14 million people had 
died from AIDS-related disease (1, 2). 
According to most recent estimates, 36.7 million people are still living with HIV 
and 35 million people have died from the disease since the start of the epidemic (14). Due 
to initiatives since the 1990s, globally 18.2 million people have access to HAART 
medication that is able to keep their infection under control (15). Currently, the World 
Health Organization (WHO) has a goal of having 90% of people with HIV identified, 
90% of that population on antiretroviral treatment and 90% of these individuals virally 
suppressed (undetectable viral load in the plasma) by 2020 (16). While there still needs to 
be improvement to meet these goals, global initiatives to lower the cost of medication and 
provide access to developing countries, particularly in Sub-Saharan Africa where disease 
burden is highest, has helped tremendously (16).   
Human disease- HIV-1 and HIV-2 
 It is now understood that the HIV pandemic originated in central Africa due to 
several cross-species transmission events from non-human primates to humans that 
resulted in two distinct viruses, HIV-1 and HIV-2 (17, 18). It is thought that these 
zoonotic transmissions occurred in the early 1900s, around 1920, though little 
information exists about disease transmission within human populations pre-1980s (19–
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22). The oldest identified infections were discovered in frozen clinical samples from 
Kinshasa, Democratic Republic of Congo obtained in 1959 and 1960 (23, 24). These 
clinical samples were used to help determine the evolutionary clock for HIV in order to 
estimate the amount of time since divergence from the most recent common ancestor (17, 
18). It is also likely that Kinshasa, which at the time was still part of Zaire and referred to 
as Leopoldville, was a cradle for HIV-1 evolution (17). The origins of all cross-species 
transmissions have been traced to nearby areas in Western Africa and all sub-groups of 
HIV-1 have been discovered to still exist in Kinshasa as well as unique viral strains that 
have remained confined to the city (17, 23, 25). At the time, in early colonial Africa, 
urban populations were expanding and Kinshasa was the largest city in the region (23). 
Emergence of HIV-1 with it would allow for the virus to spread and diversify more 
easily, creating the pandemic that has plagued the world. 
Both HIV-1 and HIV-2 are thought to have originated from a cross-species jump 
of a related simian immunodeficiency virus (SIV) from its native host to humans (17, 18). 
It is known that HIV-2 originated from at least eight independent transmission events of 
SIVsm, which is a naturally occurring lentivirus in sooty mangabeys (17, 26–28). This 
gave rise to the eight lineages of HIV-2, labeled A-H, though only A and B have spread 
to an appreciable degree (17). HIV-2 is far less pathogenic than HIV-1, and typically 
displays lower viral loads and poor transmission (17). Many individuals who become 
infected do not progress to AIDS, though those who do have symptoms that are 
indistinguishable from HIV-1-related AIDS (17).  
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HIV-1 transmission occurred from at least four independent transmission events 
of a related lentivirus, SIVcpz from chimpanzees and gorillas that gave rise to subgroups 
M, N, O, and P (17, 18, 29). Of these four groups, N and P have remained confined to a 
handful of cases in Cameroon, O has spread to a limited degree in West Africa and 
accounts for approximately 1% of the global incidence and group M is the highly-
diversified virus that is the cause of the global pandemic (17, 18). Group M has been 
further divided into 9 subtypes, A-D, F-H, J, and K, with additional recombinant forms 
between them that number greater than 40 (17). Global migration of these subtypes can 
be easily mapped, as many of them are now the predominant virus in different areas of 
the world (18). Subtype C, for example, has migrated to southern Africa, where it is now 
by far the dominant species of HIV-1. From there it has spread to India and Southeast 
Asia (17). Alternatively, subtype B initially was brought to Haiti, from where it spread to 
become the predominant virus in North America and Europe (17).  
Each group and subgroup within HIV-1 contains an immense amount of diversity. 
Due to both error-prone replication strategies and a short reproduction time, HIV evolves 
a million times faster than human DNA does, allowing it to quickly outpace our natural 
defenses to infection (30, 31). It has been reported that within subgroup variation is 
typically between 8-17% at the amino acid level, though as high as 30% variation has 
been observed (18). Additionally, intra-subgroup variation ranges from 17-35%, with as 
high as 42% for some subgroups (18). Group O virus has also been divided into 
subgroups I-V, which show similar between group variation as group M, though less 
intra-group variation has been observed due to generally more restricted spread of the 
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virus (18). Together, this complicates efforts to develop diagnostics, antiretroviral 
treatments and vaccine candidates that will work on a diverse array of viruses.  
Viral evolution and lineages- Simian Immunodeficiency Virus (SIV) 
HIV is a member of the lentivirinae family of viruses whose life cycle is defined 
by reverse transcription of the viral plus stranded RNA genome into double stranded 
DNA that is subsequently integrated into the host cell genome (32). Lentiviruses are a 
distinct subclass of the larger, retrovirus family which all reverse transcribe and integrate 
the host genome (32). Lentiviruses are unique amongst retroviruses in that they encode 
mechanisms to import the reverse transcribed viral dsDNA into the host nucleus 
independent of cellular division and are thus able to infect non-dividing cells (32). Both 
HIV-1 and HIV-2 are each derived from one of more than 40 described SIV strains 
circulating in African primates (17). Interestingly, SIVs have only been detected in 
African old world monkeys (OWMs), indicating that they infected African OWMs after 
speciation from Asian NHPs and new world monkeys in the Americas, which occurred 
six to ten million years ago (17).  
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Figure 1. Origins of human AIDS viruses.  
Old World monkeys are naturally infected with more than 40 different lentiviruses, 
termed simian immunodeficiency viruses (SIVs) with a suffix to denote their primate 
species of origin (e.g., SIVsmm from sooty mangabeys). Several of these SIVs have 
crossed the species barrier to great apes and humans, generating new pathogens (see text 
for details). Known examples of cross-species transmissions, as well as the resulting 
viruses, are highlighted in red. (17) Figure and legend from Sharp, et al. Cold Spring 
Harbor Perspectives in Medicine, 2011. 
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While there have been reported cases of SIV infections in Asian macaques, these 
occurred mostly in captivity (33). SIVsm was transmitted to Asian macaques via 
experimental injections and co-housing with sooty mangabeys (Fig. 1) (17, 33). This 
created the new strain, SIVmac, which is pathogenic and results in AIDS-like disease in 
Asian macaques (33). This species jump is of particular interest because SIVsm is non-
pathogenic in its natural host, sooty mangabeys, but gains pathogenicity following 
zoonotic transmission, suggesting host factors influence the course of disease (Fig. 1). 
Similarly, SIVsm has jumped into human populations on several instances, which has 
resulted in pathogenic HIV-2 epidemic in West Africa (26–28). Sooty mangabeys are 
frequently hunted as agricultural pests, and it is thought that exposure to humans occurred 
during instances of hunting where individuals were exposed to contaminated blood or 
tissue (17, 34). How sooty mangabeys tolerate SIV infection without noticeable 
symptoms remains unclear and is of research interest. Understanding these mechanisms 
might result in development of a functional cure for HIV infection.  
Unlike HIV-2, HIV-1 was derived from a cross-species jump of SIVcpz, likely 
through the capture or consumption of bushmeat (Fig. 1) (29, 34). SIVcpz is, itself a 
mosaic virus derived from recombination between SIV red-capped mangebey (SIVrcm) 
and an SIV from the Cercopithecus species including the greater spot-nosed, mustached, 
and mona monekys (SIVgsn/SIVmus/SIVmon) (35). Env, as well as some of the accessory 
genes, including vpu, tat, and rev are derived from SIVgsn/SIVmus/SIVmon, while the viral 
LTRs, the 5’ half of the genome and nef all more closely resemble SIVrcm (35). Exposure 
of chimpanzees to SIVs from other monkeys is thought to be due primarily to predatory 
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behavior (17). Field studies using non-invasive sampling techniques have defined the 
spread of SIVcpz amongst the 5 species or subspecies in western and central Africa (36–
38). Only 2 of these, the central and eastern chimpanzees, have detectable SIV infection 
(36–38). Infection rates among colonies can range from as high as 50% to non-existent. 
Contrary to what was noted with SIVsm, increasing amounts of data show that SIVcpz can 
cause AIDS-like symptoms and increased morbidity and mortality in chimpanzees (36–
40). The recent nature of the jump from red-capped mangabeys and monkeys to great 
apes likely has limited the amount viral tolerance that has developed in the new host (17). 
Interestingly, in addition to jumping to humans, SIVcpz has also spread to gorillas, though 
mode of transmission remains unclear, since gorillas are herbivores that do not pray hunt 
or eat other mammals (17, 41, 42). The transmission of SIVcpz that gave rise to HIV-1 
group P and potentially group O have been mapped to gorilla-derived lineages (17, 18, 
37, 43). It is less clear if group O is gorilla-derived, since it lies phylogenetically 
somewhere between known chimpanzee and gorilla lineages and may have arisen 
through contact with a chimpanzee lineage that also spread to gorillas (17, 18). Due to the 
limited amount of field studies of gorilla colonies in Africa, the extent of SIV spread and 
whether it results in pathological disease remain unclear. Though there is still a good 
amount that is unknown about disease pathogenesis during infection of diverse primates, 
pathogenesis of HIV-1 and HIV-2 in humans has been well characterized.  
Pathogenesis 
Due to the limited tropism of HIV, infection requires direct contact with immune 
cells normally resident in blood, immune organs and at mucosal sites. This restricts the 
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routes of HIV transmission to sexual contact, both intra-vaginal and intra-rectal, direct 
injection into the blood stream, either through transfusion of contaminated blood products 
or needle sharing during injection drug use, transplantation of organs from infected 
individuals, or mother-to-child transmission during child birth or breast feeding (44). The 
risk of transmission varies for each of these events, ranging anywhere from 1 in 200 to 1 
in 3000 for heterosexual transmission, 1 in 20 to 1 in 300 for men who have sex with men 
(MSM) transmission, 1 in 5 to 1 in 20 for mother-child transmission and 95 in 100 to 1 in 
150 for transmission via the bloodstream (44). A genetic “bottleneck” is frequently 
observed during transmission where one or very few viral clones establish infection in a 
new individual (18, 44). These single-founder events occur with high frequency in all 
infection routes, with approximately 80% of heterosexual transmission, 60% of MSM 
transmission, and 40% of intravenous transmission occurring from one or few founder 
viruses (18, 45). These founder viruses are typically CCR5-tropic (one of two co-
receptors used by HIV, as discussed further below), and dissimilar from the diverse 
quasispecies of virus in the transmitting host (44). This is generally thought to be due to 
the relatively low efficiency of viral transmission, resulting in an extreme bottleneck 
where only the most fit of transmitted viruses are able to establish an infection in a new 
host (44).  
Acute disease 
 After establishment of a new infection, acute disease is typically characterized by 
flu-like symptoms, consisting of a fever, rash, sore throat, and swollen/tender lymph 
nodes, which is often severe enough for the individual to seek medical attention (46, 47). 
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Due to the non-specific nature of these symptoms, patients are typically diagnosed with a 
non-specific viral infection and testing for HIV is rarely done (46). After exposure to 
virus, a successful infection begins with an eclipse phase where the virus replicates in the 
local environment, typically a mucosal site, before being trafficked to local lymph nodes 
by dendritic cells (DCs) or infected CD4+ T cells (45). The eclipse phase typically occurs 
about 10 days before viral RNA is detectable in the blood. After the eclipse phase, virus 
trafficked to the lymph nodes establishes a robust infection and begins to spread 
systemically, infecting all immune sites in the body, including the gut-associated 
lymphoid tissues (GALT) (45). At 21-28 days post infection, peak viremia is attained 
with viral RNA reaching 106 copies/mL in the plasma (45). Peak viremia is accompanied 
by a drastic loss in circulating and lymph-associated CD4+ T cells, the main target of 
infection. HIV mainly infects activated, CCR5+ (memory) CD4+ T cells, which are 
present in the blood and lymph tissues and highly enriched in the GALT. In the first 3 
weeks of infection, approximately 80% depletion of GALT-associated CD4+ T cells can 
occur due to direct cytopathic effects of infection or indirect effects of systemic immune 
activation associated with acute infection (45). Acute infection is characterized by a 
cytokine storm, driven by detection of viral infection from innate immune cells including 
conventional and plasmacytoid DCs (cDCs or pDCs), macrophages and natural killer 
(NK) cells (45). The antiviral cytokines interleukin (IL) 15, type I interferons (IFNs) and 
INFγ inducible protein 10 (IP-10) increase rapidly but transiently, while the 
proinflammatory cytokines IL-18, tumor necrosis factor α (TNFα), IFNγ, and IL-22 
increase rapidly and are maintained in the serum (45, 46). During this time, the levels of 
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circulating DCs also drop, either from activation-induced cell death or increased 
migration to the lymph nodes, where levels notably increase (45). Concurrently, the 
adaptive immune response begins to mount a response to viral infection. B cell specific 
responses can begin to be detected at 8 days post detectable plasma viremia and 
production of the first viral envelope-specific antibodies occurs between 13 and 27 days 
post plasma viremia (45). T cell-specific responses occur more rapidly and drive viral 
diversification as the virus tries to escape detection. Early T cell responses are typically 
specific to the viral Env or Nef proteins, while later responses develop against p24gag and 
Pol, which are thought to help keep viral levels in check (45). In the 12-20 weeks post 
infection, viral loads decrease and reach a “set-point,” and maintained at a fairly 
consistent level by the adaptive immune system (45, 46). During this time, plasma levels 
of CD4+ T cells rebound but GALT-associated CD4+ T cells do not (45). After these 
initial, early events in infection, viral load and CD4+ T cell count reach an equilibrium 
and disease progresses into its chronic stage. 
Chronic disease 
 Before the onset of anti-retroviral therapies (ART), chronic infection was 
characterized by persistent levels of immune activation, production of proinflammatory 
cytokines and a slow decline in immune function and CD4+ T cell levels (46). 
Consistently high levels of IL-6, TNFα, and coagulation-associated protein d-dimer drive 
chronic immune activation (48, 49). Production of antiviral IFNs are typically difficult to 
detect, but a consistent signature of interferon stimulated genes (ISGs) is noted in 
transcriptional analysis of cells from infected patients (50, 51). T cells, B cells and 
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antigen presenting cells (APCs), including DCs and macrophages which coordinate 
initiation of an adaptive response all show phenotypic and functional evidence of 
persistent activation (4, 52). T cells display increased expression of activation markers 
CD38 and HLA-DR, as well as increased expression of senescence and exhaustion 
markers CD57 and programmed cell death protein 1 (PD-1) (53–56). These markers are 
associated with decreased ability of the T cells to respond to T cell receptor stimulation 
and decreased functionality (53–56). There is also increased levels of cell-turnover and 
proliferation, indicated by Ki-67+ staining, which may be the result of homeostatic 
mechanisms of the immune system trying to fill the void of viral-induced cell death (46). 
During this time, the structure of primary and secondary lymphoid tissue begins to 
deteriorate (57). The thymus, which is the source of new, naïve T cells, undergoes severe 
morphological damage, which is thought to be responsible for some of the decline in 
circulating CD4+ T cells (46, 57). The intestine, which contains 40% of all lymphocytes 
in the body, also undergoes morphological changes, including increased epithelial cell 
apoptosis and crypt hyperplasia (46, 58, 59). The immediate and drastic loss of CD4+ T 
cells is thought to be the driving force for these changes (3–5, 46, 60). Th17 CD4+ cells 
are responsible for maintenance of the mucosal barrier and are reported to be amongst the 
first infected cells in pathological models of SIV infection (61). These cells are almost 
entirely depleted in chronic infection, which may be the reason for intestinal barrier 
breakdown and increased translocation of microbial products from the gut (46, 60, 62). 
These microbial products, including bacterial lipopolysaccharide (LPS), are thought to be 
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some of the driving force behind the high levels of serum proinflammatory cytokines 
(46).  
 During end-stage HIV infection, or onset of AIDS, CD4+ T cell levels drop below 
200 cells/mL and the host immune system essentially collapses (3–5, 46). At this point, 
the individual becomes highly susceptible to secondary infections including 
mycobacteria, cytomegalovirus, or infection by Pneumocystis jirovecii, Toxoplasma 
gondii, Streptococcus pneumoniae, or Cryptococcus (46). They also have increased rates 
of very specific malignancies including non-Hodgkin’s lymphoma and Kaposi’s sarcoma 
(46). This can occur anywhere from several months to 10 years after initial infection, 
though in rare cases of so-called “elite controllers,” they may not progress to disease in 
20+ years (46, 63, 64).  
 Since the advent of highly-active antiretroviral therapy (HAART), a combination 
of drugs that target multiple steps in the viral life cycle (described later in this section), 
course of disease during chronic HIV infection has been dramatically altered (65). In 
most cases, after HAART initiation, serum HIV drops to undetectable levels, CD4+ T cell 
levels rebound, and systemic inflammation decreases, though does not disappear entirely 
(46). Studies of individuals who initiate HAART early after infection have revealed that 
the thymus is able to regenerate/repair itself, if treatment is started early enough (57). In 
some cases, reconstitution of the GALT has also been observed, though other studies 
have reported that GALT-associated CD4+ T cell count remains low even post treatment 
(66–71). Early HAART treatment is associated with reduced disease progression and 
better restoration of CD4+ cell levels (46).  
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 In some individuals, typically those that initiate HAART later during their course 
of disease, CD4+ T cell levels are not able to rebound, despite undetectable viral load in 
the plasma (46). In these individuals, lymphoid tissue fibrosis, especially in the gut, is 
irreversible, and microbial product translocation as well as serum proinflammatory 
cytokines are maintained (46). These individuals also maintain higher levels of activation 
and proliferation markers on their circulating T cells, as well as decreased ability of theirs 
cells to respond to stimulation (46). These residual disease effects are all collectively 
associated with worse disease outcomes and increased morbidity and mortality.  
 With the advent of HAART, HIV has become a chronic disease. Individuals now 
are more likely to suffer from HIV-associated non-AIDS conditions (HANA) that are 
thought to be driven by the underlying inflammatory signature that even HAART cannot 
alleviate (72). These HANAs include cardiovascular disease, increased incidence of 
cervical and lung cancers, liver disease specifically in hepatitis co-infected individuals, 
and a variety of non-AIDS related malignancies (73–75). All of these are more common 
in HIV-infected individuals than the general population and correlated with CD4+ T cell 
count (46, 73). It is thought that the low level of viral replication that occurs, specifically 
in isolated tissue reservoirs where drug penetrance is low, is the driving force behind 
these inflammation-linked disorders. There is hope that better treatment to reduce 
residual replication or a functional cure for infection could prevent HANA entirely. In 
order to effectively design better treatments, in depth knowledge of the viral life cycle is 
necessary. 
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Molecular mechanism of disease: viral life cycle 
HIV and SIV replication, like with all viruses, initiates with attachment and entry 
into the target cell (Fig. 2). For all lentiviruses, binding is mediated by a virally encoded 
env protein (76). The HIV-1 Env is a trimer, each composed of the transmembrane 
anchor, gp41 and the receptor binding motif, gp120 which are proteolytically cleaved 
from one polyprotein encoded in the genome (76–78). For HIV-1, fusion requires the 
presence of the primary virus receptor, CD4, as well as a co-receptor, either CCR5 or 
CXCR4 (79–86). Receptor and co-receptor requirement limits HIV-1 cell tropism to 
CD4+ T cells, macrophages and dendritic cells (87, 88). The HIV-1 fusion protein is 
usually specific for usage of either CCR5 or CXCR4, though dual tropic viruses, 
although rare, have been isolated as well (89). This has given rise to the nomenclature 
CCR5- or CXCR4-tropic viruses. HIV-2 also utilizes CD4 as its primary receptor but is 
known to have a broader range of co-receptor usage including CCR1, CCR3, CXCR6, 
and GHOST(3) (90–92). SIVs, similar to HIV-2, are also thought to have a broader range 
of co-receptor usage and may be able to enter cells independent of CD4 expression with 
certain co-receptors (93–95). In HIV-1, binding to CD4 by the env protein allows for 
rearrangement of the V1, V2, and V3 loops of the viral env so that the co-receptor can be 
engaged (76). Co-receptor engagement is thought to be the trigger for insertion of the 
fusion peptide of gp41 into the host plasma membrane (76). Then, a six-helix bundle 
composed of two viral Env trimers with fusion peptides inserted into the host membrane 
undergo a conformational change that pulls the two membranes together (76, 96, 97). 
Once the virus fuses with the cell membrane, entry and uncoating occur (32).   
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Figure 2. HIV life cycle and viral restriction factors.  
Steps of the HIV life cycle are denoted with black, boxed labels and host restriction 
factors that are counteracted by virally encoded proteins are shown in red.  
  
  
17 
 
The viral core, or capsid must enter into the host cytoplasm and begin to come 
apart, or uncoat, releasing the viral genetic material to allow for infection (Fig. 2) (98). 
Timing is important in this process, as evident by the effects of the restriction factor 
TRIM5α (99–102). TRIM5α is a host protein shown to restrict SIV/HIV infection of cells 
derived from its non-native host during a cross-species transmission event (99–101). 
TRIM5α binds to capsid and mediates premature uncoating, resulting in viral restriction 
(Fig. 2) (102). It remains unclear whether this process occurs in the host cytoplasm or 
after the core reaches the host cell nucleus (98). During uncoating, reverse transcription is 
initiated by the viral reverse transcriptase (Fig. 2) (98).  
Reverse transcription utilizes a virally encoded polymerase to convert the single-
stranded RNA genome to double stranded DNA (103, 104). Reverse transcription 
initiates using a tRNA primer that binds to the primer binding site on the viral RNA, just 
downstream of the long terminal repeat or LTR (105, 106). The LTR contains sequences 
(R or repeat region) that flank both ends of the viral genome allowing for successful 
reverse transcription and U3 for initiating transcription from integrated viral DNA (105). 
HIV preferentially utilizes a lysine tRNA for reverse transcription initiation (103, 104, 
107, 108). Then the viral reverse transcriptase begins to add dNTPs to the tRNA primer 
in the direction of the 5’ LTR using the viral RNA as a template (Fig. 3) (32, 105). The 
viral reverse transcriptase, in addition to polymerase activities, also has RNAse H activity 
and degrades the template RNA as it copies it into DNA (32, 105). Once the polymerase 
extends through the 5’ end, it reaches the minus-strand strong stop, where it pauses until 
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the whole tRNA-reverse transcriptase-DNA complex will jump to the other end of the 
viral RNA (Fig. 2) (32, 105). Base pairing between the newly reverse transcribed R and 
3’ R (RNA) allows for continued duplication of the rest of the genome into DNA (Fig. 3) 
(32, 105). During this second extension, RNAse H is unable to degrade a short track of 
RNA called the polypurine tract, which acts as a primer for creation of the second strand 
of DNA (Fig. 2) (32, 105). The viral reverse transcriptase will then copy the first strand 
of DNA in the 3’ direction until it reaches the initial tRNA primer at the positive strand 
strong stop (Fig. 3) (32, 105). Again, the reverse transcriptase will pause until the newly 
made second strand DNA base pairs with the first DNA strand at the primer binding site, 
forming a loop like structure (32, 105). DNA replication can continue around the loop to 
form a complete, double stranded DNA genome (32, 105).  
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Figure 3. Viral Reverse Transcription.  
(A) Viral reverse transcription initiates via a tRNA primer binding to the primer binding 
site (PBS). The viral polymerase, reverse transcriptase, will then proceed to copy the U5 
and R sequence while the RNAse H portion of the viral polymerase degrades the template 
strand. When the polymerase comes to the end of the R sequence, base pairing can occur 
the homologous R sequence at the other end of the genome, resulting in the whole DNA-
polymerase complex to jump in a process referred to as strand transfer (B). The viral 
reverse transcriptase will again begin to copy the viral RNA into DNA, degrading the 
template RNA as it goes. The polypurine track (PP) is resistant to RNAse H degradation, 
and will remain base paired to the newly synthesized DNA. (C) The PP then acts as a 
primer, and the viral reverse transcriptase will use the newly synthesized DNA to as a 
template. Once U3, R and U5 have been synthesized, the second strand transfer will 
occur (D), and base pairing at the PBS will allow for extension in both directions to make 
a complete DNA copy of the viral genome. 
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After the double stranded DNA reaches the host cell nucleus, another virally 
encoded protein, integrase, incorporates the viral DNA into the host cell’s chromatin 
creating a provirus, or a permanently incorporated viral genome encoded by the host (Fig. 
2) (109). Integration is directed by the viral integrase protein along with a number of host 
cell proteins that are recruited to the viral DNA (109). These include the cellular protein 
Barrier to autointegration (BAF) that prevents the viral DNA from integrating into itself 
(110, 111). A pre-integration complex (PIC) is generated, which includes integrase and 
matrix and capsid proteins, all of which contribute to nuclear import (109, 110). This 
complex of proteins associate with nuclear pore proteins transportin 3 and Nup358 and 
facilitate transfer of the PIC across the nuclear membrane (109). Once in the nucleus, the 
PIC associates with the cellular protein LEDGF/p75, which is thought to help tether the 
PIC to the host DNA and play some role in integration site selection, though this process 
remains poorly understood (112–115). Though the mechanism of site selection remains 
poorly defined, integration site mapping has revealed that HIV preferentially integrates in 
euchromatic regions where active gene transcription is occurring (109). During the 
process of integration, the viral integrase removes two nucleotides from each 3’ end of 
the linear viral DNA (Fig. 4) (109, 110, 116). These 3’ ends, facilitated by the catalytic 
domain of integrase, attack the target host DNA at a phosphodiester bond at a major 
grove in the DNA (Fig. 4) (109, 117). This joins the 3’ ends of the viral DNA to the host 
DNA with a five-nucleotide, single strand gap in the host DNA between joining sites and 
a two-nucleotide, 5’ flap of viral DNA (Fig. 4) (109). Next, host cell machinery must 
remove the two-nucleotide 5’ overhang and fill in single stranded gaps (118). If this 
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process does not occur, host DNA replication for cell division will stall at the joining 
sites (119). These single strand gaps are also hot spots for accumulation of additional 
DNA damage like double strand breaks, which trigger cellular apoptosis if not repaired 
(119). Once this process is complete, the integrated viral genome can be transcribed to 
produce viral mRNA or remain dormant, not undergoing any transcription through a 
process called latency (32). Since the viral genetic material is incorporated into the host 
genetic material, the virus becomes very difficult to purge from an individual once 
infected, particularly when it is in a latent state (120). This remains one of the largest 
barriers to a cure.  
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Figure 4. Retroviral Integration.  
Integration begins with 3’ processing (A) catalyzed by the viral integrase. This process 
removes two nucleotides to create 3’ -OH groups that are attached to host DNA at 
phosphate groups (B) during strand transfer. This joining results in a five base pair gap 
and two nucleotide flap that must be repaired by host cell machinery (C). Cellular DNA 
repair proteins will fill in the gap, ligate the newly synthesized DNA to the host DNA, 
and remove the two nucleotide flap to create a transcriptionally competent provirus.  
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 After integration, the virus utilizes host cell machinery to undergo transcription 
and translation in order to make new viral proteins (Fig. 2) (32). These assemble in the 
cytoplasm and bud from the host cell membrane (32). This budding process incorporates 
host cell lipids and plasma membrane proteins into the viral membrane, which is thought 
to be advantageous to viral spread and immune evasion (121, 122). As a final step in the 
replication process, a virally encoded protease must cleave Gag and Pol polyproteins that 
make up the viral core (32). This makes the newly budded virion fully infectious and able 
to initiate a new infection in a neighboring cell (32). This entire process of viral 
replication is mediated by only a handful of virally encoded proteins which co-opt key 
cellular processes to assure propagation of virus. 
Virally encoded proteins and their functions 
 All primate lentiviruses encode three main structural and enzymatic proteins that 
are essential to replication as well as a number of accessory proteins that facilitate 
replication in vivo in cells that have high barriers to infection (32). The three main 
proteins are conserved across primate lentiviral evolution and include the polyproteins 
Gag and Pol as well as Env (Fig. 5) (32). Gag encodes the three main structural proteins, 
matrix, capsid, and nucleocapsid that provide the structure of the virion as well as form 
that viral core that protects the viral mRNA during infection and shields it from sensing 
by host machinery (32). Pol encodes the three enzymatic proteins, reverse transcriptase, 
integrase and protease (32). Reverse transcriptase converts the viral RNA to double 
stranded DNA through a process known as reverse transcription (103, 104). Integrase 
then incorporates this double stranded DNA into the host cell DNA (109, 110). Viral 
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protease is responsible for maturation (proteolytic cleavage) of both Gag and Pol 
polyproteins after viral budding, creating a mature, infectious virion (32). Without 
protease, the newly budding virions remain in an immature form and are non-infectious 
(123). Env, the viral envelope protein, mediates binding and fusion of the virion to the 
host cell. Env is extensively glycosylated during endoplasmic reticulum (ER) processing 
and is cleaved into its two components, gp120 and gp41 by the cellular protease, furin 
during protein processing in the ER (124, 125).  
 In addition to these structural and enzymatic proteins, HIV encodes six other 
proteins important for infection (Fig. 5). The proteins Tat and Rev are conserved across 
primate lentiviruses, and are both critical to viral replication (126). Tat, also known as 
trans-activator of transcription, is a highly potent HIV/SIV transcriptional enhancer that 
is critical for mediating high levels of transcriptional output from the integrated provirus 
(127). Tat binds a RNA-stem loop structure called the transactivation-responsive element 
(TAR), which recruits proteins that prevent premature RNA polymerase II pausing on 
nascent viral transcripts (128, 129). In the absence of Tat, only low levels of viral 
transcription can occur, often with premature termination at terminator sequences within 
the viral genome (127). The viral Rev protein is important for splicing and export of viral 
RNA (130).  The viral genome encodes four different splice donor sites and eight splice 
acceptor sites, allowing for more than 40 different viral transcripts to be made, likely 
more if cryptic splice sites were included (131). It is critical to the viral life cycle that 
some viral RNAs remain unspliced in order to be packaged as new viral genomes or only 
partially spliced for certain viral proteins to be expressed (131). Rev binds to a short 
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RNA sequence within the env portion of the viral genome known as the rev responsive 
element (RRE) (132, 133). Binding of rev induces a conformational change in the viral 
RNA, allowing for multimerization of Rev which is necessary for viral RNA export 
(131). Rev then facilitates singly-spliced or unspliced RNA export from the nucleus 
through associations with Crm1 for translation or virion incorporation, respectively (131, 
134–136). After nuclear export, Rev is released from the viral RNA and returns to the 
nucleus via associations with importin-β (136–139). Without Rev, mRNA encoding the 
viral enzymatic and structural genes gag, pol, and env would not be translated and new, 
progeny virions could not be made (131).  
 Finally encoded by primate lentiviruses are a number of accessory proteins. 
Accessory proteins are not necessary for replication in vitro but are absolutely essential 
for replication in vivo to counteract host restriction factors that normally would inhibit 
infection (140). Among the accessory proteins, Nef, Vif, and Vpr are encoded by all 
primate lentiviruses, while Vpu is unique to the HIV-1/SIVcpz lineage and Vpx is unique 
to SIVsm, SIVmac, and HIV-2 lineage (Fig. 5) (140). Most of these proteins have multiple 
functions during infection, many of which have been thoroughly studied and are well 
defined in the literature. 
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Figure 5. HIV-1/SIVcpz and HIV-2/SIVsm/SIVmac viral genomes.  
The viral genomes (not to scale) of HIV-1/SIVcpz lineage viruses and HIV-
2/SIVsm/SIVmac lineage viruses. The most significant difference is the presence or 
absence of the viral accessory protein Vpu or Vpx.  
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Viral accessory proteins and restriction factors 
In the arms race between pathogen and host, accessory proteins are the virus’s 
best defense against host restriction (Fig. 2). These proteins are dispensable in some in 
vitro systems but are absolutely essential in vivo to counteract host immune defense 
proteins that restrict viral infection (140). During the zoonotic transmission events that 
resulted in HIV-1 and HIV-2, the simian virus had to adapt to its new host in order to 
replicate (17, 18). We diverged from our most recent common ancestor with apes and old 
world monkeys (OWM) approximately 25 million years ago, so divergence of host 
restriction factors that block infection is a major obstacle to cross species transmission 
(17, 140). Every time a transmission event occurs, the viral accessory proteins must 
evolve to counteract their cognate restriction factor in order to successfully infect its new 
host (140, 141). This process also places pressure on the host species to accumulate 
polymorphism in viral restriction factors to enhance survival, resulting in the positive 
selection that is observed amongst lentivirus restriction factors in the primate lineage 
(140, 141). The accessory proteins Vpr and Vpx will be discussed later, as they are the 
main focus of this dissertation. Of the remaining accessory proteins, the function of viral 
infectivity factor (Vif) is the most clearly defined. It, like most of the viral accessory 
proteins, uses a conserved pathway to target a host restriction factor for degradation 
(140). This conserved pathway utilizes a cullin scaffolding protein to assemble a 
Rbx/Rox RING finger protein and an E2 conjugating enzyme to form a ubiquitin ligase 
complex (140, 142). In the case of Vif, this complex targets apolipoproteinB mRNA-
editing enzyme catalytic polypeptide-like 3G and 3F (APOBEC3G, APOBEC3F) and to 
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a lesser extent, some of the other members of the APOBEC family for proteasomal 
degradation (140, 143, 144). In the absence of Vif, APOBEC proteins will be packaged 
into the budding virion and will convert cytosine residues to uracil during early reverse 
transcription (145–147). When this strand of cDNA is used during late reverse 
transcription as a template, these changes will become fixed in the viral genome as 
guanosine to adenosine mutations in a process called G to A hypermutation (140, 146). 
Approximately 10% of the Gs can be mutated through this process, resulting in error 
catastrophe which prevents further viral spread (140). In the presence of Vif, APOBEC is 
poly-ubiquitinated and proteasomally degraded, preventing viral restriction (140).  
Similar to Vif, viral protein U (Vpu) also interacts with a ubiquitin ligase 
complex, but Vpu uses this complex to target multiple, highly divergent proteins (140). 
Vpu utilizes the cullin1-Skp1 complex to target both CD4 and BST-2 for proteasomal 
degradation (148, 149). CD4 is the main viral receptor for both HIV and SIV, as 
discussed earlier. Downregulation of this receptor allows for efficient viral egress and 
prevents super-infection of the host cell (140). Vpu utilizes the ubiquitin ligase complex 
to target env-bound CD4 in the ER during processing, preventing it from co-trafficking to 
the cell surface with viral Env (149). Vpu poly-ubiquitinates the cytoplasmic tail of CD4, 
targeting it for degradation via the proteasome (150–152). In addition to downregulation 
of CD4, Vpu is also able to target the viral restriction factor BST-2 or tetherin (153, 154). 
It was noted that in the absence of Vpu, infectious virus becomes stuck or tethered to the 
surface of infected cells, reducing viral spread (155, 156). Tetherin is an interferon 
inducible plasma membrane protein able to bind and retain budding virus to the surface 
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of the cell (153, 154, 157). Its cytoplasmic tail contains signaling motifs able to initiate 
the NF-κB signaling cascade and induce pro-inflammatory cytokine secretion. Vpu binds 
the cytoplasmic tail of tetherin at the plasma membrane and targets it for ubiquitination 
and proteasomal degradation (158). Vpu is unique to SIV lineages that gave rise to HIV-
1, SIVcpz, and SIVgor (159, 160). In other lineages, the Env protein and/or the Nef proteins 
have shown the ability to downregulate tetherin and CD4 (140).  
Interestingly, most SIV and HIV Nef proteins retain the ability to downregulate 
CD4 and MHCI independent of expression of Vpu via an ubiquitin-independent 
mechanism (161–163). Nef associates with the cytoplasmic tail of CD4 at the plasma 
membrane and recruits endocytosis machinery including AP-2 and clathrin to endocytose 
CD4 and traffic it to the lysosome for degradation (164). Recently, this has been 
suggested to help shield infected cells from antibody-dependent cell-mediated 
cytotoxicity by preventing pre-triggering of the viral glycoprotein by surface CD4 (165). 
In addition to CD4, Nef has been shown to induce endocytosis of the plasma membrane 
protein major histocompatibility complex I (MHC I) (166). MHC I is an antigen-
presenting molecule on the surface of all cells that displays both self and foreign 
antigens. When a cell becomes infected, antigen from the infection can be displayed on 
MHCI and sensed by nearby immune cells including NK cells and cytotoxic T cells (167, 
168). These immune cells will respond by killing the infected cell, limiting its ability to 
transmit the infection. It is highly advantageous to HIV and SIV to downregulate these 
presentation molecules to limit immunological detection (167, 168).  
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In addition to plasma membrane protein targets, it is well established that Nef has 
effects on virion infectivity and that this is a highly conserved function across primate 
lentiviruses (169, 170). Virions made from cells infected with a nef-deficient virus have 
been shown to be less infectious on a per particle basis than nef-expressing virus, but this 
phenotype is evident in only certain types of cells (169). For instance, viruses derived 
from cell lines such as HEK293T (human embryonic epithelial kidney cell line) or HeLa 
(human cervical epithelial cell line) cells show no difference in infectivity in the presence 
or absence of Nef, while virions derived from primary CD4+ T cells or Jurkat T cell lines 
are significantly less infectious in the absence of nef (171–173). Recently, two labs have 
discovered the reason for this and also a third family of proteins targeted by nef. Work 
done by both the Pizzato and the Göttlinger laboratories show that nef targets a family of 
proteins called SERINCs, in particular SERINC3 and SERINC5 (174, 175). Normally, 
these proteins are incorporated from the host plasma membrane into the budding virion. 
In the presence of nef, the SERINCs are endocytosed and recycled from the plasma 
membrane (174, 175), preventing incorporation. While it remains unclear what direct 
effect the SERINCs are having on infectivity, it is thought that they may be limiting 
membrane fluidity of the virion, making it too rigid to fuse fully with a target cell and 
preventing entrance of the capsid into the cytoplasm.  
The remaining two accessory proteins, Vpr and Vpx are closely related and are 
the main focus of this work (176–178). Vpx  antagonizes the viral restriction factor 
SAMHD1, a dNTPase that prevents reverse transcription in monocytes, macrophages, 
DCs, and resting CD4+ T cells (179–183). Vpr has also been shown to enhance infection 
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in DCs, macrophages, and resting CD4+ T cells, though the exact function of the protein 
remains poorly defined (184–186).  
Viral protein R (Vpr): size, structure, encapsidation 
Vpr is a 96-amino acid, 14 kDa accessory protein encoded by HIV-1 (187). It is 
expressed from a singly-spliced Rev-dependent mRNA (188). Though an individual 
crystal structure has not been solved, NMR has revealed that the protein is composed of 
three alpha helices with flexible N- and C-terminal domains (189). Alpha helices span 
amino acids 17-33, 38-50 and 56-77 (189). These three alpha helices are folded around a 
hydrophobic core consisting of leucine, isoleucine and valine residues (189). The N-
terminus of Vpr is responsible for associations with the p6 region of gag, which allows 
for incorporation into virions (190–195).   
Vpr evolution: duplication, rise, function of Vpx 
Vpr can trace its origins back through primate lentiviral evolution (177, 178, 196). 
All described primate lentiviral isolates contain a functional Vpr gene, suggesting that it 
plays a critical role during infection (177, 178, 196). In many old-world monkey (OWM) 
lentiviruses, like SIVagm, Vpr has two ascribed functions, initiation of G2 cell cycle arrest, 
which is conserved amongst all Vpr alleles in their host cells, and degradation of the 
restriction factor SAMHD1 (178). SAMHD1, a dNTPase, is highly expressed in myeloid 
cells, including monocytes, macrophages and dendritic cells, as well as resting CD4+ T 
cells (179, 180, 183), that lowers the resting dNTP pool in cells, thus affecting the 
kinetics and magnitude of reverse transcription (181, 182, 197). The ability of Vpr to 
degrade SAMHD1 has been lost, or more likely never existed in some SIV lineages, 
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including that which gave rise to SIVcpz/HIV-1 (178). In others, Vpr underwent a 
duplication event after which the two functions of the protein diverged, giving rise to 
Vpx that encoded the SAMHD1 antagonism (176, 178). Vpx has been found only in two 
lentivirus lineages, the SIVsm/HIV-2 lineage and a lineage that includes SIV red capped 
mangabeys (SIVrcm) (178). Though, surprisingly, pathogenesis studies suggests Vpx may 
be more important than Vpr in primate models of infection (198, 199).  
Transactivation 
One of the original prescribed functions for Vpr is its ability to transactivate the 
viral LTR. It has been suggested that some of the differences in viral replication seen in 
the presence or absence of Vpr may be due to the ability of Vpr to transactivate, or 
stimulate transcription from the viral LTR (200). It has been shown by a number of 
groups that Vpr acts in primary human CD4+ T cells and T cell lines to enhance output 
from the viral LTR (200–202). Work from Gummuluru, et al shows that this process does 
not occur in primary human macrophages, suggesting that it may be limited to CD4+ T 
cells or cycling cells where Vpr expression results in cell cycle arrest (201, 203). 
Transactivation is a conserved function of all primate lentiviral Vprs, suggesting it plays 
an important role in the viral life cycle (204). Vpr from SIVagm, a distant relative to 
strains that gave rise to HIV-1 and HIV-2 maintains the ability to transactivate in human 
cells, even though it loses the ability to induce cell cycle arrest and apoptosis, suggesting 
that Vpr functions independently of host-cell machinery in order to increase viral 
transcription (205). It is also possible that transactivation is just an outcome of the viral 
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LTR being more active in G2 phase, which cycling cells are arrested in in the presence of 
Vpr (203). 
Vpr function and interactions: G2 arrest/apoptosis 
The most well described and studied function of Vpr is its ability to induce G2 cell 
cycle arrest during infection of cycling cells (206, 207). G2 arrest is conserved across all 
characterized primate lentiviral Vprs studied within their own host cells, though function 
is sometimes lost during infection of cells from other species (207, 208). It has been 
suggested that Vpr-induced G2 arrest increases viral progeny production, since the viral 
LTR has been shown to be most active in G2 phase (203). It is thought that arrest at G2 
prevents further cellular resources from going into cell division and DNA replication, 
allowing for their use in manufacturing new, progeny virions (203). In addition to the 
enhancement of viral transcription, expression of Vpr results in the induction of apoptosis 
(209–211). It remains somewhat of a debate if apoptosis is a result of G2 arrest or occurs 
independently, being driven by other functional regions of Vpr or through associations of 
Vpr with the mitochondrial cell death pathway (212–215). Regardless of the mechanism, 
induction of apoptosis is a driving force for loss of Vpr expression upon serial passage of 
HIV-1 in cells in vitro; cell death selects for Vpr-null mutations (216). In contrast, 
inactivating mutations in Vpr are selected against in vivo in both experimental SIVmac 
infections of Asian macaques (217). Furthermore, long-term non-progressor (LTNP) 
populations have been described with inactivating mutations in Vpr (218–220), 
suggesting that maintenance of Vpr function is required for pathogenesis in vivo. The 
differences that determine selection for maintenance or deletion in cell lines versus in 
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vivo remain unclear. However, it is well understood that G2 arrest is mediated by 
interactions with the Cul4A/DCAF/DDB1 ubiquitin ligase complex (DCAFCRL4 complex) 
(221–224). 
DCAF complex and DNA-damage proteins 
  It has been well characterized that induction of G2 arrest is reliant on Vpr 
associating with the DCAFCRL4 complex (221–224). It is generally thought that Vpr 
associates with the DCAFCRL4 complex to target an unidentified host restriction factor for 
ubiquitin-mediated proteasomal degradation. The complex is similar to that used by other 
HIV-1 accessory proteins and the same as that used by HIV-2/SIVsm/SIVmac Vpx to target 
SAMHD1 for degradation (140, 225–227). Multiple groups have performed proteomics 
studies to find potential binding partners for the Vpr-DCAFCRL4 complex, which have 
resulted in the identification of a number of targets. The first identified target of Vpr-
DCAFCRL4 was uracil DNA glycosylate 2 (UNG2), which excises uracil that has been 
misincorporated into DNA (228). Vpr expression mediates proteasomal degradation of 
UNG2, though the effect of UNG2 on the viral life cycle remains unclear (229–231). 
Alternatively, it has been proposed that Vpr interacts with UNG2 to recruit it to the viral 
DNA for removal of misincorporated uracils, but the clear reduction in UNG2 levels in 
the presence of HIV-1 Vpr provide contrary evidence to this suggestion (232–234). 
Additionally, interactions with UNG2 do not correlate with induction of G2 arrest, 
suggesting that UNG2 may not be the primary target of the Vpr-DCAFCRL4 complex 
(235). 
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 Association with DNA damage response (DDR) proteins is thematic for Vpr-
DCAFCRL4. This complex also associated with the structure specific endonuclease 4 
complex (SLX4com), which is a complex of proteins involved in Holliday junction repair 
(236). It has been suggested that Vpr recruits this complex to induce a DDR, which 
results in the observed G2 arrest (236). Not all primate lentiviral Vprs interact with 
SLX4com, and it has been shown that interaction does not necessarily mediate cell cycle 
arrest (235–237). Similar to SLX4com, helicase like transcription factor (HLTF) 
associates with HIV-1 Vpr in complex with DCAFCRL4, but interaction does not mediate 
G2 arrest, nor is the interaction conserved amongst primate lentiviral Vprs (238, 239). 
HLTF is a DNA translocase involved in repair of damaged replication forks (238, 239). 
Though, it remains unclear what role these interactions have in the viral life cycle, 
association of Vpr with cellular proteins involved in the induction of DDR is a conserved 
function for all lentiviral Vpr alleles.  
 The Vpr-DCAFCRL4 complex interacts and degrades a handful of other proteins 
that are less clearly associated with induction of G2 arrest. Vpr has been shown to 
degrade the miRNA processing protein DICER, which was shown to enhance infection of 
macrophages (240). Vpr also  degrades certain histone deacetylases (HDACs) which 
remove acetyl groups from histones, condensing DNA (241, 242). It has been suggested 
this this interaction enhances transcriptional output by reducing quiescent or latent viral 
integration (241, 242). Again, the importance of these interactions to the viral life cycle 
remains unclear, but many of them have been linked to a Vpr-mediated regulation of IFN.  
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Interferon (IFN) regulation 
Since induction of type I IFN responses are rarely observed during HIV-1 
infection in vitro, a hypothesis that the virus encodes a protein that specifically blocks 
this induction has been pervasive in the literature. IFN-I is highly restrictive to most viral 
infection, including HIV (243–245). To counteract this, many viruses, including 
paramyxoviruses, arenaviruses, influenza and filoviruses encode viral proteins that shut 
down IFN signaling in order to allow for infection (246–251). The role of Vpr in 
regulation of IFN-I, if any, remains relatively unclear. There are publications arguing 
divergent hypotheses, suggesting both downregulation and upregulation of IFN-I 
responses by Vpr (236, 252–259). There have been a number of reports that Vpr 
specifically down-modulates IFN-I signaling during infection at IRF3, either through 
direct degradation or sequestration of IRF3 in the cytoplasm to prevent signaling (256, 
257, 260). Other, contradictory reports have either attributed this function to Vpu and 
others have shown no difference in IRF3 levels and signaling during infection of both 
primary cells and cell lines with any of the viral accessory proteins (255, 261–264). 
Additionally, other groups have looked at IFN induction downstream of IRF3. Mashiba, 
et al noted in primary macrophages, infection with a Vpr-null virus resulted in a ten-fold 
increase in IFNA1 mRNA in primary human macrophages (252). Work from Laguette, et 
al in HeLa cells also shows induction of IFN-α and IFN-β mRNA in response to infection 
with a Vpr-null virus in an SLX4com-dependent manner (236). Alternatively, multiple 
groups have shown a Vpr-specific activation of IFN-response during infection, though 
the benefit of such a response to viral fitness remains unclear (255, 258, 265). Vermeire, 
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et al recently reported that Vpr amplifies cGAS-dependent sensing of viral transcripts but 
Vpu acts to counteract IFN production (255). It is possible that differences in cell types 
and viral isolates used, as well as divergent Vpr-expression systems, as opposed to 
productive infections may account for these differences, though more work is necessary 
to clarify what role Vpr plays in IFN-I immune signaling during infection. 
Regulation of viral env production in macrophages and dendritic cells (DCs) 
In addition to potentially modulating type I IFN signaling, some recent studies 
have suggested that Vpr may regulate HIV-1 Env stability and processing. Data from 
Mashiba, et al shows that during infection of macrophages, Env is degraded via the 
lysosome in the absence of Vpr (252), resulting in a defect in viral production and viral 
spread (252). This work stands in contrast to that published by others in the field who 
show little to no replication defect in macrophages in the absence of Vpr (238). In a 
follow up paper from the same lab, they extend their work to show that this defect results 
in a defect in spread to CD4+ T cells. In the absence of Vpr, they see significantly 
reduced viral infection of CD4+ T cells co-cultured with infected macrophages in the 
absence of Vpr (266). Vpr-mediated enhancement of Env production has also been 
shown to occur in moDCs and certain cell lines by the Zheng lab by mediating proper 
folding of HIV-1 Env in the ER (267). In the absence of Vpr, enhanced ER stress due to 
accumulation of misfolded proteins induced an unfolded protein response that shuttles 
Env to the lysosome for degradation (267). Together, their work suggests that Vpr may 
play a role in promoting production of HIV-1 Env during infection of myeloid-derived 
cells. Since Env expression in productively infected cells is a late event in the viral life 
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cycle, modulation of Env production is unlikely to be determined by incoming virion-
associated Vpr, but rather dependent on de novo expressed Vpr. Whether Vpr has roles at 
both early and late steps in the viral life cycle remains to be validated.    
Replication defect in macrophages/DCs 
The effects of Vpr on cell-type specific viral replication have been well studied, 
but remain somewhat controversial. It is well established that Vpr is not necessary for 
efficient replication in most cell lines, but effects in primary cells remain unclear (186). It 
was first reported by Balliet, et al in 1994 that Vpr is important for infection of 
macrophages, but dispensable for infection of PBMCs, (268). Additional evidence for 
this hypothesis was reported the following year when Connor et al published similar data, 
again showing that Vpr is dispensable for infection of resting or activated PBMCs but 
was required for infection of monocytes and macrophages (186). Since then, there have 
been a number of contradictory reports. Eckstein, et al also show a requirement for Vpr 
in tissue resident cells (269). Alternatively, Gummuluru, et al show contradictory work 
with single cycle viruses, indicating that Vpr enhances transcription from primary CD4+ 
T cells, but may not have an effect on single cycle viral production from macrophages 
(201). Höhne, et al recently has shown the necessity of Vpr for infection of resting CD4+ 
T cells (185), which may diverge from previously reported findings because they are the 
first to use purified, resting CD4+ T cells rather than resting PBMCs. Additionally, work 
from the Kathleen Collins’ lab has shown that Vpr-mediated regulation of Env 
production is essential for viral replication in macrophages and that this process enhances 
spread from macrophages to CD4+ T cells (266), though this is contradicted by work 
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from Lahouassa, et al again showing that presence of Vpr has little effect on viral 
replication in macrophages (238, 252, 266). Work done in our lab has shown significant 
donor-to-donor variability in replication of Vpr-deficient viruses in macrophages, with 
some donors displaying a replication defect for Vpr-deficient virus while macrophages 
derived from other donors showing no differences in replication between WT and Vpr-
deficient viruses (Akiyama, unpublished data). While these reports are confusing at best, 
what has been clearly defined in the literature is the effect of Vpr on replication in DCs. 
Our work, along with work from de Silva et al and Zhang et al are all in agreement that 
Vpr-deficient viruses replicate poorly in DCs, though the identified cause of this defect 
differs amongst the studies (184, 267). Our work identifies virion incorporated Vpr as 
being necessary for enhancing viral LTR-driven transcription in single round and 
spreading infection, possibly due to Vpr-mediated regulation of integration, whereas de 
Silva, et al identified de novo synthesized Vpr as being important for enhancing reverse 
transcription and viral LTR-driven transcription (184). Alternatively, work by Zhang, et 
al indicates that Vpr is important for proper Env production in DCs, implying that the 
replication defect only occurs over multiple rounds of replication (267). Published and 
unpublished work from our group suggests that this is not the case; I do not observe any 
differences in Env production in infected DCs and I cannot rescue replication with the 
ERAD inhibitors utilized by Zhang, et al in their studies (267).  
Together, there are still many unanswered questions about the role for Vpr during 
infection. My work focusing on Vpr function during infection of DCs, discussed in this 
document, attempts to clarify some of the controversies regarding Vpr and extend the 
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understanding of its function. It is my hope that with better understanding of the 
molecular mechanisms of infection, better therapeutics will be developed to counteract 
infections.  
Current therapeutic approaches 
Current pharmacological approaches targeting HIV-1 infection can be roughly 
divided into two main strategies, either targeting the virus early, during acute infection 
with high doses of HAART and latency limiting agents or targeting the virus during 
chronic infection using the “shock and kill” strategy (270). The “shock and kill” strategy 
utilizes latency reversing agents (LRAs) which target and reactivate latent virus in the 
host cell (270). After reactivation, it is thought that a combination of the host immune 
system and high doses of HAART could act to purge the virus from the infected 
individual, though to date no studies have achieved robust enough reactivation (270). 
Though both approaches have met with limited success in patients, they have provided 
important insights into HIV-1 pathogenesis that will help shape future therapeutic 
approaches (270).  
Treating with high doses of HAART and other pharmacological agents early, 
during acute infection, is becoming a popular area of study after a number of case reports 
of undetectable viral load in HIV-infected individuals (271, 272). HAART treatment can 
either be initiated at extremely high doses early post infection, like with the case of the 
recent “Mississippi baby” or coupled with an agent that limits seeding of a latent 
reservoir by killing or limiting the expansion of memory CD4+ T cells, such as 
hydroxyurea (273, 274). In the case of the “Mississippi baby,” an HIV-positive infant 
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was treated with high doses of HAART 30 hours after birth/viral detection and remained 
on the treatment for 18 months (274).  At this time, the child was removed from therapy 
because of lack of parental consent, after which she remained HIV-negative (within 
limits of detection) for 27 months before her virus rebounded (274). While the 
“Mississippi baby” was not cured like many scientists had hoped, she did show long 
lasting control of virus replication and provided insight into disease pathogenesis that 
may lead to better treatment regimens in the future (274). 
An alternative approach to the treat-early strategy is to couple HAART with 
another drug regime that limits seeding of a latent reservoir. One such agent, 
hydroxyurea, a cytostatic drug that halts the cell cycle in the G1 phase, has had mixed 
results (270, 273). There are several reports that early treatment with combination 
HAART/hydroxyurea can decrease viral load, in one case to undetectable levels (272). 
These studies are limited to few individuals, and while experiments in a SIVmac model of 
infection has reaffirmed these findings, use of hydroxyurea is not recommended due to 
possible liver and pancreatitic toxicity (275–277). Continued research is underway to 
determine if a treatment regimen coupled with hydroxyurea may be a viable therapeutic 
approach, as well as to identify other possible drugs with similar reservoir-limiting effect 
(270). Unfortunately, the treat-early approach will never work for many patients, since 
most HIV-positive individuals are not identified until they are in the chronic stage of 
infection (270).   
For chronic infection, the current therapeutic approach primarily under 
investigation is called the “shock and kill” strategy (270). During the “shock” phase, a 
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latency reversing agent (LRA) is used to reactivate HIV in latently infected cells so that 
they begin to make new virus (270). During the “kill” phase, either viral cytopathic effect 
or the host immune system will target and eliminate the infected, newly-transcribing cells 
(270). These therapies are employed while the patient remains on HAART to prevent 
reinfection and reseeding of the reservoir (270). Pharmacological agents under 
investigation include chromatin modifying compounds like histone deacetylate inhibitors 
or bromodomain inhibitors, cytokines like IL-7, and T cell activating compounds like 
phorbol 12-myristate 13-acetate (PMA) or anti-CD3/CD28, though use of pan-T cell 
activating agents is typically restricted to in vitro work (270). So far, clinical data from 
these studies has yielded mediocre results, likely due to incomplete viral reactivation by 
these compounds in vivo (270). Currently, there remains hope that development of better 
LRAs paired with multiple rounds of “shock and kill” could eventually purge viral 
reservoirs from infected individuals (270). Until now though, the only therapeutic 
strategy that has resulted in a functional cure was the result of a bone marrow transplant.  
Bone marrow transplants 
The only successful treatment to date has come from the treatment of high risk 
HIV+ patients with secondary malignancies (270, 278). In this singular case, the “Berlin 
patient,” later identified as Timothy Brown, underwent an aggressive combination 
treatment of ablative chemotherapy and radiotherapy to treat acute myeloid leukemia 
(270, 278). After which, he was placed on immune suppression drugs and received a 
allogeneic stem cell transplant from a donor who was homozygous for the ∆32 deletion 
of the CCR5 gene, shown to confer protection against HIV-1 transmission (270, 278). At 
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the time of therapy, HAART treatment was ceased, and his viral load since that point has 
remained undetectable in both his blood and tissues, even in the absence of HAART 
(270, 278). While there is some evidence that there may be some residual HIV infection 
in Mr. Brown, he remains the only successful case of a functional cure, where viral load 
is successfully controlled to an undetectable level by the host immune system.  
In order to understand the contribution of the ∆32CCR5 deletion, several other 
studies employing bone marrow transplantation have been conducted. One, conducted on 
two “Boston patients” utilized allogeneic stem cell transplantation from donors with wild 
type CCR5 alleles (279, 280). It was the hope that graft-versus-host response would 
rapidly eliminate the remaining virally infected cells within the infected individuals 
before the virus is able to spread to the engrafted immune system (279, 280). Post 
transplantation, both patients were kept on HAART to minimize the ability of the virus to 
spread to the transplanted cells (279, 280). Both had no detectable HIV DNA in the 
periphery while on antiretroviral therapy. Furthermore upon treatment interruption, 
patients remained HIV(-) for a period of 12 to 32 months (or weeks) post HAART 
interruption before viral rebound (279, 280). Together, this suggestion that stem cell 
transplant alone is inadequate to purge the latent host reservoir in the absence of a 
protective mechanism like the ∆32CCR5 deletion. Since the frequency of the ∆32CCR5 
deletion is low, ~1% of the Caucasian population is homozygous for it, alternative 
strategies, including gene therapy approaches, are being investigated for inducing 
protection from reinfection after stem cell transplants (270, 278).  
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Despite these rapid advances in stem cell therapy approaches, treatment is 
unlikely to provide a viable cure for most of the world’s HIV-positive population. High 
cost of care is highly restrictive, limiting treatment availability primarily to developed 
countries (270, 278). Additionally, the procedure is incredibly risky for patients and has a 
high mortality rate due to treatment complications and uncontrollable graft-versus-host 
disease (270, 278). Altogether, while advance in bone marrow transplant techniques may 
be able to provide a functional cure for some, it is likely that these procedures will remain 
limited, since patients are subject to high-risk secondary complications including bone 
marrow disorders and leukemias.  It is the hope of many researchers that development of 
pre-exposure therapeutics, like an effective vaccine, may help to stem infection in the 
absence of an accessible cure.  
Vaccine development 
Development of a broadly effective HIV-1 vaccine poses many challenges. 
Typically, vaccine development is modeled around mimicking a successful, sterilizing 
immune response in an infected host, but a sterilizing response to infection with HIV-1 
has never been reported (281, 282). With no information to determine what a protective 
immune response against HIV might look like, scientist and vaccine developers are at a 
severe disadvantage in the fight against HIV. The first challenge posed by the virus is its 
sheer diversity; there are nine clades that may vary as much as 45% at the amino acid 
level, which makes it difficult to design a vaccine that provides broad protection against 
many or all clades (18). Additionally, HIV-1 is able to rapidly mutate its surface exposed 
proteins in order to avoid detection by host antibodies, allowing the virus to escape 
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detection and neutralization by a primed host immune system (283–285). To date, there 
have been a handful vaccine trials in humans, only one of which has had any efficacy in 
protecting against infection and provided only mild protection, at best (282).  Current 
strategies in vaccine design are now frequently focusing on designing vaccines to illicit 
broadly neutralizing antibodies (bnAbs). 
Broadly neutralizing antibodies 
 The discovery of bnAbs has given new hope that long lasting protection against 
HIV is possible. BnAbs target and neutralize a broad range of gp120 trimers across all 
clades of HIV (282). Examples include PG9 and PG16 that neutralize approximately 80% 
of HIV strains, VRC-01 which neutralizes 90% and 10E8 which neutralizes 98% of 
tested HIV-1 viruses (282). Studies conducted to identify similarities between bnAbs 
have shown that they all target one of four conserved areas on gp120, either the 
membrane-proximal region of gp41 which anchors the protein to the viral membrane, the 
first or second variable region on gp120 which are highly mutable to prevent antibody 
recognition, the V3 region on gp120 which determines co-receptor usage, or the CD4 
binding site (286, 287). Additionally, these antibodies are also unique in containing 
extensive hypermutation and/or an unusually long complementary-determining region 
(282). These antibodies are exciting due to their potential therapeutic value. Studies using 
passive immunization against SHIV (chimeric simian-human immunodeficiency virus 
that encodes HIV-1 Env) challenges in non-human primates (NHPs) have shown robust 
protection against infection (282). Unfortunately, passive immunization with bnAbs is 
costly and time consuming for at-risk individuals, and thus is not practical for use as a 
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wide-spread therapeutic (282). An ideal therapy would be a vaccine that induces 
production of these broadly effective antibodies in the host (282). Unfortunately, their 
extensive hypermutation and long complementary-determining regions suggests that 
these antibodies come from B cells that have undergone significant affinity maturation in 
the presence of continuous antigen stimulation during chronic disease (282). Even 
amongst chronically infected individuals, they are quite rare, occurring in only 10-30% of 
individuals (282). Together, this suggests that stimulating production of bnAbs in vivo 
will be quite challenging. Despite challenges in therapeutic design, there have been some 
successes in development of strategies to prevent transmission. Pre-exposure prophylaxis 
(PrEP) has had enormous success in the prevention of transmission.  
Pre-exposure prophylaxis 
 PrEP is a relatively new strategy to counteract HIV-1 infection. PrEP is blanket 
term for one of several possible HAART regimens high risk individuals can take to 
reduce the potential of transmission of HIV-1 in the event of an exposure (288). 
Development of PrEP is based on work done using SIVmac models of transmission that 
characterized what dosing of antiretrovirals is required to provide protection from 
transmission, both pre- and post-exposure (289–292). Post-exposure studies indicated 
that 3-4 weeks of continuous HAART, initiated within hours of an exposure event is 
required to significantly reduce the likelihood of infection, which has come to be defined 
as the standard of care for accidental laboratory or hospital exposures (288, 293–295). 
Post-exposure studies in macaques have revealed two different antiretroviral regimens 
that are efficacious in human trials. The first requires a daily dose of either tenofovir 
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disoproxil fumarate (TDF) in combination with emtricitabine (FTC), also called Truvada, 
or TDF alone (296). Effectiveness of this approach has been shown in men who have sex 
with men (MSM), heterosexual men and women, serodiscordant couples, and injection 
drug users (297–300). In the iPrEx human trial in populations of MSM, daily dosing 
shows a 44% risk reduction overall (300). If the trial group is broken down further, this 
increases to 73% when limited to high self-reported adherence and 92% when drug was 
detectable in the plasma (300). While this trial and others like it have shown high efficacy 
under high adherence, daily PrEP is not without its faults. Tenofovir-based treatment is 
known to have potential side-effects including reduced bone density as well as renal 
toxicity in uninfected individuals (301–304). Sub-optimal drug adherence may also 
increase the prevalence of tenofovir-resistant HIV circulating in infected populations, 
ultimately limiting the long-term efficacy of PrEP (305) and the high cost of daily 
medication, especially during periods of low risk, remains a major hurdle for many at-
risk groups. Despite these downfalls, the WHO is now recommending daily PrEP for 
high-risk populations to combat the spread of HIV (306).  
 The second antiretroviral regimen developed is an event-based strategy that has 
individuals take antiretrovirals based on high-risk behavior or potential exposures. With 
event-based PrEP, two doses of Truvada are taken before intercourse and one dose per 
day for two days after (307, 308). Two studies, both PROUD and IPERGAY have 
investigated this efficacy in MSM populations and both reported an 86% reduction in 
HIV acquisition (307, 308). This approach has the advantage of using far less doses of 
Truvada than daily dosing and to-date has not produced any tenofovir-resistant mutations 
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(296). Additionally, there is lower risk of drug toxicity than daily dosing, reducing any 
long-term side effects of treatment (288). Event-based dosing is not without its pitfalls as 
well. There are concerns that the complexity of the regimen will lead to lower adherence 
and it is thought to be a less effective therapy in women due to low vaginal drug levels 
(288, 309). Currently this strategy is only recommended for MSM populations in certain 
areas of the world (296).  
Though research on viral protein functions and studies on viral life cycle in vitro 
have provided numerous approaches to therapeutic development, and a number of these 
therapies have provided clear benefit for HIV-infected individuals, a cure remains out of 
reach, primarily because of the ability of the virus to establish to a latently infected tissue 
reservoir that has proven difficult to purge.  
Dendritic cells: role in immune response 
HIV-1 infection of DCs is the primary focus of this work. DCs are critical sentinel cells 
that lie at the interface of innate and adaptive immunity (310). They are antigen 
presenting cells able to initiate T cell immunity and help develop B cell immunity (310). 
There are a number of different DC subsets, all with crucial roles in innate and adaptive 
immune response. Plasmacytoid DCs (pDCs) are a small subset of DCs that mostly 
localize to the blood and lymphoid organs (311, 312). They have a tightly controlled 
range of pattern recognition receptors that are specialized to enhance pathogen detection 
that results in production of ant-viral type I interferons (type I IFNs) (311, 312). 
Plasmacytoid DCs, more than any other cell, are able to make enormous quantities of 
type I IFNs in response to viral pathogen detection (311, 312). Conventional DCs (cDCs) 
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make up the other main class of DCs that localize to tissue compartments and are critical 
for T cell immunity (311, 312). Upon pathogen detection, these cells will enter the 
lymphatics and travel to the paracortical T cell zone of the regional lymph nodes, engage 
naïve T cells and initiate a specific T cell response to the detected pathogen (313). 
Conventional DCs also localize to the marginal zone of the spleen where they interact 
with blood to acquire circulating blood and tissue antigens for T cell presentation (311, 
312). The final subset are monocyte derived DCs (moDCs), also known as inflammatory 
DCs (311, 312). Unlike other subsets of DCs that differentiate from hematopoietic 
precursors, moDCs differentiate from circulating blood monocytes under inflammatory 
conditions or during infection (311, 312). These cells are the most abundantly studied 
human DC subset, due to the ease of isolation and creation ex vivo (311, 312, 314). 
Monocytes are relatively abundant in the circulating blood and can be isolated by CD14+ 
selection. They can then be differentiated in the presence of interleukin 4 (IL-4) and 
granulocyte-monocyte colony-stimulating factor (GM-CSF) to differentiate into MHCII+, 
CD11c+, CD25+ and DC-SIGN+ immature moDCs (311, 312). These cells can 
subsequently be matured with a variety of stimuli including LPS, IFNγ, TNFα and CD40 
ligand (311, 312). While they share many characteristics of cDCs, they remain an 
imperfect model and studies should be carefully conducted to reaffirm results in cDCs.  
Initiation of an immune response 
Initiation of a CD4- or CD8- immune response requires more than just MHC-
antigen recognition. A secondary signal is required in order to limit immune over-
reaction to an innocuous antigen (315). These secondary signals are typically provided by 
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the antigen presenting cell, either through co-stimulatory molecules on the cell surface or 
cytokine secretion (315, 316). Both of these responses are initiated in the antigen 
presenting cell by triggering one of a number of pathogen recognition receptors (PRRs) 
by a pathogen association molecular pattern (PAMP) (317, 318).  DCs are highly 
enriched in these pathogen detection molecules that allow them to sense and initiate an 
immune response in reaction to infection (317, 318). There are a number of different 
initiation proteins, present in the cytoplasm and endosomes as well as cell-surface 
exposed sensors on the plasma membrane (317, 318). These PRRs are able to detect 
conserved patterns on or within common pathogens including bacteria, viruses, fungi and 
parasites (317–322). Commonly detected PAMPs include surface structural molecules 
unique to bacteria or prokaryotic cells or viral nucleic acids (319–322). There are a 
number of different PRRs, including toll-like receptors (TLRs) which detect bacterial and 
viral proteins, glycans or lipids, and nucleic acid sensors such as, RIG-I-like receptors 
(RLRs) and cyclic GMP-AMP synthase (cGAS) which detect abnormal nucleic acid 
structures in the cytoplasm (319–322). All of these molecules result in initiation of 
signaling cascades that culminates in upregulation of co-stimulatory molecules and 
secretion of cytokines, though the exact response varies slightly based on which PRR is 
triggered (317–322). The ability of DCs to initiate an immune response to a foreign 
pathogen complicates their interactions with HIV.  
Role in HIV-1 infection 
It is a limitation of HIV research that most studies, ours included, have focused on 
interactions of the virus solely with moDCs, due mostly to ease of attainability (314). 
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Despite this, much has been discovered using ex vivo IL-4 and GM-CSF stimulated, 
moDCs as a model system for HIV infection (314). In general, CCR5-topic HIV-1 infects 
immature moDCs at a low but measurable level (Fig. 6) (184). This restriction is due 
primarily to the presence of the dNTPase SAMHD1, but it has also been reported that a 
low molecular weight form of APOBEC3G may play a role in viral restriction as well 
(179, 180, 323). SAMHD1 is present in DCs regardless of activation status and acts to 
lower dNTP pools, preventing successful reverse transcription (179–182). Alternatively, 
APOBEC3A is upregulated with maturation, and may be partially responsible for 
complete viral restriction that is observed in mature DCs (323, 324). In mature moDCs, 
additional restriction from the downregulation of CCR5 limits viral entry (323).  Viruses 
that do manage to enter and complete reverse transcription suffer from additional post-
integration restriction of viral transcription (323). In vivo studies of patient cohorts have 
been able to detect low levels of infected tissue DCs and studies using the SIVmac model 
of infection have shown that tissue resident DCs are amongst the first cells to become 
infected after exposure, indicating that they are relevant target cell for infection (61, 325). 
In addition to cis-infection, DCs mediate HIV trans-infection.  
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Figure 6. Summary of HIV-1 interactions with dendritic cells.  
Typical exposure to HIV-1 first occurs at mucosal surfaces. HIV can cross mucosal 
barriers, either through active transport or via cell associated transport. Once the virus is 
in the submucosal layer, it can interact with a number of tissue-resident immune cells that 
are directly susceptible to infection, including macrophages, CD4+ T cells, and immature 
DCs. Mature DCs, present because of either HIV- or non-HIV-related inflammatory 
signals can capture the virus with high efficiency. Both DCs and CD4+ T cells are 
migratory and will travel to nearby lymph nodes where there is a high concentration of 
target CD4+ T cells. Follicular dendritic cells in germinal centers will also capture and 
retain virus, increasing spread.   
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HIV trans-infection is the process by which DCs capture virus through surface 
receptor binding to a viral component and transfer it with high efficiency to target cells 
(Fig. 6) (326). This process is far more efficient than cell-free infection and is mediated 
almost exclusively by mature DCs (327, 328). It was originally thought that the surface 
receptor responsible for this interaction was dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN), which is capable of binding to lectins on 
the surface of the virion (329). DC-SIGN is expressed highly on immature DCs, which 
are poor conductors of trans-infection, and is downregulated with maturation (327, 328). 
Mature DCs instead utilize CD169, a type I IFN-induced cell surface protein that binds 
sialic acid residues on the lipid membrane of the virion (121, 122, 330, 331).  Our lab and 
others have characterized these interactions and have shown that CD169 binding to 
virions results in receptor clustering and formation of a surface-connected compartment 
that protects the virus until transmission to CD4+ T cells (332). Dissemination of virus 
via mature DC-mediated trans infection pathway may be a critical early step in 
establishment of infection in the peripheral mucosal tissues (Fig. 6).  
In this work, I have tried to address some of the unanswered questions regarding 
the role of Vpr in the HIV infection cycle. Based on what was reported by de Silva, et al 
(184) I hypothesized that infection of MDDCs might be a robust system to address some 
of the controversies and unanswered questions about the role of Vpr during infection. I 
found that infection of MDDCs with Vpr-deficient virus is attenuated as compared to 
wild type (WT) infection. MDDCs are a unique system in which to study Vpr function 
since they are the only cell type to consistently show differences in infection in the 
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absence of Vpr. I sought to determine what step of the viral life cycle was affected in the 
absence of Vpr, as well as clarify some of the controversial roles prescribed to Vpr during 
infection, including regulation of Env production and IFN induction.  
I also sought to determine whether the functions I characterized for HIV-1 Vpr in 
MDDCs were maintained in diverse primate lentiviral Vprs. As discussed above, Vpr is 
present in all primate lentiviruses, suggesting a critical function during in vivo infection 
(177, 196). Decreased pathogenicity has been seen in both SIVmac models of infection 
and cohorts of long term non-progressors that have mutations in Vpr (198, 218–220). I 
hypothesized that a critical function of Vpr would be conserved across lineages, similar 
to functions ascribed to Vif and Nef (140). In the process, I discovered a novel role for 
Vpr in regulating sensing of integration. In the absence of Vpr, I observe increases in the 
antiviral cytokine IFN, which would restrict replication in vivo (333–335). I propose that 
this function is critical for in vivo pathogenesis and the reason for maintenance of Vpr 
expression.   
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CHAPTER ONE 
Introduction 
HIV-1 encodes a number of proteins that allow for entry and replication in human 
cells.  In addition to the structural or enzymatic proteins that have well defined functions 
in the replication cycle, there are also a number of small, accessory proteins. Accessory 
proteins encoded by HIV-1 are not always necessary for replication in vitro, but are 
absolutely essential for replication in vivo (140). These proteins serve to counteract host 
restriction factors that would normally limit HIV-1 infection (140, 336). Of the accessory 
proteins encoded by HIV-1, Vpr is the only one whose function remains relatively 
unclear.  
Vpr is a small, 96 amino acid, 14 kDa protein that is packaged into the budding 
virion through associations with the p6 region of Gag (187, 191–194, 337–339). This 
association allows Vpr to be present in the cell at a relatively high quantity (~200-300 
molecules/virion) upon initial infection (340). Previous studies have extensively 
characterized the outcome of Vpr expression in various cell types. In cycling cells, Vpr 
expression results in G2/M cell cycle arrest which culminates in induction of apoptosis 
(206, 341, 342). It is well established that Vpr-mediated G2/M cell cycle arrest is 
mediated though its association with the Cul4A/DCAF/DDB1 E3 (CRL4DCAF1) ubiquitin 
ligase complex (224, 343, 344). In addition, HIV-1 Vpr recruits and degrades a number 
of DNA-damage response (DDR) proteins, including the SLX4-SLX1/MUS81-EME1 
structure-specific endonuclease complex (SLX4com), Uracil DNA glycosylase 2 
(UNG2), and helicase-like transcription factor (HLTF) (228, 236, 238, 239) via the 
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CRL4DCAF1 complex resulting in G2/M cell cycle arrest though it still remains unclear 
what role this process plays during HIV-1 infection.  
Though a number of previous studies have examined the requirement of Vpr on 
HIV-1 replication in various cell types, including primary CD4+ T cells and monocyte-
derived macrophages (MDMs), differences in virus replication have not been consistently 
observed (185, 236, 238, 266, 268, 269, 345). Vpr expression is dispensable for infection 
in activated CD4+ T cells in vitro (266, 268, 269, 345, 346), presumably due to the well 
characterized cytostatic and cytopathic functions of Vpr in cycling cells (341). In 
contrast, recent studies in MDMs suggest that Vpr is necessary for HIV-1 envelope (Env) 
expression, and the purported consequence of infection of MDMs with Vpr-deficient 
viruses was reported to be decreased viral production and reduced cell-to-cell spread to 
CD4+ T cells (252, 266). Notably, there has been considerable heterogeneity in 
replication differences between wild type and Vpr-deficient viruses and host responses to 
virus infection in MDMs, presumably due to donor and experimental variability between 
studies (186, 341, 347). Additionally, it has also been reported that Vpr expression in 
macrophages can both inhibit or induce type I interferon (IFN) responses (236, 252, 256, 
258, 265, 348).  
Dendritic cells (DCs) are sentinel cells that bridge innate and adaptive immunity 
(310). They actively patrol peripheral tissues, including mucosal sites of HIV-1 
transmission, in search of foreign pathogens. Because of this, MDDCs are among the first 
cells to interact with HIV-1 upon sexual transmission of the virus (61, 349–352). While 
MDDCs are less susceptible to infection than activated CD4+ T cells and macrophages, 
  
58 
they are still able to be infected ex vivo at a low but consistent level (184, 267, 353, 354). 
In contrast to work with MDMs and CD4+ T cells, there have been isolated descriptions 
of effects of Vpr on HIV-1 replicative capacity in MDDCs (184, 267), with no consensus 
on the mechanisms accounting for Vpr-mediated enhancement of virus replication. In this 
study, I use MDDCs as a model system to investigate the role of Vpr during infection. I 
found a robust replication defect of Vpr-deficient HIV-1 in MDDCs and, contrary to 
previous studies (267), the replication defect was not due to decreased Env expression in 
Vpr-deficient HIV-1 infected cells. Rather, the block to ΔVpr virus infection was at the 
step of viral transcription and could be rescued by addition of Vpr in trans into the virion 
in a single round infection analysis. I found that mutations, Vpr-Q65R and Vpr-H71R, 
which ablate association of Vpr with the CRL4DCAF1, or Vpr-R90K which does not 
induce G2 cell cycle arrest (201, 221, 222, 224, 355–357), displayed similar decreases in 
replication and viral transcription in single round of infection analysis. Together these 
data show a novel post integration block to HIV-1 replication in MDDCs at the point of 
viral transcription that is alleviated by virion-associated Vpr.  
 
Results 
Vpr-deficient viruses display a replication defect in DCs.  
HIV-1 replication in MDDCs is restricted at the reverse transcription step by 
SAMHD1 that controls the size of the cytosolic dNTP pools (179, 180). Despite the 
presence of SAMHD1, MDDCs remain susceptible to HIV-1 infection in vitro at a low 
but measurable level (267, 358–360). I infected MDDCs with replication competent wild 
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type (WT) or Vpr-deficient (∆Vpr) CCR5-tropic Lai-YU2 and harvested cells for 
intracellular p24Gag expression by flow cytometry analysis 3 days post infection. Input for 
these infections was normalized based on infectious titer of the viruses on TZM-bl cells. 
As expected, CD11c+ DC-SIGN+ MDDCs were susceptible to viral infection, albeit to 
low levels (Fig 7A and B). Interestingly, Lai-YU2/∆Vpr failed to establish a robust 
infection in MDDCs (Fig. 7A and B), and there was a reproducible 3- to 5-fold decrease 
in percentage of p24Gag+ cells in ∆Vpr virus infections as compared to WT virus 
infections (Fig. 7B). To determine the functional consequences of Vpr-deficiency on 
virus spread, DCs and PHA/IL-2-activated CD4+ T cells were infected with infectious 
viruses (MOI = 1) and cell-free culture supernatants were harvested every 3 days and 
analyzed for p24Gag content by an ELISA. While there was some donor variability, Lai-
YU2/∆Vpr infection of MDDCs derived from 3 independent donors consistently resulted 
in significantly lower levels of replication than wild type Lai-YU2 infection (Fig. 7C). In 
contrast to the substantial attenuation of virus spread in Lai-YU2/∆Vpr infected DCs, 
both viruses replicated to a similar extent in activated CD4+ T cells (Fig. 7E), in 
agreement with previously published studies (266, 268, 269, 345, 346). These results 
suggest that Vpr plays an important role in facilitating HIV-1 infection of DCs.  
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Figure 7. Infection with Vpr-deficient HIV-1 results in attenuated virus replication 
in MDDCs and MDDC-T co-cultures.  
(A) FACS profiles of mock infected MDDCs or MDDCs infected with Lai-YU2 or Lai-
YU2/∆Vpr (MOI =1) at day 3 post infection. Cells were stained for CD11c, DC-SIGN 
and p24Gag. From left to right, plots shown depict the gating strategy for the flow 
cytometry analysis and include plots of forward scatter/side scatter to exclude cellular 
debris, anti-CD11c/anti-DCSIGN staining to identify MDDC population, and DC-
SIGN/p24Gag staining to identify productively infected MDDCs in mock infected, or WT 
(Lai-YU2) and ∆Vpr infected DCs. (B) The mean (± SEM) percentage of DC-SIGN+ 
intracellular p24Gag positive MDDCs determined from infections of cells derived from 
three donors infected as in (A). (C) Replication kinetics of Lai-YU2 and Lai-YU2/∆Vpr 
in MDDCs infected at MOI =1. MDDC supernatants were harvested every three days and 
analyzed for p24Gag content by an ELISA. Data shown are the mean (± SEM) for three 
independent experiments with MDDCs derived from three independent donors. (D) 
Schematic of DC-T cell co-culture set up. MDDCs were infected with Lai-YU2 or Lai-
YU2/∆Vpr (MOI = 1). At two days post infection, autologous CD4+ T cells (PHA/IL2 
treated) were added at a 2:1 ratio to MDDCs or infected with cell-free virus in parallel 
(MOI = 1). Supernatants were harvested on day 6 and day 9 post infection (day 3 or 6 for 
cell-free CD4+ T cell infection), and the p24Gag content in the culture supernatants 
determined by an ELISA. (E) The data shown is the kinetics of p24Gag production in cell 
culture supernatants from a representative infection of MDDCs only, CD4+ T cell only or 
MDDC - CD4+ T cell co-cultures. (F) The mean (±SEM) p24Gag present in the 
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supernatant from five independent donor infections of CD4+ T cells only or DC-CD4+ T 
cell co-cultures at day 6 post infection (day 3 post infection for cell free CD4+ T cell 
infections). Significance calculated using paired student’s T tests where *p<0.05, 
**p<0.01, ***p<0.001. 
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Numerous studies have demonstrated robust HIV-1 replication in DC-T cell co-
cultures at levels greater than that observed in infections of either cell type alone, and is 
dependent on rapid highly efficient transmission of DC-derived progeny virions to CD4+ 
T cells across infectious synapses (326, 353, 354, 359–364). I sought to determine the 
effect, if any, of Vpr-deficiency on DC-mediated virus spread to CD4+ T cells. MDDCs 
were first infected with wild type Lai-YU2 or Lai-YU2/∆Vpr and cultured for two days, 
prior to initiation of co-culture with autologous activated CD4+ T cells (Fig. 7D). There 
was a substantial enhancement of virus replication in co-cultures infected with WT virus, 
compared to ∆Vpr virus infections (Fig. 7E and F; ~7-fold increase).  Interestingly the 
difference between WT and ΔVpr virus replication in DC-T cell co-cultures was greater 
than that observed in infections of MDDCs or CD4+ T cells alone (Fig. 7E and F). 
Together, these results suggest that the replication defect observed in MDDCs infected 
with HIV-1/ΔVpr translates to CD4+ T cells during cell-to-cell contact and transmission.  
 
Defects in Vpr infection are independent of viral glycoprotein expression.  
Previous studies have suggested a requirement for Vpr in maintaining robust 
HIV-1 gp120 expression in MDMs and MDDCs by counteracting a myeloid cell-intrinsic 
mechanism of Env degradation (252, 266, 267). To begin to understand the underlying 
mechanism accounting for the replication defect of HIV-1/ΔVpr in DCs, I examined viral 
protein expression in MDDCs infected with wild type Lai-YU2 or Lai-YU2/∆Vpr (MOI 
= 3). Infected cells were lysed 6 days post infection for quantitative western blot analysis. 
I did not observe any steady-state differences in gp120 expression when normalized to 
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Gag (p55 and p24) levels in MDDCs infected with WT or ΔVpr viruses (Fig. 8A). 
Quantification of immunoblots from infected MDDC lysates derived from four 
independent donors showed no significant differences in gp120 expression (Fig. 8B). I 
next sought to determine if Vpr-deficiency might result in decreased gp120 incorporation 
in virus particles derived from productively infected DCs. MDDC culture supernatants 
were harvested on multiple days post infection and pooled supernatants were 
concentrated over a sucrose cushion prior to western blot analysis. I again failed to 
observe any significant differences in levels of gp120 incorporation between virus 
particles derived from WT or ΔVpr infected MDDCs (Fig. 8C and D). The consistency of 
the replication defect of HIV-1/ΔVpr virus in MDDCs in the absence of any significant 
differences in gp120 expression suggests that previously hypothesized Vpr-dependent 
enhancement of gp120 production is unlikely to account for the observed replication 
defect in the present study (252, 267).  
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Figure 8. Vpr does not regulate Env expression in infected MDDCs or incorporation 
of Env into MDDC-derived virions.  
(A) Western blot analysis of mock infected, Lai-YU2 (WT) or Lai-YU2ΔVpr infected 
MDDCs (MOI = 3) for p55Gag and gp120 expression at day 6 post infection. (B) 
Quantification of western blots for p55Gag and gp120 in infected MDDCs as in (A) from 
four independent experiments. The gp120 band intensity was quantified and normalized 
to p55Gag from experiments with infected MDDCs derived from 4 donors. Data shown are 
mean (± SEM). (C) Western blot analysis of p24Gag and gp120 expression in mock 
infected, Lai-YU2 (WT) or Lai-YU2ΔVpr infected MDDCs (MOI = 5). MDDC culture 
  
66 
supernatants were harvested at days 3, 6, and 9 post infection, pooled and concentrated 
over a 20% sucrose cushion and virus pellets lysed for western blot analysis. (D) 
Quantification of western blot analysis from MDDC-derived virions from three 
independent donors. The band intensity for gp120 was quantified and normalized to 
p24Gag band intensity. Data shown are mean (± SEM). Significance calculated using a 
one sample T test where N.S>0.05. 
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Infection with Vpr-deficient HIV-1 does not induce type 1 IFN.  
Exposure of target cells to type I IFN potently restricts HIV-1 replication in vitro 
(243, 245, 333–335, 365–368). In addition, recent studies have suggested that infection 
with ∆Vpr virus induces type I IFN (236, 252, 256, 258, 265, 348). Hence, I sought to 
determine if induction of an early type I IFN response in HIV-1/∆Vpr infections of 
MDDCs accounts for the restricted virus replication and spread. MDDCs infected with 
wild type Lai-YU2 or Lai-YU2/ΔVpr virus were harvested 48 h post infection, and the 
mRNA expression levels of IFNβ and the type I IFN-inducible protein, interferon-γ-
inducible protein 10 (IP-10) were quantified by qRT-PCR. At 48 h post-virus exposure, I 
did not detect significant increases in IFN-β mRNA levels in wild type or ΔVpr infected 
cells compared to mock infected cells (Fig. 9A). While expression of the ISG, IP-10, was 
robustly induced by establishment of productive HIV-1 infection of DCs, differences in 
IP-10 mRNA levels between WT and ΔVpr virus infections were not statistically 
significant (Fig. 9B). Note that pre-treatment of cells with azidothymidine (AZT) reduced 
induction of IP-10 mRNA levels to that observed in mock infected cells, suggesting that 
induction of IP-10 expression in virus-exposed cells was dependent on de novo reverse 
transcription. In contrast, LPS treatment of MDDCs for 4 hours resulted in robust 
increases of both IFN-β and IP-10 mRNAs (Fig. 9A, B). Inability to detect differences in 
mRNA expression levels of IFNβ in MDDCs infected with WT and ΔVpr viruses was 
also mirrored with the absence of differences in protein levels in infected MDDC culture 
supernatants (data not shown).  I used a sensitive bioassay to measure type I IFN 
production in infected MDDC supernatants, and failed to detect any type I IFN 
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production in HIV-1 infected MDDCs over mock infected controls (data not shown) 
(369). In contrast, IP-10 was robustly secreted in both Lai-YU2 (WT) and Lai-YU2ΔVpr 
infected MDDC culture supernatants at day 3 post-infection, though the magnitude of IP-
10 induction was donor-dependent (Fig. 9C). Furthermore, I observed a significant 
increase in IP-10 production upon WT virus infection of MDDCs as compared to mock-
infected cells (Fig. 9C). Again, AZT pre-treatment reduced secretion of IP-10 indicating 
that IP-10 production is dependent on completion of reverse transcription (Fig. 9C). 
Taken together, these results suggest that Vpr deficiency does not result in the induction 
of type I IFNs during establishment of productive HIV-1 infection of MDDCs and is 
unlikely to play a role in the restriction of HIV-1/∆Vpr in DCs.  
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Figure 9. Vpr-deficiency does not result in enhanced type I IFN production in 
productively infected MDDCs.  
Quantitative RT-PCR for IFNβ (A) and IP-10 (B) transcripts in infected MDDCs at 48 
hours post infection. MDDCs were mock-infected or infected with Lai-YU2 or Lai-
YU2/∆Vpr (MOI = 2) in the presence or absence of AZT (10 µM). The amount of IFNβ 
or IP-10 transcripts in infected MDDCs was normalized to the number of cells using a 
GAPDH control, and reported as relative to that of mock infected MDDCs (set as 1) for 
four independent donors. LPS treatment for 4 hours was used as a positive control for 
IFNβ and IP-10 production. Data is the log-transformed mean (± SEM) of seven donors. 
(C) Secreted IP-10 in MDDC culture supernatants infected with Lai-YU2 or Lai-
YU2/∆Vpr (MOI = 1) at day 3 post infection was measured by an ELISA. The data 
shown are the log-transformed mean (± SEM) of independent experiments with MDDCs 
derived from four donors for (A) and (B) and six donors for (C). Significance calculated 
using a paired student’s T test or a one value T test (when comparing normalized data) 
where N.S>0.05, *p<0.5, **p<0.1, ***p<0.01, ****p<0.001, *****p<0.0001. 
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Infection with ∆Vpr viruses results in decreased infection in a single round of replication 
and is rescued by virion-associated Vpr.  
To identify the step of the virus replication cycle in MDDCs that is affected by 
Vpr, I next performed single cycle of infection analysis. MDDCs were infected with 
HIV-1 reporter viruses pseudotyped with VSV-G and expressing luciferase upon 
establishment of infection that do (Lai-luc ∆env/G or WT) or do not express Vpr (Lai-luc 
∆env/G ∆Vpr or ΔVpr). Infection with ΔVpr virus resulted in a 3- to 5- fold decrease in 
luciferase expression compared to infection with WT virus (Fig. 10A), suggesting that 
Vpr acts early in the HIV-1 replication cycle in MDDCs at steps preceding virion 
assembly and maturation. Since Vpr is a virion-associated protein, I next sought to 
determine whether incoming virion-associated Vpr was sufficient or if de novo 
synthesized Vpr was required for enhancement of virus replication in DCs. I produced 
Lai-luc ∆env/G ∆Vpr complemented with HA-epitope tagged Vpr in trans (Lai-luc 
∆env/G Vpr-trans) via co-transfection of HEK293T cells with a functional HA-Vpr 
expression plasmid and the Lai-luc∆env/G ∆Vpr proviral plasmid. HA-Vpr was 
efficiently incorporated in ΔVpr virus particles to levels similar to that observed in WT 
virus particles (Fig. 10B). I then infected MDDCs with Lai-luc ∆env/G-WT, ΔVpr, or 
Vpr-trans viruses and lysed the cells on day 3 post-infection. Incorporation of Vpr in 
trans within incoming virus particles rescued ΔVpr virus infection in a single-round 
assay (Fig. 10C), suggesting that virion incorporated Vpr is sufficient for overcoming 
cell-intrinsic blocks to early steps in HIV-1 replication in DCs.  
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Figure 10. Infection of MDDCs with Vpr-deficient viruses results in block to HIV-1 
replication in single round infection analysis.  
(A) MDDCs infected with 40 ng p24Gag equivalent of VSV-G pseudotyped Lai-luc ∆env 
(WT or ∆Vpr) were lysed 3 days post infection, and viral replication was quantified by 
measuring luciferase activity in cell lysates. The luciferase activity in ΔVpr infected cell 
lysates was normalized to that of WT virus-infected MDDC lysates and reported as mean 
(± SEM) of four independent experiments with MDDCs derived from four independent 
donors. (B) Western blot analysis of Vpr incorporation in virus particles (Lai-luc ∆env/G, 
Lai-luc ∆env/G ∆Vpr, or Lai-luc ∆env/G Vpr-trans) derived from transient transfection 
of HEK293T cells. (C) MDDCs were infected with 40 ng p24Gag equivalents of viruses 
(Lai-luc∆env, Lai-luc∆env∆Vpr, or Lai-luc∆env∆Vpr + HA-Vpr), and lysed 3 days post 
infection. Cell lysates were analyzed for luciferase activity and the data reported is 
normalized to that observed with WT-virus infection and is mean (± SEM) from 4 
independent experiments. Significance calculated using a paired student’s T test or a one 
value T test (when comparing normalized data) where *p<0.05, **p<0.01. 
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Proviral LTR-mediated transcriptional activity is attenuated in Vpr-deficient virus 
infection in DCs.  
Since the block to HIV-1/∆Vpr infection in MDDCs is evident within a single 
round of replication, and is independent of the mode of virus entry (VSV-G pseudotyped 
virus infection was also restricted, Fig. 10A), I assessed the effect of Vpr-deficiency on 
HIV-1 reverse transcription (RT) and integration efficiency in DCs. I used qPCR to 
measure RT-products and the number of proviruses at day 3 post-infection using R-U5 
and Alu-Gag primer pairs, respectively (370, 371). Infections were also performed in the 
presence of AZT to control for contaminating input plasmid DNA. In contrast to 
previously published findings (184), I saw no decrease in the number of RT products 
(Fig. 11A) or integrants (Fig. 11B, C) upon infection with ΔVpr virus compared to WT 
virus infections (Fig. 11A, B and C). Previous studies have suggested that Vpr can 
modulate HIV-1 LTR transcriptional activity (186, 200, 201, 204, 372). I therefore asked 
if the block to HIV-1/∆Vpr infection occurs at the stage of viral transcript production. To 
determine the effect of Vpr on LTR-mediated transcription from proviruses, I used qRT-
PCR to measure multiply-spliced tat/rev/nef transcripts at 48 h post infection (Fig. 11D). 
Similar to my findings with luciferase reporter expression in infected DCs, I observed a 
4-fold decrease in the number of multiply-spliced HIV-1 transcripts in HIV-1/∆Vpr-
infected cells suggesting that Vpr-deficiency results in inhibition of proviral LTR-
mediated transcription in DCs.  
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Figure 11. Viral transcription is attenuated in ΔVpr virus infected MDDCs.  
(A-C) MDDCs infected with WT or ΔVpr viruses (MOI = 2) in the presence or absence 
of AZT (10 µM) were lysed 72 h post infection, and processed for DNA isolation. Note 
that infected cells were cultured in the presence of indinavir (1µM) to prevent viral 
spread. QPCR was used to detect early RT products (A) and integrated proviruses (B) by 
R-U5 and Alu-PCR primer sets and the number of integrated proviruses normalized to 
early RT products for each infection is shown in (C). The data reported is the mean (± 
SEM) of three independent experiments. (D) The numbers of multiply-spliced viral 
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transcripts (tat-rev-nef) in MDDCs infected with Lai-YU2 or Lai-YU2/∆Vpr (MOI = 1) 
was determined at 48 hours post infection by qRT-PCR. Viral transcripts were measured 
using primers specific to tat/rev/nef multiply-spliced transcripts. Data shown are mean (± 
SEM) of four independent experiments with MDDCs derived from four donors. (E) 
Quantification of 4 kb class of splice variants for MDDCs infected with Lai-YU2 or Lai-
YU2/∆Vpr (MOI = 2) for 72 hours. The data was normalized, log10 transformed, and 
then graphed according to slice acceptor usage. Histograms show fold changes in splicing 
from D1 to each of the 5 viral splice acceptor sites A1 through A5 relative to a WT 
control.  Splicing was quantified using a PrimerID-splicing assay for MDDCs from two 
independent infections (e), productively infected CD4+ T cells (F) and HeLa cells (G) and 
is data from a single deep sequencing experiment. Significance calculated used unpaired 
student’s T test where *p<0.05, **p<0.01, and ***p<0.001. 
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I next sought to determine if the decrease in multiply-spliced viral mRNA levels 
in HIV-1/ΔVpr-virus infected MDDCs were driven by changes in the pattern of viral 
mRNA splicing. I, with the help of collaborators used a novel PrimerID-tagged deep 
sequencing assay (373, 374) to determine the relative abundance of different splice 
variants in WT and ΔVpr infected DCs, and compared viral splice site usage to that 
observed in WT or ΔVpr-infected CD4+ T cells and HeLa cells (Fig. 11E-G). Data 
depicts the relative quantity of 4 kb singly-spliced mRNA for each splice acceptor and is 
reflective of the changes observed in the 1.8 kb multiply-spliced mRNA (data not 
shown). We detected minor differences in splice acceptor usage between WT and ∆Vpr 
infections in MDDCs. We observed small decreases in the use of the Vif [A1] and Vpr 
[A2] splice acceptors and a small increase in the use of the Tat [A3] splice acceptor, but 
these differences were well within the normal range of splicing variation seen in 
productive viral infections (374). These small differences in splice site usage were 
consistently observed in infections of CD4+ T cells and HeLa cells.  Since the differences 
in splicing are both relatively small and observed in two cell types (primary activated 
CD4+ T cells and HeLa cells) that do not restrict ∆Vpr virus replication, it is unlikely that 
efficiency of viral mRNA splicing or choice of mRNA splice acceptor sites is a 
contributing factor to the restricted replication of ΔVpr virus in MDDCs. 
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Mutations in the C-terminal end of Vpr or those that disrupt binding to CRL4DCAF1 
ubiquitin ligase attenuate viral replication in DCs.  
A range of functions have been attributed to Vpr, including G2/M cell cycle 
arrest, enhancing fidelity of reverse transcription, nuclear import and/or nuclear tethering 
of the pre-integration complex, and induction of apoptosis (184, 201, 206, 341, 342, 347, 
375). To clarify which of the known functions of Vpr are important for enhancing HIV-1 
replication in DCs, a panel of mutations were introduced in Vpr ORF with previously 
characterized effects on Vpr functions. HEK293Tderived virus particles were analyzed 
by quantitative western blotting to assess incorporation of mutant Vpr proteins into viral 
particles (Fig. 12A). While all viral mutants expressed and incorporated Vpr in virus 
particles, the mutants Vpr-F34I and Vpr-H71R had slightly decreased incorporation 
levels of Vpr compared to wild type viruses (Fig. 12A), though both wild type and Vpr-
mutant viruses were equally infectious on TZM-bl cells on a per particle basis (Fig. 12B). 
MDDCs were infected with replication competent HIV-1 (WT or Vpr-mutants) at equal 
MOIs and the extent of viral replication was measured by periodic quantification of 
p24Gag in cell-free culture supernatant by an ELISA (Fig. 12C). Since there was donor-to-
donor variability in the kinetics and extent of virus replication in DCs, I calculated the 
area under the curve of replication kinetics obtained from four independent infections 
(Fig. 12D). As depicted in Fig. 12C and D, infection with both Vpr-Q65R and Vpr-H71R 
mutant viruses resulted in significantly attenuated virus replication and spread, similar to 
what was observed with ΔVpr virus replication in MDDCs (Fig. 12C and D). In contrast, 
replication of both Vpr-F34I and Vpr-W54R mutants was not significantly different from 
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that observed with wild type virus infections (Fig. 12C and D). Cumulative analysis 
revealed that replication of Vpr-Q65R and Vpr-H71R mutants, which lack the ability to 
associate with the CRL4DCAF1 complex (201, 222, 224, 235, 236, 344, 347, 355, 376), 
was significantly reduced (p<0.01), similar to that observed with ΔVpr virus infection 
(Fig. 12D). Interestingly, replication of Vpr-F34I mutant which incorporates reduced 
levels of Vpr in virions (Fig. 12A), and displays reduced association with the nuclear 
envelope, (347, 355, 357) was slightly enhanced over that observed with wild type virus 
replication (Fig. 12D; p<0.01), suggesting a threshold amount of functional Vpr that is 
still present in the incoming virus particle is sufficient for establishment of productive 
infections in DCs. The mutation Vpr-W54R, which ablates binding of Vpr to UNG2 
(228, 230, 232, 235, 355) had a negligible effect on viral replication in DCs.  
I next sought to determine which of these Vpr mutants could recapitulate the 
single cycle of replication defect observed with HIV-1/ΔVpr infection in MDDCs (Fig. 
10A). I infected MDDCs with either replication competent viruses (Lai-YU2, WT or Vpr 
mutants, MOI = 1) in the presence of a protease inhibitor (indinavir) or with equal 
amounts of p24Gag equivalents of Lai-luc ∆env/G encoding the various Vpr mutations. 
Similar to the results observed with replication competent viruses, both the number of 
p24Gag-postitive cells (Fig. 12E) and luciferase production (Fig. 12F) from infections with 
Vpr-Q65R and Vpr-H71R mutants were significantly attenuated in a single round of 
infection compared to isogenic WT viruses. While the host protein targeted by HIV-1 
Vpr to induce G2 cell cycle arrest has not been identified, the C-terminal tail of the 
protein has been proposed to bind the unknown host factor, and mutations in the C-
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terminal tail of Vpr abrogate the ability of Vpr to induce G2 cell cycle arrest (355).  To 
determine the role of Vpr-mediated G2 cell cycle arrest on virus infection enhancement 
in DCs, an additional mutation, Vpr-R90K was introduced in GFP-expressing single-
cycle virus (Lai-GFP ∆env/G). The Vpr-R90K mutant can bind CRL4DCAF1 complex but 
fails to induce G2 arrest in cycling cells (235, 355, 357). Despite equivalent incorporation 
into the virion as WT Vpr (Fig. 12G), infection of MDDCs with Vpr-R90K mutant 
resulted in significant infection defect in single round analysis (Fig. 12H), similar to what 
was observed in infections with ∆Vpr or Vpr-Q65R viruses, suggesting that interaction 
with a putative host factor whose degradation is critical for the induction of G2 cell cycle 
arrest is required to enhance HIV-1 infection of DCs. Together, my data suggests that 
there is a novel block to HIV-1 infection in MDDCs in the absence of Vpr that is present 
in a single round of infection and manifests at the stage of viral transcription. Further 
studies are underway to determine the exact mechanism by which Vpr alleviates the DC-
intrinsic block to HIV-1 replication.  
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Figure 12. Vpr mutants deficient for interaction with DCAF1/DDB1/E3 ubiquitin 
ligase and inducing G2 cell cycle arrest are attenuated in a single cycle of replication 
analysis in MDDCs.  
(A) Representative western blot analysis of HEK293T- derived Lai-YU2 (WT) and 
indicated Vpr mutant viruses used for MDDC infections. Blots were probed with anti-
p24Gag, anti-Vpr and anti-gp120 antibodies. (B) Infectivity of Lai-YU2 and corresponding 
Vpr mutants in TZM-bl cells is reported as the number of infectious units (blue cells) per 
ng of p24Gag equivalent and are the mean (± SEM) of three independent viral 
preparations. (C) Viral growth curves of four independent infections of MDDCs with 
Lai-YU2 and indicated Vpr mutants in DCs. Viral growth was determined by analyzing 
p24Gag release into cell culture supernatants at days 3, 6, 9 and 12 post infection and 
determined by ELISA. (D) Area under the curve compiled for four independent MDDC 
infections represented in (C) normalized to WT virus infection, set as 1 (mean ± SEM). 
(E) The percentage of p24Gag positive MDDCs at day 3 post infection as measured by 
intracellular p24Gag staining and FACS analysis. Cells were treated with indinavir (1 µM) 
post virus exposure to prevent viral spread. The data was normalized to WT virus 
infection, set as 1, and depicts the mean (± SEM) of three independent infections of 
MDDCs from three donors. (F) MDDCs infected with 40 ng p24Gag equivalents of Lai-
luc ∆env/G (WT or Vpr mutants) were lysed 3 days post infection, and viral replication 
was quantified by measuring luciferase activity in cell lysates. The luciferase activity in 
Vpr-mutant infections was normalized to that of WT virus infections, set as 1, and the 
data shown are the mean (± SEM) for three independent experiments. (G) Western blot 
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analysis of HEK293T-derived Lai-GFP ∆env/G (WT) or indicated Vpr mutant virus 
particles. (H) MDDCs infected with Lai-GFP ∆env/G (WT) or indicated Vpr-mutants 
(MOI = 3) were harvested at day 3 post infection and processed for FACS analysis. The 
data shown is the mean percentage of GFP+ cells (± SEM) of five independent 
experiments with cells derived from five independent donors. Significance calculated 
using a paired student’s T test or a one value T test (when comparing normalized data) 
where *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Discussion 
 In the work presented here, I examined the role of Vpr in establishing productive 
HIV-1 infection of DCs. Previous work in the field suggests that Vpr likely regulates a 
complex network of host interactions that may vary depending on the cell type infected. I 
find that, unlike what has been previously observed in activated CD4+ T cells and MDMs 
(186, 238, 266, 268, 269, 345), infection of MDDCs with ∆Vpr viruses was significantly 
attenuated when compared to WT HIV-1 infections (Fig. 7), similar to the findings 
reported by de Silva et al (184). Interestingly, Vpr-mediated enhancement was observed 
within both a single round viral infection as well as in spreading infections, contrary to 
what has been reported previously (184, 252). Furthermore, the single round replication 
defect could be rescued by complimenting back Vpr in trans in the incoming virion (Fig. 
10) indicating that incoming virion-associated Vpr is necessary for the establishment of 
efficient HIV-1 infection of DCs. Initiating infections with the Vpr mutants, Vpr-Q65R, 
Vpr-H71R and Vpr-R90K that either lack the ability to engage the CRL4DACF1 complex 
or bind the yet-to-identified host factor(s) necessary for inducing G2 cell cycle arrest, 
displayed similar replication deficits to that observed with ∆Vpr virus in both spreading 
infections and single round infection analysis (Fig. 12).  
 Surprisingly, the block to ΔVpr virus replication in MDDCs was evident at a post-
integration step and resulted in reduced numbers of viral mRNAs, suggesting that Vpr is 
acting either directly or indirectly to enhance transcription from the viral LTR (Fig. 11). 
It has been reported previously that Vpr can transactivate the viral LTR in a number of 
cell types and that this function correlates with the ability of Vpr to induce G2 cell cycle 
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arrest (185, 186, 200, 201, 372). Previous studies have also shown that both SIVmac and 
SIVagm Vpr can also transactivate their respective LTRs (204, 205, 377), suggesting that 
this is a conserved function among non-human primate lentiviral Vpr proteins. While it is 
possible that Vpr-mediated transactivation could be more robust in DCs than in CD4+ T 
cells (Fig. 7E), another hypothesis is that Vpr is indirectly activating transcription to 
promote infection in cells that have a higher barrier to infection.  
Unlike most of the other lentiviral accessory proteins, Vpr is actively packaged 
into the budding virion through associations with the p6 region of Gag (187, 191, 194, 
337, 339). Our work in MDDCs suggests that there may be a novel role for virion-
associated Vpr to enhance viral transcription and increase infection of DCs. These 
findings are at odds with recently published studies on the role of Vpr in modulating de 
novo HIV-1 Env production in productively infected macrophages and MDDCs (252, 
267). While I do occasionally see a decrease in viral Env production during infection 
with ΔVpr virus in MDDCs (one out of four donors tested), infection of MDDCs from 
most of the donors revealed no differences in Env expression or virion incorporation (Fig. 
8). It is possible that the use of different viral clones, primary cell variation derived from 
multiple donors, or different infection conditions might play a role in the differences 
between my results and those described previously. Since I observed infection differences 
in a single-round infection assay, putative effects of Vpr on Env expression are unlikely 
to play a role in establishment and spread of virus infection in MDDCs and DC-T cell co-
cultures. 
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HIV-1 is not unique among primate lentiviruses in expressing a protein that 
functionally allows for infection of DCs. HIV-2 and certain SIV lineages express Vpx, 
another small accessory protein that targets host restriction factor SAMHD1 for 
proteasomal degradation by recruiting it to the CRL4DACF1 complex, and facilitates 
infection of MDDCs (179, 180, 378). Interestingly, Vpr-mediated replication 
enhancement in MDDCs was substantially attenuated upon infection with Vpr mutants 
(Q65R or H71R; Fig. 12F) that lack ability to interact with CRL4DCAF1 complex, or upon 
infection with Vpr-R90K mutant (Fig. 12H), that fails to interact with the host factor(s) 
hypothesized to be recruited to the CRL4DCAF1 complex for proteasomal degradation. 
Since Vpr is introduced into target cells along with the incoming virion because of its 
association with the viral capsid, I hypothesize that early interactions of Vpr with a host 
factor and recruitment of that protein to the CRL4DCAF1 complex for proteasomal 
degradation is essential for promoting HIV-1 replication in DCs, similar to the ability of 
Vpx from SIVmac/SIVsmm/HIV-2 lineages to promote infection of DCs.  
 Across primate lentiviral Vpr evolution, induction of DDR and G2 cell cycle 
arrest are conserved functions, and Vpr proteins from diverse primate lentiviruses have 
been shown to associate with and degrade many DDR regulatory proteins including the 
SLX4com, HLTF, and UNG2 (228, 229, 232, 234–239, 379). While DDR activation may 
represent a cell-intrinsic antiviral response, it has been suggested that both RNA and 
DNA viruses induce DDR signaling to promote cellular conditions that are favorable for 
viral replication (205, 207, 208, 380, 381). For instance, induction of DDR signaling 
activates ataxia-telangiectasia mutated (ATM) kinase which results in nuclear factor 
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kappa-light-chain-enhancer of activated B cells (NF-κB) activation (382, 383). 
Additionally, the DDR pathway also directly activates pro-inflammatory responses 
through the induction of interferon regulatory factors (IRFs) or through the recruitment of 
co-activators and chromatin modifying complexes, such as ten-eleven translocation 
methylcytosine (TET) dioxygenases, which I hypothesize might also activate viral 
transcription (384). Since the barrier to successful establishment of infection in non-
cycling, metabolically quiescent cells like MDDCs is higher than that in activated CD4+ 
T cells or MDM, Vpr-mediated activation of NF-κB and co-activator recruitment to the 
viral LTR might be a viral strategy for overcoming the restrictive cellular environment 
and for optimal production of progeny virions.  In line with this hypothesis, numerous 
studies have documented that Vpr is able to modulate NF-κB activity in different cell 
lines and primary cells, though these studies rarely agree on the mechanism of regulation 
or direction of modulation (185, 253, 254, 372, 385–388). Recent work from Höhne, et al 
has shown similar effects of Vpr on viral replication in non-activated primary CD4+ T 
cells, which have similar barriers to infection as MDDCs including increased expression 
of SAMHD1 and low baseline NF-κB activity (183, 185, 389). Some studies have shown 
virion-associated Vpr-dependent activation of NF-κB occurs via a transforming growth 
factor-β-activated kinase 1 (TAK1) signaling cascade, while other studies have shown 
that secreted or synthetic Vpr stimulates NF-κB signaling through a TLR4-dependent 
mechanism (253, 254, 372, 387). My data also demonstrates upregulation of IP-10 upon 
HIV-1 (WT) infection (Fig. 9C) which is also dependent on NF-κB activation (390–
392).These results suggest a link between Vpr-mediated NF-κB activation in MDDCs 
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and enhanced viral gene expression and pro-inflammatory cytokine secretion, which may 
act in vivo to enhance recruitment, activation and infection of CD4+ T cells, resulting in 
increased viral dissemination (Fig. 7E) (346, 372, 387).  
Studies with peripheral blood myeloid MDDCs and monocyte-derived MDDCs 
from HIV-1 elite controllers have shown that these cells may be critical for viral control, 
acting to capture virus and enhance T cell-specific immunity to HIV-1, while being less 
susceptible to HIV-1 infection compared to MDDCs from healthy controls (393, 394). 
Understanding the mechanisms that control HIV-1 replication in MDDCs which are 
overcome by Vpr, might lead to new insights on viral dissemination and persistence in 
vivo, and development of novel anti-HIV-1 therapeutics. 
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CHAPTER TWO 
Introduction 
 During the course of the HIV-1 replication cycle, viral genomic RNA is reverse 
transcribed to dsDNA, which is incorporated into the host cell genome via a virally 
encoded integrase. Due to poorly defined restrictions to virus integration or because of 
actions of host DNA repair machinery, fully reverse transcribed viral DNA can be 
maintained as linear DNA or as recombination circles (395).  These circles are the result 
of two different types of recombination events. Non-homologous end joining (NHEJ) 
results in the joining of the ends of linear viral DNA, forming 2-LTR circles and 
homologous recombination at the viral LTRs results in the looping out of one of the 
LTRs, forming 1-LTR circles (395). While linear viral DNA is degraded with time via 
the action of nuclear exonucleases, 1-LTR and 2-LTR circles are relatively stable and 
only decrease with cell death or division (396, 397). All three forms of unintegrated DNA 
can be transcribed to make new viral proteins and virions which can spread to 
neighboring cells (398). Mathematical models predicting the relative contribution to 
infection of unintegrated DNA could be as high as 20% in vivo (399). Clinical studies 
have shown that the majority of viral DNA in patient cells is episomal and that 
accumulation of unintegrated DNA in neuronal tissue is associated with development of 
AIDS-related dementia, suggesting that these forms of extrachromosomal DNA are  
relevant to in vivo pathogenesis (400–403). Furthermore, with the use of integration 
inhibitors as part of HAART regimens, the accumulation of unintegrated HIV DNA and 
its role in HIV pathogenesis needs to be carefully explored.(395).  
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Expression from unintegrated HIV-1 DNA has been described and a number of 
groups have correlated expression from unintegrated DNA with the presence of Vpr (404, 
405). Whether Vpr regulates expression of unintegrated DNA in primary cells and if the 
function of Vpr is conserved in other primate lentiviruses is not known (406, 407). Here, 
I characterize the ability of HIV-1 Vpr to enhance expression from unintegrated DNA in 
diverse cells, including primary human MDDCs, human MDMs, murine BMDCs and 
murine BMDMs. In the presence of Vpr, I find that there is an increase in formation of 2-
LTR circles in human MDDCs. Additionally, I show that residues important for Vpr-
mediated induction of DDR, are also important for mediating viral gene expression from 
unintegrated DNA. Finally, I show that Vpr from diverse primate lentiviruses is able to 
maintain expression of unintegrated DNA in human MDDCs and similar DDR mutations 
in SIVmac Vpr also map to unintegrated DNA maintenance. 
 
Results 
HIV-1 Vpr promotes expression of unintegrated DNA in a variety of cell types 
It has been reported by other groups that Vpr is able to enhance expression of 
unintegrated DNA in multiple cell lines and CD4+ T cells, but little work has been done 
to characterize this function in primary myeloid cells. I have developed several tools to 
explore Vpr function, including a panel of diverse single cycle of replication competent 
primate lentiviral clones lacking Vpr as well as proviral clones encoding point mutations 
in Vpr that abrogate DDR induction. I first wanted to ask if Vpr enhances expression of 
unintegrated DNA in primary human MDDCs and MDMs. MDDCs were infected with 
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40 ng p24gag content of Lai-luc Δenv/G or Lai-luc Δenv/G ΔVpr in the presence of the 
integration inhibitor raltegravir. Cells were lysed and luciferase expression was assessed 
at three days post infection. Similar to what other groups have observed in cell lines and 
CD4+ T cells, a low level of luciferase expression was detected in WT-virus infections in 
the presence of raltegravir that was ablated in the absence of Vpr (Fig. 13A). I observed 
similar effects in MDMs, in PMA-differentiated THP-1 cells (human monocytoid cell 
line) and in HeLa cells, suggesting that Vpr-mediated enhancement of gene expression 
from unintegrated viral DNA is observed in a variety of human cell types (Fig. 13B-D). 
Furthermore, the ability of Vpr to enhance expression from unintegrated viral DNA was 
independent of its effects on enhancing expression from integrated viral LTR in these 
cells (Fig. 13C and D). While contribution of unintegrated DNA to infection is modest 
compared to untreated controls, it may still significantly impact in vivo spread in the 
presence of an integration inhibitor.  
Previous studies have suggested that there is exquisite species-specificity to Vpr 
functions (208).  Hence, I wanted to assess whether Vpr-mediated enhancement of viral 
gene expression from unintegrated DNA was conserved across diverse species. I infected 
mouse (C57/Bl6) bone marrow derived macrophages (BMDMs) with Lai-luc Δenv/G or 
Lai-luc Δenv/G ΔVpr in the presence of raltegravir and measured luciferase expression in 
cell lysates at day 3 post infection. Interestingly, I observed no difference in luciferase 
expression in the presence or absence of Vpr from unintegrated viral DNA (Fig. 13E). 
These results suggest that host factor(s) involved in Vpr-mediated expression from 
unintegrated DNA have diverged between mice and humans to be unusable by Vpr. 
  
91 
 
  
  
92 
Figure 13. Vpr enhances expression of unintegrated DNA.  
Luciferase expression from (A) MDDCs (n=3), (B) MDMs (n=2), (C) PMA-
differentiated THP-1s (n=2), or (D) HeLa cells (n = 2) infected with Lai-luc Δenv/G -WT 
or -ΔVpr in the presence of 30 µM raltegravir to block integration. (A). MDDCs were 
infected with 40 ng p24gag per 1x105 cells and harvested at day 3 post infection. (B). 
MDMs were infected at MOI = 2 and lysed for luciferase production at day 2 post 
infection. (C) THP-1s were stimulated with PMA (0.1 µM) for two days and then seeded 
at 5x104. Cells were infected with 50 ng p24gag and lysed at 3 days post infection. (D) 
1x104 HeLa cells were infected with 3 ng p24gag and harvested at 2 days post infection. 
Data shown had background subtracted and is depicted as percent of luciferase 
expression from untreated infections with the respective virus. (E). 5x105 Black-6 (B6) 
BMDMs were infected at MOI = 2 with Lai-luc Δenv/G -WT or -ΔVpr in the presence of 
30 µM raltegravir to block integration. Data is the mean +/- SEM of four independent 
experiments. Significance was calculated using a paired student’s T test. 
  
  
93 
To confirm that Vpr mediated expression from unintegrated viral DNA is not due 
to off-target effects of raltegravir treatment, I constructed a catalytically inactive mutant 
of integrase (D116N) that fails to catalyze the strand transfer reaction and invasion of the 
viral DNA into the host genome (408). HeLa cells and PMA differentiated-THP1s were 
infected with luciferase-expressing viruses (Lai-luc Δenv/G) encoding the integrase 
catalytic site mutant IntD116N that did (WT) or did not (ΔVpr) express Vpr. I observed a 
similar enhancement in unintegrated DNA expression from WT but not ΔVpr-infected 
cells (Fig. 14A and B).  
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Figure 14. Vpr enhances expression of HIV-1 containing the catalytic mutation 
IntD116N. 
(A-B) 5x104 PMA-THP-1s (A) or 1x104 HeLa cells (B) were infected as in (Fig. 13C) 
with Lai-luc Δenv/G -WT, -IntD116N, -ΔVpr, or -IntD116N/ΔVpr. Data represents 
single replicates. 
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Vpr expression of unintegrated DNA correlates to its ability to regulate DDR 
responses 
I hypothesized, due to the role of Vpr in coordinating DDR responses during 
infection, Vpr may be acting to promote viral DNA repair such as NHEJ to form 2-LTR 
circles. 2-LTR circles are considered dead-end products of viral infections, though they 
can be maintained episomally in the nucleus and used as a template for viral transcription 
(396–398). To test this, I first wanted to determine if episomal expression from 
unintegrated DNA was fleeting or if it could be maintained for an extended period of 
time. I infected human MDMs with Lai-luc Δenv/G -WT or -ΔVpr. Cells were harvested 
for luciferase expression at 3, 6, and 9 days post infection. Expression from unintegrated 
DNA was maintained over this time in the presence of Vpr, suggesting that Vpr acts to 
maintain expression from unintegrated DNA in the nucleus (Fig. 15A). Interestingly, this 
enhancement was not observed at any of the times post virus infection of mouse BMDMs 
or BMDCs, nondividing cells that would turn over unintegrated DNA relatively slowly 
(Fig. 15B, C). 
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Figure 15. Expression from unintegrated DNA is maintained with time in the 
presence of Vpr. 
(A). Human MDMs were infected with 40 ng p24Gag content per 2x105 cells. Cells were 
lysed on day 3, 6, or 9 post infection for luciferase content. Data is the mean +/- SEM of 
infections with three independent donors. (B-C) 1x104 (B6) BMDCs or 5x104 B6 BMDM 
(C) were infected with 40 ng p24Gag in the presence of 30 µM raltegravir and lysed every 
2 (C) or 3 days (B). Data shown from two independent experiments. (C) MDMs were 
infected with 3 ng p24Gag content Lai-luc Δenv/G -WT or -ΔVpr in the presence of 30 
µM raltegravir for 3, 6, or 9 days before lysis for luciferase expression. Data represents 
three independent experiments with three donors. Data shown had background subtracted 
and is depicted as percent of luciferase expression from untreated infections with the 
respective virus. Data shown represents the mean +/- the SEM, where applicable. 
Significance was calculated using a paired student’s T test where *p<0.05, **p<0.01. 
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Linear DNA is subject to degradation at higher rates, due to the presence of 
cellular endonucleases. I hypothesized that Vpr stabilizes unintegrated DNA by 
promoting end joining and production of 2-LTR circles. I measured 2-LTR circles in the 
presence and absence of Vpr in MDDCs. I chose to focus on MDDCs as an infection 
model because of its in vivo relevance and my previous findings showing that Vpr 
expression impacts infection of these cells (Chapter 1). MDDCs were infected with Lai-
YU2 or Lai-YU2 ΔVpr at MOI = 3 for 12, 24 or 48 hours and 2-LTR circles were 
measured by qPCR. The RT-inhibitor efavirenz was used as a negative control. I 
observed similar levels of 2-LTR circles at 12 hours, suggesting similar input of virus 
was achieved, but by 24 and 48 hours, there was an increase in 2-LTR circles in WT-
infected MDDCs as comparted to ΔVpr (Fig. 16), suggesting that Vpr promotes 
formation of 2-LTR circle form of unintegrated viral DNA. 
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Figure 16. Vpr increases 2-LTR circles during HIV-1 infection of MDDCs. 
MDDCs were infected at MOI = 3 with Lai-YU2 or Lai-YU2 ΔVpr for 12, 24, or 48 
hours before lysis for DNA. Efavirenz (1 µM) was used as a control for plasmid DNA 
input. QPCR was used to analyze 2-LTR circle content as compared to a standard curve. 
Data represents a single experiment. 
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I next wanted to determine what functional domain of Vpr is important for 
preservation of unintegrated DNA. I infected Hela cells or MDMs with HIV-1 Vpr 
mutants, Vpr-W54R which lacks association with UNG2, Vpr-Q65R, which lacks 
association with the SLX4com and DCAFCRL4, and Vpr-H71R, which lacks association 
with DCAFCRL4 in the presence or absence of raltegravir. I observed a similar increase in 
expression of unintegrated DNA from Vpr-W54R, but not -Q65R or -H71R, both of 
which lack the ability to associate with DCAFCRL4 complex (Fig. 17A, B). The  
association of Vpr  with the DCAFCRL4 complex results in G2 arrest, which is thought to 
be the outcome of Vpr-mediated induction of a DDR (195, 207, 237, 355, 375). This 
suggests that the ability of Vpr to induce DDR is important for enhancing expression 
from unintegrated viral DNA.  
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Figure 17. Vpr maintenance of stable forms of episomal DNA is reliant on its ability 
to associate with the DCAFCRL4 complex.  
(A). HeLa cells were infected with 40 ng Lai-luc Δenv/G -WT or indicated Vpr mutant in 
the presence of 30 µM raltegravir. Data represents a single experiment. (B). MDMs were 
infected with 40 ng p24gag per 5x104 cells with Lai-luc Δenv/G -WT or indicated Vpr 
mutant for 3 days before lysis. Data represents two independent experiments. Data shown 
represents the mean +/- the SEM, where applicable. 
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Vpr-mediated preservation of unintegrated DNA is conserved among primate 
lentiviruses and correlates with the ability of SIVmac Vpr to regulate DDR responses 
 I next asked if Vpr-dependent enhancement of viral gene expression from 
unintegrated viral DNA was a conserved function amongst Vpr alleles from different 
primate lentiviruses. I utilized GFP-expressing single cycle of replication competent 
viruses from SIVsm, SIVmac or HIV-2 (viral clones SIVsm-GFP Δenv/G, SIVmac-GFP 
Δenv/G and HIV-2 Rod9-GFP Δenv/G, respectively) that encoded WT or Vpr null-
mutations. I infected MDDCs at MOI = 3 in the presence or absence of raltegravir. GFP 
expression in infected cells was determined by FACS analysis. I found Vpr from all three 
lentiviruses maintained the function of enhanced gene expression from unintegrated viral 
DNA in the presence of raltegravir (Fig. 18A, B, C). This expression from unintegrated 
viral DNA was not observed in cells infected with the corresponding ΔVpr viral clones in 
the presence of raltegravir (Fig. 18D, E, F). It should be noted that SIVsm/SIVmac/HIV-2 
ΔVpr viruses were much more infectious in MDDCs than HIV-1 ΔVpr due to their 
expression of Vpx.  
  
  
103 
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Figure 18. Diverse primate lentiviral Vprs promote expression from unintegrated 
DNA.  
(A-F). MDDCs were infected at MOI = 3 with HIV-2/Rod9-GFP Δenv/G -WT or -ΔVpr 
(A, D), SIVmac-GFP Δenv/G -WT or -ΔVpr (B, E), or SIVsm-GFP Δenv/G -WT or -
ΔVpr (C, F) in the presence of 30 µM raltegravir. GFP expression was analyzed by 
FACS analysis 3 days post infection. Raltegravir treated infections are depicted in (A-C) 
and corresponding untreated controls in (D-F). Data represents seven (A, D), six (B, E), 
or four (C, F) independent experiments. Data shown represents the mean +/- the SEM. 
Significance was calculated using a paired student’s T test. 
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I next asked what domains of SIVmacVpr are important mediating expression of 
unintegrated DNA. I introduced two mutations in the open reading frame of SIVmac Vpr, 
VprV21A and VprS81A. I characterized their expression in cells and ability to be 
incorporated into virions (Fig. 19A).  Both mutants have been previously characterized to 
lack G2 arrest capacity (409). Work is currently underway to characterize this further, as 
well as determine other functions of Vpr these mutations impact. I next infected MDDCs 
with SIVmac-GFP Δenv/G encoding WT, ΔVpr, or the Vpr mutants in the presence and 
absence of raltegravir and assessed expression of unintegrated DNA by FACS analysis. I 
found one of the mutants that lacked the ability to induce a DDR response, Vpr-S81A, 
also lacked the ability to preserve unintegrated DNA expression (Fig. 19B). Together, 
these results suggest that formation of and expression from unintegrated viral DNA is a 
conserved function of primate lentiviral Vpr alleles and requires Vpr-association with 
DDR. 
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Figure 19. The ability of SIVmac Vpr to promote expression of unintegrated DNA 
correlates with induction of cell cycle arrest. 
(A). Flag-tagged expression constructs of SIVmac Vpr -WT and mutants -V21A and -
S81A were co-expressed with SIVmac Δenv/G ΔVpr in 293T cells via transient 
transfection. Cell lysates (left) and concentrated virion lysates (right) were analyzed for 
p27Gag and Flag-Vpr content via western blot analysis. (B). MDDCs were infected at 
MOI = 3 with SIVmac-GFP Δenv/G -WT or indicated Vpr mutant for 3 days before GFP 
analysis by FACS. Data represents five independent experiments with five different 
donors. Data shown represents the mean +/- the SEM. Significance was calculated using 
a paired student’s T test.  
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Future Work 
Experiments to further characterize Vpr-mediated maintenance of unintegrated 
DNA expression are currently ongoing. In my future work, I plan on using the DDR 
response inhibitor Caffeine and PARP-1 inhibitors during HIV-1 infection in the 
presence of raltegravir. I hypothesize that I will observe reduced maintenance of and 
expression from unintegrated viral DNA in both HeLa cells and MDDCs from WT 
infection in the presence of these inhibitors. Work is also underway to characterize the 
SIVmac Vpr mutants further, as well as to determine if I observe similar results with 
integrase-null SIVmac as those observed with HIV-1.  
 
Discussion 
 Together, these data suggest a conserved role for Vpr in enhancing expression 
from unintegrated DNA. This effect is seen in human cells with all primate lentiviruses 
tested, but not observed during HIV-1 infection of murine cells. As was discussed 
previously in this manuscript, it has been shown that a number of DDR response proteins 
have undergone positive selection in the primate lineage, though the reason for this 
selection remains unclear (410, 411) Mutations in DNA-repair proteins often result in 
genomic instability, making the host more likely to develop malignancies, like in the case 
of BRCA1 and BRCA2 mutations (410). The overlap I observe between Vpr-mediated 
expression of unintegrated DNA and the ability of Vpr to block IFN secretion during 
infection of MDDCs, described in Chapter 1, suggests that the two effects of Vpr may be 
linked. It is possible that the integration sensor proposed in Chapter 2 may be part of the 
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DDR pathway that regulated degradation of extrachromosomal DNA. In the presence of 
Vpr, this pathway is inhibited, allowing for other DNA-repair machinery to convert viral 
DNA into stable 2-LTR circles.  
 Despite a measurable enhancement in 2-LTR circles in WT HIV-1 infections as 
compared to ΔVpr, this difference I observed is only about 2-fold. I see a much bigger 
difference in transcription from unintegrated DNA in the presence of Vpr (10- to 20-fold 
enhancement). This result suggests that 2-LTR circle accumulation may not be the sole 
determinant for unintegrated DNA expression. In Chapter 1 of this dissertation, I describe 
the ability of Vpr to enhance transcriptional output from the proviral (integrated) LTR 
during infection of MDDCs, resulting in increased expression. It is possible that my 
observations on unintegrated DNA expression may also be regulated by a Vpr-mediated 
enhancement of transcription, rather than a DNA-repair mechanism. Vpr has been 
reported to transactivate the viral LTR, though this work has mostly focused on CD4+ T 
cells or T cell lines (200–202). It has also been noted that immediately after entry of the 
viral pre-integration complex (PIC) into the nucleus, histones are loaded on linear viral 
DNA (412). Histones on the viral DNA can, in theory, be modified to promote or inhibit 
transcription of the viral DNA, either pre- or -post integration. Vpr has been shown, at 
least indirectly, to modify histone markers through its ability to regulate levels of histone 
deacetylases (HDACs), which modify histones to transcriptionally repress areas of DNA 
(241, 242). Vpr may be changing the overall transcriptional state of the cell by reducing 
HDAC levels, thus promoting expression from aberrant, extrachromosomal DNA that 
would normally be transcriptionally repressed. Alternatively, Vpr may simply be acting 
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as a required transcriptional activator for unintegrated DNA, though it is unclear why 
differences in transcriptional output was not observed from integrated LTRs in MDDCs 
infected with SIVsm/SIVmac/HIV-2 in the presence or absence of Vpr. Together, these data 
show a conserved role for Vpr in maintenance of unintegrated DNA during infection. 
Expression from the episomal DNA may be a critical source for low-level viral 
replication that maintains tissue reservoirs in infected individuals, even in the presence of 
HAART. 
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CHAPTER THREE 
Introduction 
Vpr is a well-studied HIV-1 accessory protein whose sequence and function(s) is 
conserved through primate lentiviral evolution (177, 196). Though Vpr has been ascribed 
a number of functions, the most thoroughly characterized of which is its ability to induce 
G2 cell cycle arrest, the mechanisms responsible for inducing G2 arrest and the 
consequences of the G2 cell cycle arrest on viral replication and fitness are still poorly 
understood (206, 207). Induction of G2 cell cycle arrest by Vpr is dependent on its 
interaction with the DCAFCRL4 ubiquitin ligase complex, components of which have been 
shown to be involved in or regulate DNA replication and DNA damage repair (221, 224, 
413, 414). In the presence of Vpr, the DCAFCRL4 complex associates with a number of 
DNA-damage repair proteins, including the SLX4com, which is involved in Holliday 
junction repair, UNG2, which is part of the base-excision repair pathway that removes 
uracils misincorporated into DNA, and HLTF, a DNA helicase involved in chromatin 
remodeling (228, 230, 236, 238, 239). Interestingly, these interactions are not conserved 
across primate lentiviral Vprs, nor are they necessary for Vpr-mediated cell cycle arrest, 
indicating that these interactions may not be responsible for maintenance of Vpr-
mediated DNA damage response and G2 arrest in vivo during infection or that additional, 
unidentified cofactors are involved in Vpr function (237, 239, 379).  
 The reasoning behind Vpr-mediated cell cycle arrest has remained equally 
unclear. It has been suggested that G2 arrest increases virus production, since the viral-
LTR appears to be most active in G2 phase (203). Additionally, G2 arrest would allow 
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cellular resources to be diverted from cell division to viral production, allowing the virus 
to replicate more efficiently (203). But in cell lines and cycling CD4+ T cells, Vpr is 
dispensable for infection (345). Vpr expression is lost in virus serially passaged CD4+ T 
cell lines in vitro, suggesting the function of Vpr may be more complex than what can be 
delineated from ex vivo or in vitro infections (216). Another, contending hypothesis is 
that G2 arrest is the outcome of a Vpr-controlled DNA-damage response (DDR). Recent 
studies have demonstrated that Vpr orthologs from diverse primate lentiviruses can 
activate the DDR in human cells, suggesting that activation of DDR is a conserved 
function of lentiviral Vpr alleles (237). It has been proposed that Vpr may intentionally 
induce double-strand breaks in the host genome to initiate DDR, resulting in both G2 
arrest and suppression of an antiviral interferon response, though the mechanism remains 
unclear (236). Alternatively, it has also been suggested that Vpr modulates signaling 
through either ATM or ATR, both of which are DDR initiator kinases (382, 383), to 
induce pro-inflammatory responses, thus enhancing virus replication and spread. 
 My recent work has used primary human MDDCs, which are susceptible to 
infection at a low but measurable level, as a model for infection (184). In this model, I 
see a robust restriction to infection in the absence of Vpr that is unique to MDDCs and 
potentially resting CD4+ T cells (185). In my work, I note that this restriction occurs post-
integration in a single round of infection and is alleviated by Vpr-association with the 
DCAFCRL4 complex. In my current work, I looked at infection of MDDCs with diverse 
primate lentiviruses to determine if my observations with HIV-1 were conserved across 
primate lentiviral evolution, specifically amongst those that encode Vpx. Vpx, similar to 
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Vpr, is a small accessory protein encoded by primate lentiviruses in the 
SIVsm/SIVmac/HIV-2 lineage (176). It is incorporated into the virion, similar to Vpr, 
through association with the same p6 region of Gag and also associates with the same 
DCAFCRL4 complex to counteract host cell restriction (194, 225–227). The reason for the 
high level of overlap between Vpx and Vpr function is due to the origin of Vpx. Vpx is 
thought to have originated from a duplication event of Vpr, after which the host cell 
targets of the two proteins diverged; Vpr initiates a DDR by targeting an unknown host 
factor while Vpx targets SAMHD1 for proteasomal degradation (176–180, 183, 415). 
SAMHD1 is a dNTPase that reduces dNTP pools in macrophages, DCs, and resting 
CD4+ T cells, hampering reverse transcription (179, 180, 182, 183). Presence of 
SAMHD1 is thought to be the main reason HIV-1 is poorly infectious in MDDCs (182). 
Surprisingly, I found that infection of human MDDCs with HIV-2, SIVsm, or 
SIVmac -ΔVpr viral isolates had no effect on infection when compared to WT viruses. 
Rather, I found that infection with ΔVpr-HIV-2 or -SIVmac induces robust type I IFN 
production from productively infected MDDCs that is absent or decreased in WT virus 
infection. Type I IFN production was induced at a post-reverse transcription step and was 
prevented upon initiation of infections in the presence of integration inhibitor or infection 
with SIVmac Vpr mutants that do not induce G2 cell cycle arrest. Finally, type I IFN 
induction could be blocked upon initiating infection of SIVmac ΔVpr viruses in the 
presence of inhibitors to NF-κB signaling pathway. Together, my data suggests a 
conserved role for Vpr in harnessing the DDR pathway to prevent viral sensing that 
occurs during integration of the viral dsDNA into the host genome.  
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Results 
Vpr expression does not affect single round replication of SIVmac. 
 I have previously reported a robust, single round block to HIV-1 infection of 
MDDCs in the absence of Vpr. I wanted to assess whether this restriction was present 
during infection with primate lentiviruses that encode Vpx, (179, 180). Previous studies 
have demonstrated that human MDDCs can be efficiently transduced by SIVmac 
lentivectors (416) suggesting an absence of species-dependent restrictions to SIVmac 
infection of human cells. I infected human MDDCs with single-cycle, VSV-G 
pseudotyped, GFP reporter SIVmac, (SIVmac-GFP Δenv/G) -WT, -ΔVpr, -ΔVpx, or -
ΔVpr/ΔVpx at MOI = 1 to determine the individual and cumulative effects of Vpr and 
Vpx on viral infectivity in MDDCs. I hypothesized that, similar to HIV-1, the SIVmac-
GFP Δenv/G ΔVpr virus would be poorly infectious in human MDDCs. SIVmac-GFP 
Δenv/G -ΔVpx and -ΔVpr/ΔVpx were used as negative controls that I assumed would be 
poorly infectious, since Vpx is known to enhance infectivity in MDDCs by targeting 
SAMHD1 for degradation. Surprisingly, I observed slightly enhanced infection levels 
upon infection with SIVmac-GFP Δenv/G ΔVpr virus compared to WT virus. As expected, 
Vpx-deletion completely ablated infection of human MDDCs by SIVmac (Fig. 20).  
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Figure 20. Vpr does not affect infection of human MDDCs with primate lentiviruses 
that encode Vpx.  
MDDCs were infected at MOI = 1 with SIVmac-GFP Δenv/G -WT, -ΔVpr, -ΔVpx, or -
ΔVpr/ΔVpx for three days. GFP expression was assessed by FACS analysis. Data is the 
mean +/- SEM of infections of six independent donors. Significance calculated using a 
paired student’s T test where *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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SIVmac Vpr regulates type I IFN induction during infection of MDDCs.   
Numerous studies have described that infection with Vpx-encoding lentiviruses 
results in proteasomal degradation of SAMHD1 and robust enhancement of lentiviral 
reverse transcription in MDDCs (179, 180, 417–419). Reverse transcription is an error-
prone process and can result in generation of aberrant dead-end viral DNA intermediates 
that can be subject to innate immune sensing. Furthermore, infection of MDDCs with 
Vpx-encoding HIV-2 virus particles, or HIV-1 infection in the presence of Vpx, results in 
cGAS-dependent sensing of viral RT-products (320, 420). Interestingly, previous studies 
have suggested that Vpr recruits structure specific endonuclease regulator, SLX4com that 
has been implicated in regulation of numerous DNA repair pathways and in Holiday 
junction resolution, and activation of endonuclease activity (236) to process non-
productive reverse transcription intermediates and thus avoid innate immune sensing. I 
hypothesized that infection of MDDCs with Vpx-encoding SIVmac-GFP Δenv/G viruses 
might result in increased level of reverse transcripts that in the absence of Vpr be 
detected by nucleic acid sensors in MDDCs. To test this, I first measured late-RT 
products during SIVmac-GFP Δenv/G -WT, -ΔVpr, and -ΔVpx infection of two 
independent donors of MDDCs by qPCR at 18 and 42 hours post infection. I observed an 
increase in late RT-products in the absence of Vpr at both 18 h and 42 h post infection 
(Fig. 21A and B). Note that the primer-probe combination (U5-Gag region) used for the 
quantification of viral DNA detects all forms of viral dsDNA forms including viral 
integrants. 
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Figure 21. SIVmac Vpr modestly increases the amount of late RT products during 
infection of MDDCs.  
MDDCs were infected at MOI = 3 with SIVmac-GFP Δenv/G -WT, -ΔVpr, -ΔVpx, or -
ΔVpr/ΔVpx. Viral stocks had been pre-treated with DNase to reduce background plasmid 
contamination from virus stocks used for infections. Cells were harvested for DNA at 
either 18 or 42 hours post infection. Late RT products were quantified via qPCR as 
compared to a known standard of plasmid DNA. Two respective donor infections are 
shown. 
  
  
117 
The effect of HIV-1 Vpr on type I IFN regulation during infection has been 
extensively studied in the literature, with varying results. Opposing studies have shown 
specific downregulation of type I IFN in the presence of HIV-1 Vpr or, alternatively, 
induction of a type I IFN response due to HIV-1 Vpr expression (236, 252, 256, 258, 259, 
265, 372). I failed to detect induction of type I IFN responses in MDDCs infected with 
HIV-1/WT or ΔVpr viruses (Fig. 9). Since SIVmac Vpr did not modulate MDDC infection 
like HIV-1 Vpr, I hypothesized that modulation of type I IFN response by SIVmac Vpr 
might be divergent as well. MDDCs were infected with SIVmac Δenv/G -WT, -ΔVpr, -
ΔVpx or -ΔVpr/ΔVpx viruses (MOI =3), and cell-free supernatants were harvested on 
day 3 post infection. The amount of type I IFN released in cell-free supernatants was 
measured using a previously described bioassay (369). For quantification, secreted IFN 
was compared to a known standard of IFNα. I observed a significant increase in type I 
IFN secretion in MDDCs infected with SIVmacΔVpr virus as compared -WT infection 
(Fig. 22). Both -ΔVpx, or -ΔVpr/ΔVpx viruses were non-infectious on MDDCs (Fig. 20) 
and did not result in production of type I IFN (Fig. 22).  
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Figure 22. SIVmac Vpr suppresses type I IFN production during infection of 
MDDCs.  
MDDCs were infected at MOI = 3 with SIVmac-GFP Δenv/G -WT, -ΔVpr, -ΔVpx, or -
ΔVpr/ΔVpx. Supernatants were harvested at day three post infection and type I IFN was 
quantified using a sensitive bioassay as compared to a standard of IFNα. Briefly, HEK 
293 cells containing an ISRE-driven luciferase reporter were incubated with cell culture 
supernatants or a standard curve of recombinant IFNα-containing growth media for 21 
hours before quantification of luciferase expression. Data is representative of the mean 
+/- the SEM for infections of six independent donors. Data was log transformed to 
normalize the distribution and significance was calculated using a paired student’s T test 
where *p<0.05, **p<0.01, ***p<0.001. 
  
  
119 
Host sensing of lentivirus integration is blocked by SIVmac Vpr. 
 Since infection with SIVmacΔVpr viruses resulted in increased amounts of viral 
DNA in MDDCs at early times post infection (Fig. 21), I determined if type I IFN 
production was the result of differential RT-product accumulation and sensing in the 
absence of Vpr. To test this further, MDDCs were infected with SIVmac Δenv/G -WT, -
ΔVpr, -ΔVpx or -ΔVpr/ΔVpx viruses (MOI =3), in the presence or absence of the RT-
inhibitor tenofovir and the integrase inhibitor raltegravir to block different stages of the 
viral life cycle, and determine the step of the virus life cycle that is subject to host sensing 
and innate immune activation. I hypothesized that if induction of type I IFN occurs upon 
sensing of reverse transcripts, only tenofovir will block type I IFN production. 
Alternatively, if host sensing of SIVmacΔVpr virus replication occurs after completion of 
reverse transcription, both inhibitors (tenofovir and raltegravir) will be able to block type 
I IFN secretion. Interestingly, tenofovir pre-treatment of MDDCs which efficiently 
blocked viral infection, was able to completely abrogate type I IFN secretion (Fig. 23A, 
B), suggesting that SIVmac reverse transcripts might be sensed in MDDCs in the absence 
of Vpr.  
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Figure 23. SIVmac ΔVpr triggers innate immune sensing at a post-reverse 
transcription step in MDDCs.  
(A-B). MDDCs were infected at MOI = 3 with SIVmac-GFP Δenv/G -WT, -ΔVpr, -ΔVpx, 
or -ΔVpr/ΔVpx for three days. Parallel infections were treated with the RT-inhibitor 
tenofovir or the integration inhibitor raltegravir. Cells were analyzed for GFP expression 
(A) and type I IFN production in the supernatants was quantified using a bioassay (B). 
Data is representative of the mean +/- SEM of infections of five independent donors. 
Significance was calculated using a paired student’s T test where *p<0.05, **p<0.01. 
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All integrases have a characteristic catalytic core domain, the D,D35E motif 
(421–423), and hence can be inhibited by raltegravir. Raltegravir prevents lentiviral DNA 
from inserting itself into the host genome. Because integrase inhibitors are known to 
cause nuclear accumulation of unintegrated lentiviral DNA (Fig. 14 (395, 404)), I 
hypothesized that raltegravir pre-treatment might result in the accumulation of linear or 
circularized viral DNA forms that may exacerbate innate immune activation and type I 
IFN secretion in SIVmacΔVpr-infected MDDCs. Surprisingly, raltegravir pre-treatment, 
which inhibited productive infection of MDDCs by GFP-expressing SIVmacΔVpr Δenv/G 
virus (Fig. 23A) also completely abrogated production of type I IFN (Fig. 23B), 
suggesting that integration of lentiviral DNA into the host genome or post-integration 
steps of the viral life cycle were subject to host sensing mechanisms that result in 
production of type I IFN.  
 In order to tease apart the kinetics of induction of type I IFN in SIVmacΔVpr-
infected MDDCs, reverse transcription was arrested at different times pre- and post-
infection by addition of tenofovir. The percentage of GFP+ cells obtained at each time 
point (time of tenofovir addition) was then determined at day 3 post infection by FACS 
analysis.  In addition, cell-free supernatants were harvested at day 3 and type I IFN 
production was quantified by a bioassay. Addition of tenofovir at 3 hours before addition 
of virus, or at 0, 3, or 9 hours post infection significantly inhibited type I IFN production 
in SIVmac-GFP Δenv/G-ΔVpr infected cultures, confirming that neither virus entry, 
sensing of incoming viral RNA genome or initiation of reverse transcription result in 
viral sensing and type I IFN production (Fig. 24A, B). Addition of tenofovir at 18 hours 
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post infection blocked infection by ~50% (Figure 24A), but type I IFN production was 
robustly induced (Fig. 24B), suggesting that steps after completion of reverse 
transcription are subject to host sensing mechanisms.  
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Figure 24. Completion of reverse transcription in MDDCs is necessary for host 
sensing of infection with SIVmac ΔVpr.  
(A-B.) MDDCs were infected at MOI = 3 with SIVmac-GFP Δenv/G or SIVmac-GFP 
Δenv/G ΔVpr. Tenofovir was added to block reverse transcription at 3 hours prior to 
infection, at the time of infection, or 3, 9 or 18 hours post infection. At day three post 
infection, cells were analyzed for GFP expression (A) or type I IFN secretion into the 
supernatants was quantified (B). Data is the mean +/- SEM of infections with five 
independent donors.  
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HIV-2 Vpr and SIVsm Vpr also block IFN induction in human MDDCs.  
I next wanted to characterize whether these results seen with SIVmac could also be 
extended to other viruses in the same lentiviral lineage. These include SIVsm, which 
causes non-pathogenic infections in its natural host, sooty mangabeys (424), and HIV-2, 
which can cause AIDS in humans. SIVmac originated from multiple cross species 
transmissions of SIVsm from sooty mangabeys to macaques that were co-housed in 
captivity (33). Similarly, HIV-2 is thought to be the result of a transmission event of 
SIVsm to humans through preparation of game meat (17). MDDCs were infected with 
HIV-2 Rod9-GFP Δenv/G -WT, -ΔVpr, or -ΔVpx and SIVsm-GFP Δenv/G -WT, -ΔVpr, 
or –ΔVpx viruses (MOI = 3), and cells were harvested at day 3 post infection for FACS 
analysis.  Similar to SIVmac infection of MDDCs, absence of Vpr had negligible impact 
on infection of HIV-2 (Fig. 25A) and SIVsm (Fig. 25B) in MDDCs, while Vpx deletion 
completely ablated infection of both HIV-2 and SIVsm (Fig. 25A, B).  
I next determined if infections of MDDCs with HIV-2 or SIVsm in the absence of 
Vpr could also induce type I IFN production similar to that observed with SIVmacΔVpr 
infections of MDDCs. MDDCs were infected at MOI = 3 with SIVsm Δenv/G -WT, – 
ΔVpr or -ΔVpx and Rod9 Δenv/G -WT, – ΔVpr, or -ΔVpx in the presence or absence of 
tenofovir and/or raltegravir. Similar to what I observed with SIVmac, type I IFN 
production was significantly increased in both HIV-2 ΔVpr and SIVsmΔVpr infections 
(Fig. 25C, D). Furthermore, type I IFN production in HIV-2 ΔVpr and SIVsmΔVpr-
infected MDDCs was completely blocked upon pre-treatment with either tenofovir or 
raltegravir (Fig. 25C, D). Alternatively, infection with both HIV-2 Rod9-GFP Δenv/G-
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WT and SIVsm GFP Δenv/G- WT (encoding WT-Vpr) also induced low but detectable 
levels of type I IFN, suggesting that HIV-2 and SIVsm viruses are subject to additional 
Vpr-independent sensing mechanisms in human MDDCs (420) . Alternatively, Vpr 
alleles encoded by HIV-2 and SIVsm might not be as efficacious as SIVmac Vpr in 
suppressing virus sensing mechanisms in human MDDCs.  
To determine if the findings observed with single-cycle HIV-2 viruses are also 
observed with infections of MDDCs with replication competent HIV-2, I infected 
MDDCs (MOI = 3) with VSV-G-pseudotyped Env-encoding replication competent HIV-
2 Rod9 -WT or -ΔVpr and harvested cell-free supernatants at three days post infection. 
Tenofovir and raltegravir were again used as controls to ensure sensing is due to infection 
and not virus particle addition. Similar to what I observed with single-round infection 
analysis, infection of MDDCs with replication competent HIV-2 ΔVpr resulted in 
enhanced secretion of type I IFN that is reduced in WT HIV-2/Rod9 infection. 
Furthermore, infections of HIV-2 Rod9 -WT or -ΔVpr in the presence of RT or 
integration inhibitors reduced type I IFN production (Fig. 25E). Together, these data 
suggest that members of SIVsm/SIVmac /HIV-2 lineage encode Vprs that suppress sensing 
of lentiviral integration into host genome.   
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Figure 25. Vpr from Vpx-encoding lentiviruses antagonizes type I IFN signaling in 
MDDCs.  
(A). MDDCs were infected at MOI = 3 with Rod9-GFP Δenv/G -WT, -ΔVpr, or -ΔVpx 
for three days and GFP was asses by FACS analysis. Data is the mean +/- SEM of 
infections with seven independent donors. (B). MDDCs were infected as in (A) with 
SIVsm-GFP Δenv/G -WT, -ΔVpr, or -ΔVpx. Data is the mean +/- SEM of infections with 
six independent donors. (C). MDDCs were infected as in (A) with Rod9-GFP Δenv/G -
WT, -ΔVpr, or -ΔVpx. Parallel infections were treated with tenofovir or raltegravir to 
block reverse transcription or integration, respectively. Supernatant from day 3 post 
infection was analyzed for type I IFNs using a quantitative bioassay. Data is the mean +/- 
SEM from seven independent donors. (D). MDDCs were infected as in (B) with SIVsm-
GFP Δenv/G -WT, -ΔVpr, or -ΔVpx in the presence of tenofovir or raltegravir. 
Supernatants were harvested at day 3 post infection for type I IFN quantification using a 
sensitive bioassay. Data is the mean +/- SEM of six independent donors. (E). MDDCs 
were infected at MOI = 3 with replication competent Rod9/G or Rod9 ΔVpr/G. Parallel 
infections were treated with the RT inhibitor tenofovir or the integration inhibitor 
raltegravir. Supernatants were analyzed at day 3 post infection for the presence of type I 
IFNs. Data is the summary of six infections with six independent donors. Significance 
calculated using a paired student’s T test where *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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Suppression of host sensing of lentiviral integration in MDDCs is NF-κB dependent 
and is correlated to the ability of Vpr to induce DDR. 
G2 cell cycle arrest is a conserved function of Vpr and is thought to be the 
outcome of Vpr-mediated regulation of the DDR. I hypothesized that ability of 
SIVsm/SIVmac/HIV-2 Vpr to block type I IFN induction is the result of Vpr-mediated 
degradation of a viral integration sensor, resulting in initiation of a DDR response. In 
support of this hypothesis, it has also been reported that many members of DDR 
pathways are under positive selection, which is a hallmark of retroviral restriction factors 
(410, 411). To determine if G2 arrest/DDR induction function of SIVmac Vpr correlates 
with its ability to suppress type I IFN production, I made several mutations to SIVmac Vpr 
that had previously been characterized to block Vpr-mediated G2 cell cycle arrest (377, 
409). Work is underway to confirm differential regulation of the cell cycle by these Vpr 
mutants. I infected MDDCs with SIVmac Vpr mutants -VprV21A and -VprS81A at MOI 
= 3 and analyzed supernatants for type I IFN production at day 3 post infection. All Vpr 
mutants were incorporated into virions at levels similar to WT-Vpr (Chapter 2) and were 
infectious in MDDCs, though VprV21A shows reduced infectivity (Fig. 26A). 
Interestingly, I found that infections of MDDCs with one mutant that has reduced cell 
cycle arrest capacity, VprS81A, results in enhanced type I IFN production, a phenocopy 
of the SIVmac ΔVpr infection (Fig. 26B). Furthermore, the VprV21A mutant blocks type I 
IFN production, which I hypothesize correlates with increased cell cycle arrest capacity 
(Fig. 26B). Work to confirm this hypothesis is in progress.  
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Figure 26. Vpr antagonism of innate immune sensing correlates with its ability to 
induce G2 arrest.  
(A-B) MDDCs were infected with SIV SIVmac-GFP Δenv/G -WT, -ΔVpr, -VprV21A, or -
VprS81A for three days. Parallel infections were treated with tenofovir or raltegravir. 
Cells were analyzed for GFP expression (A) and IFN secretion in infection supernatants 
(B). Data is the mean +/- SEM of infections with four independent donors.   
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Previously published work has demonstrated that treatment of cells with etoposide 
(induces DNA double strand breaks)-induced type I IFN responses in a IRF3-
independent, NF-κB dependent manner (425). I hypothesized that a similar mechanism 
underlies lentiviral integration-induced type I IFN responses. To test this hypothesis, 
MDDCs were infected with SIVmac GFPΔenv/G –WT or ΔVpr viruses in the presence of 
small molecule inhibitors that block pro-inflammatory signaling cascades. I utilized the 
inhibitors, BAY11-7082, an inhibitor of IκB-α that blocks NF-κB activation, (5Z)-7-
Oxozeaenol, which inhibits TAK1, a signaling protein upstream of NF-κB, the NLRP3-
inflammasome inhibitor, glybenclamide, and BX795, a TBK1 inhibitor, that blocks IRF3 
activation (426). None of the inhibitors had any impact on cell viability at the 
concentrations tested (data not shown). Treatment with BAY11-7082, (5Z)-7-Oxozeaenol 
and BX795 enhanced infections of both WT and ΔVpr viruses, though differences were 
not statistically significant (Fig. 27A). Interestingly, both BAY11-7082 and (5Z)-7-
Oxozeaenol that reduce NF-κB activation potently reduced type I IFN secretion from 
SIVmac-GFP Δenv/G ΔVpr infected cells, while treatment with glybenclamide or BX795 
had no effect on type I IFN secretion (Fig. 27B). Together, these experiments suggest that 
NF-kB activation is necessary for induction of type I IFN responses downstream of 
sensing of lentiviral integration into host genomes.   
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Figure 27. Type I IFN secretion from SIVmac ΔVpr infected MDDCs is dependent on 
the NF-κB signaling cascade.  
(A-B) MDDCs were infected at MOI = 3 with SIVmac-GFP Δenv/G -WT, -ΔVpr, -ΔVpx, 
or -ΔVpr/ΔVpx in the presence of the inhibitors BAY11-7082 (1 µM), an IκB-α inhibitor, 
(5Z)-7-Oxozeaenol (1 µM), a TAK1 inhibitor, glybenclamide (50 µM), a NLRP3-
inflammasome inhibitor and BX795 (0.1 µM), a TBK1 inhibitor. No treatment or 
equivalent concentrations of DMSO were used to confirm drug efficacy. Cells and 
supernatants were harvested on day 3 post infection to determine GFP expression (A) or 
type I IFN secretion (B). Data is the summary of infections with two or three independent 
donors. 
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Future Studies 
Additional work to confirm that integration is the step of the viral life cycle that is 
sensed is ongoing. In the future, I plan on adding raltegravir to SIVmac infected MDDCs 
at 0, 6, 9, and 18 hours post-infection, to further clarify the kinetics of the sensing 
mechanism. I predict that addition of raltegravir at 0, 6, and 9 hours will potently block 
IFN secretion, while raltegravir addition at 18 hours will neither block type I IFN 
production nor block viral gene expression. In the case that completion of virus 
integration takes longer than 18 hours, I will adjust my raltegravir addition times to better 
fit the SIV replication cycle. I also plan on using integrase catalytic site mutants to 
provide additional support for my hypothesis. I am currently in the process of making 
integrase-null (IntD116N) clones of SIVmac Δenv/G -WT and -ΔVpr. I expect that neither 
D116N-WT nor D116N-ΔVpr (which are predicted to not integrate in the host genome) 
will trigger type I IFN production. 
Work is still ongoing to demonstrate that Vpr-mediated regulation of DDR is 
preventing sensing of viral infection. I plan to use inhibitors that selectively block the 
DDR response in order to tie the DDR to viral sensing. I will use selective DDR 
inhibitors including caffeine, which blocks ATM and ATR mediated DDR sensing (383, 
427). ATM and ATR are DNA-damage sensing kinases that broadly amplify signaling to 
recruit DNA repair machinery, ATM in response to double stranded breaks and ATR in 
response to single strand breaks or gaps (428–431). I will also use commercially available 
PARP-1 inhibitors, which block the ability of PARP-1 to detect and mark single strand 
breaks for repair (432–434). If viral sensing occurs through any of these pathways, I 
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would expect to ablate type I IFN production in the presence of inhibitors. I also plan on 
using chemical agents that induce DNA damage, like etoposide, which induces double 
strand breaks, to recapitulate the sensing I observe during integration in the absence of 
Vpr.  
Additionally, I hope to show that HIV-1 Vpr antagonizes IFN production similar 
to SIVmac/SIVsm/HIV-2. I expect I may have to supplement HIV-1 infections of MDDCs 
with SIVmac Vpx in order to achieve enough high levels of HIV-1 integration for 
detection by host sensing machinery. My future work in this area also involves repeating 
some of the experiments I have planned using DDR-regulating inhibitors, including 
caffeine, etoposide, and PARP-1 inhibitors with HIV-1 in the presence of SIVmac Vpx. I 
also plan to measure RT-products and integrated proviruses in the presence of SIVmac 
Vpx to better characterize the effect of Vpr on reverse transcription and integration in my 
system. Collectively, I hope to definitely show a conserved role for Vpr in targeting a 
DDR-pathway sensor that detects conserved patterns during primate lentiviral integration.  
Currently, my data reveal a viral sensor that detects viral infection during or post 
integration. This sensor is antagonized by Vprs encoded by diverse primate lentiviruses 
in the SIVmac/SIVsm/HIV-2 lineage, and may also be antagonized by HIV-1 Vpr, though 
work is currently underway to determine this conclusively. Sensing occurs through an 
NF-κB-dependent mechanism. Vpr-mediated coordination of cell cycle arrest appears to 
be necessary to block IFN secretion in reaction to infection. Together, these data suggest 
the presence of a novel viral sensor that may play a crucial role in driving Vpr 
maintenance amongst primate lentiviruses. 
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DISCUSSION 
The human evolutionary lineage has been riddled with exposure and infection by 
retroviruses, as evident by the 8% of our DNA that is composed of viral elements (435). 
Individual cellular defenses against infections have co-evolved with viral evasion in a 
race for survival (436). In this work, I identified a novel detection point for viral invasion, 
retroviral integration. Individual cellular host defenses have evolved  to counteract viral 
infection, either by creating barriers that prevent conserved steps in the viral life cycle 
from occurring or by developing sensing mechanisms that detect infection  (436, 437). 
These barriers to infection must be actively circumvented by viral proteins in order for a 
successful, spreading infection to occur. Lentiviral accessory proteins, including Vpr, are 
encoded specifically to counteract these host defense mechanisms, often referred to as 
restriction factors, and must evolve every time a species jump occurs (140). Restriction 
factors have undergone millions of years of positive selection to detect and counteract 
conserved stages of the retroviral life cycle (436). Restriction factors have been identified 
that block or detect most stages of the viral life cycle, including uncoating, reverse 
transcription, nuclear entry, and virion release, but until this work, viral detection at the 
step of integration has not been identified (336, 438, 439). 
Vpr’s role during infection has remained elusive to researchers for years. It has 
clear involvement with some sort of DDR, as evident by the conserved role in initiating 
G2 cell cycle arrest, but outcomes or advantages of this arrest remain poorly defined (236, 
355, 375). Expression of Vpr in cells induces DNA-damage foci which are the result of 
multiple DDR pathways including the Fanconi anemia (FA) pathway, the ataxia 
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telangiectasia mutated (ATM) and ataxia telangiectasia mutated Rad3 (ATR) pathways 
(236, 382, 383, 440). These pathways are all critical for coordination of DNA-damage 
repair, suggesting Vpr may act to directly induce DNA damage (236, 428, 441). Despite 
this evidence,  interactions that would mediate Vpr-induced DNA damage remain poorly 
defined (237, 379, 442). We can take clues from pull down studies about the function of 
Vpr; Vpr associated with a number of DNA-damage repair proteins including UNG2, 
SLX4com, and HLTF (228, 235, 236, 238, 239). UNG2 is part of the base excision repair 
pathway that recognizes and removes misincorporated uracils or deaminated cytosines 
from DNA (443). The SLX4com is a key intermediary in the FA pathway, which  
coordinates proteins involved in  nucleotide excision repair, homologous recombination 
and translesion synthesis in order to resolve Holliday junctions (444, 445). People with 
mutations in key regulators in the FA pathway have a hypermutable phenotype that 
significantly increases their risk for a variety of cancers (444, 445). SLX4 itself is a 
nuclear scaffold protein that binds and coordinates the activity of three different structure 
specific nucleases (444). Vpr, in the context of DCAFCRL4 binds directly to SLX4, but has 
been shown to regulate the activity of fellow complex member MUS81/EME1, an 
endonuclease that cleaves Holliday junctions during repair (236, 444). It has been 
suggested that Vpr selectively activates MUS81/EME1 to create double strand breaks in 
the host DNA in order to induce G2 arrest and prevent accumulation of viral DNA that 
would be subject to sensing (236). Finally, the most recently identified interactor with 
Vpr that has been discovered is HLTF, a protein that is involved with resolution of stalled 
replication forks (238, 239). In addition to these Vpr-DCAFCRL4 interactors, the 
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DCAFCRL4 complex  itself has been indicated as a regulator of DNA-damage repair, 
which poses the possibility that the Vpr-DCAFCRL4- interaction may regulate the DDR 
independently of other host factors (413, 414, 446). Together, the extensive interactions 
of Vpr with host DDR pathway proteins suggest that Vpr plays a crucial role in 
regulating DNA-damage repair to the advantage of the virus.  
Vpr is incorporated into virions and enters infected cells associated with the viral 
capsid (191–194, 339, 447). After entry, Vpr localizes to the nuclear membrane, shuttling 
in between the nucleus and cytoplasm, though some molecules also remain associated 
with the PIC (447, 448). The localization of Vpr supports the long held hypothesis that 
Vpr aids nuclear import, though it has become clear this is not the case (347, 449). My 
work in Chapter 1 reveals a role for virion associated HIV-1 Vpr in enhancing 
transcriptional output from the viral LTR. It is unclear whether this is the result of Vpr 
acting directly as a transcription factor or, instead, somehow modifying the integration 
site to make it more transcriptionally active. There is evidence to support both 
hypotheses. Vpr has been shown to degrade histone modifiers responsible for condensing 
DNA and reducing transcription (241, 242). Vpr is also capable of binding and 
transactivating the viral LTR, directly increasing production of viral transcripts (200–
205). Similarly, in Chapter 2, I reported that presence of Vpr increases expression from 
unintegrated DNA. Again, this could be the result of Vpr acting directly on the viral LTR 
to promote transcription or, instead, modifying unintegrated DNA to increase its 
transcriptional competency. I propose that the effect of Vpr on chromatin structure is 
responsible for both observed effects of Vpr. Histones are loaded onto viral DNA rapidly 
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after entering the nucleus (412). Vpr-mediated degradation of HDACs may be critical for 
early, rapid transcription, both for integrated and unintegrated DNA (241, 242). I propose 
that in the absence of Vpr, viral DNA is rapidly silenced by chromatin modifications, 
potentially as a mechanism of host defense to prevent expression from foreign DNA in 
the nucleus (Fig. 28). In the presence of Vpr, chromatin modification is prevented, via 
direct engagement with the DCAFCRL4 complex, allowing for transcription from LTR via 
the host PolII polymerase (Fig. 28). It is possible that chromatin remodeling is due to 
direct targeting of HDACs by the Vpr-DCAFCRL4 complex, or it may be the outcome of 
general induction of DDR, which is known to relax chromatin structure in order for DNA 
repair to occur (241, 242, 450–452). This is only observed in cells where there is a block 
to integration, like the indirect block of low nucleoside pool in MDDCs or the artificial 
block of raltegravir or mutations in viral integrase. In more active, dividing cells that are 
far more permissive to infection, chromatin structure in in flux more often, due to events 
like cellular division, and other viral proteins like tat are sufficient to drive transcription. 
Alternatively, it is also possible that a common mechanism could be resulting in both the 
enhanced transcriptional output I characterized in Chapter 1 and 2 and the antagonism of 
viral sensing of integration I observe in the presence of Vpx, characterized in Chapter 3.  
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Figure 28. HIV-1 Vpr enhances viral transcription via modification of chromatin 
structure.   
HIV-1 Vpr, in associates with the DCAFCRL4 complex, results in modification of 
chromatin structure for enhanced recruitment of Pol II and increased LTR-driven 
transcription. It remains unclear if this is the effect of general induction of DDR, which is 
known to relax chromatin structure or due to DCAFCRL4-mediated targeting of a host 
protein that regulates chromatin architecture, such as host HDAC proteins.  
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 Vpr is maintained across all known primate lentiviruses and its ability to induce 
G2 arrest, presumable through interactions with the DDR pathway is also conserved (141, 
176, 177, 196, 207, 208, 237, 415, 436). It has been shown that a number of proteins 
involved in DDR pathways are under positive selection, though the reasoning for this is 
somewhat unclear (410, 411). Positive selection is a process by which viral infection 
drives host species diversification of proteins that restrict the virus (453, 454). Many of 
these genes, including BRCA1 and BRCA2, are integral for genome stability and 
mutations can confer significantly increased susceptibility to various cancers (410). It has 
been proposed by others that the only logical reason for selecting for genome instability 
is to counteract a greater threat, like viral invasion into the host genome, like occurs 
during retroviral integration (410). I believe that there is an interplay between Vpr-
orthologs in primate lentiviruses and the host DDR response which has resulted in 
positive selection of proteins that are critical for genome integrity, despite the potential 
deleterious effects of non-sense mutations in these genes. My results in Chapter 3 suggest 
Vpr mediates antagonism of host sensor of viral integration and I propose that this host 
sensor is a DDR pathway protein that detects retroviral integration products (Fig. 29).  
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Figure 29. SIVsm/SIVmac/HIV-2 Vpr suppress integration-induced production of type 
I IFN.  
SIVsm/SIVmac/HIV-2 Vpr blocks DDR-induced signaling pathways triggered by 
integration of Vpx-encoding primate lentiviruses. This block occurs only in pathways that 
lead to production of type I IFN and not pathways involved in integration site repair, 
allowing for successful infection without production of antiviral IFNs. In this model, 
ATM or ATR are the proposed DNA-damage sensors that signal through a TAK1-
dependent pathway to trigger IFN.  
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Integration offers an unconventional target for viral sensing, since double-
stranded DNA in the nucleus resembles normal host DNA. Unpublished data from 
Hisashi Akiyama in my lab has revealed a Vpr-independent late infection sensor that 
detects de novo synthesized viral RNA (Akiyama, unpublished data). Based on work he 
has done to characterize this viral sensor, I believe that Vpr-mediated antagonism of IFN 
occurs earlier in infection, pre-viral RNA production but post integration (Akiyama, 
unpublished data, Fig. 23, 25). Integration occurs through a conserved mechanism for all 
known retroviruses, creating a pattern that may be susceptible to sensing by host DNA 
repair machinery. In all cases, the end result is a two nucleotide, 5’ flap and a 3’ gap in 
the DNA (110). For HIV-1 this gap is five nucleotides, though the exact length varies 
slightly between viruses (109, 110). These structures are dissimilar from other naturally 
occurring patterns of DNA damage and must be repaired before DNA replication in order 
for cellular division to occur (109, 110). The consequence of a lack of repair in cycling 
cells is DNA damage-induced cell death, which occurs before the virus can successfully 
create new progeny. This would be detrimental to viral spread and persistence in a host. 
In non-cycling cells, like MDDCs, I propose that the outcome of this DNA-damage is 
viral sensing and IFN production. This outcome, like DDR-induced cell death, would be 
detrimental to viral spread via the creation of an antiviral environment. Both outcomes 
would result in strong selective pressure for maintenance of a viral protein to block 
sensing of integration to allow for viral propagation.  
 Human DNA already encodes a number of proteins to counteract both current and 
ancient retroviruses due to persistent exposure to and infection by retroviruses over our 
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evolutionary history (436, 453). One such protein is SAMHD1, a dNTPase that lowers 
the nucleoside pool in cells, restricting reverse transcription (179, 180, 389). In addition 
to its anti-HIV-1 activity, SAMHD1 has been reported to regulate retroelements within 
the human genome (455, 456). SAMHD1, along with a handful of other proteins, 
prevents LINE-1 and LINE-1-related retrotransposition in human cells (455). Naturally 
occurring mutations in SAMHD1 domains responsible for regulating LINE-1 elements 
result in Aicardi-Goutières Syndrome, an inflammatory disorder characterized by 
massive type I IFN production, similar to what I see during infection of MDDCs with 
ΔVpr virus in the presence of Vpx (455). Vpx causes SAMHD1 levels to drop and 
remain low for at least 5 days post exposure (457). Under these conditions, reverse 
transcription occurs much more efficiently, similar to what occurs with retroelements in 
AGS cells (457). Until now, research on SAMHD1 deficiency-induced IFN has been 
limited to retroviral transcription, ignoring the potential for integration-mediated sensing 
(119). With the potential deleterious effects of retroelement transposition, a mechanism 
to detect cells in which a mass of integration events is occurring would be advantageous 
for detection and clearance of cells in which retrotransposition is going unchecked (119).  
 In my studies, all Vpx-encoding viruses tested induced IFN in the absence of Vpr 
expression. HIV-1, the only virus tested that does not encode a Vpx gene, did not induce 
any measurable type I IFN in human MDDCs (Miller, unpublished data). HIV-1 is 
normally poorly infectious in MDDCs, due to high expression of the restriction factor 
SAMHD1 (179, 180). I believe that the requirement for Vpx in viruses sensed during 
infection of human MDDCs is not a direct one. Vpx enhances reverse transcription in 
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these cells, which are normally far less permissive to infection, increasing the number of 
integration events and thus increasing the likelihood of detection of such events (418). In 
the absence of Vpx, integration events are rare, so the ability to measure a response to 
integration in a population of cells diminishes. Work is currently underway to determine 
if HIV-1 Vpr regulates sensing of integration, similar to SIVmac/SIVsm/HIV-2. 
Interestingly, the Vpr from SIVsm is the least effective at counteracting sensing in 
human MDDCs, suggesting that species-specific evolution of Vpr is necessary for 
function. SIVsm is the most ancient of the lentiviruses tested and the ancestor that gave 
rise to both SIVmac and HIV-2 (17). Co-evolution between virus and host restriction is a 
defining characteristic of long term exposure to viral infection and suggestive of a 
conserved mechanism for detecting viral infection throughout primate evolution (436, 
453). Additionally, published data suggests that SIVsm Vpr has reduced ability to induce 
G2 arrest in human cells (208). It is also non-pathogenic in its natural host, whereas 
SIVmac and HIV-2 infection result in progressive, AIDS-like disease in macaques and 
humans, respectively (17). It is possible that, similar to G2 arrest in human cells, SIVsm 
Vpr is unable to fully antagonize sensing of integration and IFN production in human 
MDDCs. Alternatively, IFN production from incomplete antagonism of sensing could be 
a mechanism by which viral infection is controlled in sooty mangabeys.  
Collectively, my work in Chapter 3 strongly suggests that Vpr is acting to 
selectively regulate the DDR to allow for successful integration in the absence of viral 
sensing. I hypothesize that this function is the result of selective regulation of an ATM- 
or ATR-triggered DDR response (Fig. 29). ATM, ATR and DNA protein kinase (DNA-
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PK) are the three initiator kinases responsible for regulating the induction of DDR 
pathways (458). ATM and DNA-PK initiate a response to DNA double strand breaks, 
while ATR initiates a response to DNA single-strand breaks (458). While it is easy to 
assume a single strand break response would be more relevant to lentiviral integration, 
proteins involved in NHEJ have been shown to be critical for successful integration 
(380). Interestingly, cells deficient in NHEJ factors also are incapable of making 2-LTR 
circles, a form of unintegrated DNA that is competent for gene expression (109, 459). It 
is possible, as proposed by Li, et al, that circularization of unintegrated DNA is important 
to prevent pro-apoptotic signals that result from detection of linear viral DNA in the 
nucleus resembling double strand breaks (460). Additionally, it has been shown that Vpr 
can induce an ATM or ATR response, and induction of ATR independently of Vpr 
expression results in S/G2 cell cycle arrest (380, 382, 383, 461). It has been suggested 
that activation of these pathways may even enhance integration, though that remains 
somewhat controversial (462–464). ATM and ATR both signal through NF-κB and can 
result in induction an IFN response (425), similar to what I observe during infection of 
MDDCs in the absence of SIVsm/SIVmac/HIV-2 Vpr. I propose that Vpr is selectively 
regulating the ATM/ATR responses to allow for repair of integration but block DNA-
damage induced NF-κB-dependent IFN production (Fig. 29). I hypothesize that this 
occurs through direct, DCAFCRL4-mediated degradation of host protein involved in the 
IFN signaling pathway, but my current work has yet to prove this (Fig. 29). In the 
absence of Vpr, host machinery will repair integration-induced DNA damage, but 
antiviral IFNs will be produced which ultimately will restrict viral spread (335, 367). I 
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hypothesize that in cycling cells, the outcome of integration in the absence of Vpr, 
instead of IFN, is increased susceptibility to DNA-damage induced apoptosis.  
It remains unclear whether similar mechanisms are involved in HIV-1 Vpr 
enhancement of infection of MDDCs, the ability of diverse Vprs to increase expression of 
unintegrated DNA and SIVsm/SIVmac/HIV-2 Vpr antagonism of sensing of viral infection 
in MDDCs. The primary data supporting this hypothesis is from my work with both HIV-
1 and SIVmac Vpr mutants. Though work to characterize G2 arrest capacity of the SIVmac 
Vpr mutants is in progress, it is interesting that the same mutations that preserve 
expression of unintegrated DNA (Chapter 2) also prevent IFN production during 
infection (Chapter 3). Taken a step further, HIV-1 Vpr mutations that block association 
with the DCAFCRL4 complex, which are subsequently unable to induce G2 arrest are also 
unable to enhance expression of unintegrated DNA (Chapter 2) and increase expression 
from the viral LTR during MDDC infection (Chapter 1). Additionally, Vprs that are less 
efficient at inducing G2 arrest in human cells, namely SIVsm Vpr, are also less efficient at 
blocking IFN induction. The commonality could be that Vpr-engagement with DNA-
damage machinery, the result of which is induction of G2 arrest, is necessary for all 
observed effects of Vpr I have reported in this work. Further work is underway to better 
understand the mechanisms of all of these processes, which should bring clarity to this 
question. 
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Figure 30. HIV-1 and SIVmac/SIVsm/HIV-2 Vpr induce a DNA damage response via 
the DCAFCRL4 complex in order to enhance infection.  
HIV-1, HIV-2, SIVsm, and SIVmac Vprs all function to induce a DNA damage response 
during infection. This culminates in the G2 cell cycle arrest that has been the well 
characterized effect of Vpr expression. HIV-1 does this in order to remodel chromatin in 
cells with high barriers in to infection, like resting cells or in the presence to a block to 
integration. HIV-2/SIVmac/SIVsm all encode Vpx, which increases infectivity in cell types 
that normally restrict HIV-1 infection, like MDDCs and resting CD4+ T cells. Because of 
this, the virus can readily integrate and becomes susceptible to detection during 
integration site repair. Vpr from these viruses, in addition to increasing expression of 
unintegrated DNA when there is a block to integration, blocks DDR-triggered innate 
immune signaling that would result in type I IFN production. Whether these functions are 
entirely separate, like depicted above, or more intricately linked through a common Vpr-
DCAFCRL4 target has yet to be clarified. 
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At this time, I propose a model by which HIV-1 Vpr and HIV-2/SIVsm/SIVmac 
Vprs have divergent functions (Fig. 30). HIV-1 Vpr regulates chromatin modification to 
enhance transcriptional output from both integrated and unintegrated DNA (Fig. 30). It 
appears that HIV-2/SIVsm/SIVmac Vpr may also perform this role, but due to the presence 
of Vpx, it is only observed when there is a block to integration (Fig. 30). HIV-
2/SIVsm/SIVmac Vprs also act to prevent sensing of integration in MDDCs (Fig. 30). HIV-
1 Vpr may also have this function as well, but at this time I have not been able to identify 
MDDC sensing of viral integration due to the low infectivity of HIV-1 on MDDCs. 
Together, this work strives to better understand the role of Vpr during infection. Future 
studies should focus on clarifying the mechanism of action for the observed effects of 
Vpr. It is my hope that with continued studies, we as a field can fully understand what 
interactions Vpr has with host cell machinery and why it is maintained throughout 
primate lentiviral evolution.  
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METHODS 
Common buffers and reagents 
Buffers  
Phosphate buffered saline (PBS): Tissue culture grade PBS was purchased from 
Invitrogen (catalog #14190-250). Non-tissue culture PBS was made as a 10x solution in 
water: 1.36 M sodium chloride, 0.026 M potassium chloride, 0.0176 M monopotassium 
phosphate, 0.1M sodium phosphate dibasic heptahydrate in nanopore water 
PEB: 2mM EDTA, 0.5% BSA in PBS (Invitrogen, catalog #14190-250) 
4% paraformaldehyde (PFA) in PBS: Boston bioproducts (catalog #BM-155) 
6x DNA loading dye: 0.5 mM EDTA, 30% glycerol, 0.125% bromophenol blue, 0.125% 
xylene cyanol FF 
Western blot running buffer (5x): 1.52% tris base, 7.2% glycine, 0.5% SDS in nanopure 
water; dilute 1:5 in nanopure water before use 
Western blot transfer buffer: 39 mM glycine, 48 mM tris base, 0.037% SDS, 20% 
methanol in nanopore water 
ELISA wash buffer: 0.2% tween-20 (Fisher, catalog #BP337-500) in PBS (Invitrogen, 
catalog #14190-250) 
6x SDS loading dye: 0.3% Bromophenol blue, 3.33% SDS, 1.67% β-mercaptoethanol 
Triton X lysis buffer: 50 mM Tris hydrochloride pH 8.0, 150 mM sodium chloride, 5 mM 
EDTA, 1% Triton X-100, 1 protease inhibitor tablet in 10 mL nanopure water 
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Media 
Unless otherwise indicated, all cells were cultured in either Roswell Park Memorial 
Institute (RPMI) medium (Invitrogen, catalog #11875-119) with10% heat inactivated 
fetal bovine serum (FBS) (Invitrogen, catalog #2022-01-30) and 1% 
penicillin/streptomycin (P/S) (Fisher, catalog #SV30010) (R10) or Dulbecco’s Modified 
Eagle Medium (DMEM) (Invitrogen, catalog #11965-118) with 10% FBS and 1% 
pen/strep (D10). Unless stated otherwise, adherent cells were lifted for passaging or 
seeding using trypsin-EDTA (0.25%) (Invitrogen, catalog # 25200056). 
Plasmids 
HIV-1 plasmids 
HIV-1 proviral plasmids Lai/YU2 env, Lai/Bal env, Lai-luc ∆env (Env deficient HIV-1 
containing a luciferase reporter gene in place of nef), Lai-GFP ∆env (Env deficient HIV-1 
containing GFP in place of nef) and the HA-Vpr expression plasmid have been 
previously described and were obtained from Dr. Michael Emerman at the Fred 
Hutchinson Cancer Research Institute (347, 465). Proviral Lai (CXCR4-tropic) clones 
containing Vpr mutations, F34I, W54R, and H71R and frame-shift mutation in Vpr 
(ΔVpr) have been described previously and were also obtained from the Dr. Michael 
Emerman (201, 235, 347, 466). These Vpr mutations were transferred to Lai-YU2 env, 
Lai-luc ∆env or Lai-GFP ∆env proviral plasmids using Apa I and Sal I restriction sites or 
the Nhe I and Sal I restriction sites. To create proviral clones encoding Vpr-Q65R 
mutation, the Apa I – Sal I fragment of Lai-YU2 env was subcloned into pSL1180 
cloning vector (Stratagene) and site directed mutagenesis was preformed using a kit 
  
151 
(QuikChange II, Aligent Technologies, catalog #2005235) and the following primers: 5’-
GCCATAATAAGAATTCTGCGACAACTGCTGTTTATCCATTTC-3’ and 5’-
GAAATGGATAAACAGCAGTTGTCGCAGAATTCTTATTATGGC-3’. The mutated 
fragment was ligated back into Lai-YU2 env, Lai-luc ∆env or Lai-GFP ∆env using Apa I-
Sal I restriction sites. The point mutation Vpr-R90K was derived by sub-cloning the Sal I 
– BamH I fragment of both Lai-luc ∆env into pSL1180 (Stratagene) and via site directed 
mutagenesis (QuikChange II, Aligent Technologies, catalog #2005235) using the 
following primers: 5’-
CGTTACTCAACAGAGGAGAGCAAAAAATGGAGCCAGTAGATCCTAGAC-3’ 
and 5’-GTCTAGGATCTACTGGCTCCATTTTTTGCTCTCCTCTGTTGAGTAACG-
3’. The mutated fragment was ligated back into Lai-luc ∆env and Lai-GFP ∆env using 
Sal I – BamH I restriction sites. Integrase-null (catalytic mutant, D116N) clones of Lai-
luc ∆env -WT and -ΔVpr were created by ligating the Nhe I – Sal I fragment of Lai-luc 
∆env into pSL1180 (Stratagene) and via site directed mutagenesis (QuikChange II, 
Aligent Technologies) with the following primers: 5’-
GCCAGTAAAAACAATACATACAAACAATGGCAGCAATTTCACCAG-3’ and 5’-
CTGGTGAAATTGCTGCCATTGTTTGTATGTATTGTTTTTACTGGC-3’. Clones 
were confirmed via sequencing (Genewiz) and sub-cloned back into Lai-luc ∆env and 
Lai-luc ∆env ΔVpr using Nhe I and Sal I restriction sites to create Integrase-deficient 
(Lai-luc ∆env/D116N and Lai-luc ∆env ΔVpr/D116N. 
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HIV-2 plasmids 
Single cycle HIV-2 proviral plasmids, Rod9-GFP Δenv and Rod9-GFP Δenv ΔVpx, were 
gifts of Dr. Masahiro Yamashita at the Aaron Diamond AIDS Research Center. 
Replication competent HIV-2 proviral plasmid, Rod9, was obtained from Dr. Geoffrey 
Gottlieb, University of Washington (467). The ΔVpr mutation was created by subcloning 
the Bcl I – Hind III fragment of Rod9 into pSL1180 (Stratagene) and conducting site 
directed mutagenesis (QuikChange II, Aligent Technologies, catalog #2005235) using the 
following primers: 5’-CAGGTCTGGTCTAAGGGCTTAAGCACCAACAGAGC-3’ and 
5’-GCTCTGTTGGTGCTTAAGCCCTTAGACCAGACCTG-3’. ΔVpr mutation was 
ligated back into Rod9 using Bcl I - Hind III restriction sites or into Rod9-GFP Δenv 
using Avr II – BsmB I restriction sites. 
 
SIVsm Plasmids 
Env-deficient GFP expressing SIV proviral plasmid (SIVsm-GFP Δenv) was a gift from 
Dr. Welkin Johnson, Boston College. The viral clone contains the gag-pol region, as well 
as vif, vpx, and the majority of vpr from the E543 isolate of SIVsm and has been 
previously described (101, 468). I ligated the Sph I – Bcl I fragment of SIVsm-GFP Δenv 
into pSL1180 (Stratagene) and introduced mutations using site directed mutagenesis 
(QuikChange II, Aligent Technologies, catalog #2005235) to abrogate Vpr or Vpx 
expression. Primers to mutate the start codon of Vpr to a stop codon were as follows:  5’-
CCTCCAGGACTAGCATAAATAGGCAGAAAGACCTCCAGAAG-3’ and 5’-
CTTCTGGAGGTCTTTCTGCCTATTTATGCTAGTCCTGGAGG-3’ and primers to 
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introduce a premature stop codon into Vpx were as follows: 5’-
CCTGGGAATACTGGCATGAATGAAATGGGAATGTC-3’ and 5’-
GACATTCCCATTTCATTCATGCCAGTATTCCCAGG-3’. Clones were confirmed via 
sequencing (Genewiz) and fragments containing mutated Vpr or Vpx sequences were 
ligated back into SIVsm-GFP Δenv using Sph I – Bcl I restriction sites to generate SIVsm-
GFP Δenv ΔVpr or SIVsm-GFP Δenv ΔVpx proviral plasmids. 
 
SIVmac plasmids 
Env-deficient, SIVmac-GFP Δenv was obtained from Dr. Welkin Johnson, Boston 
College, and has been previously described (101, 468). It is a proviral clone based on the 
SIVmac239 isolate. Replication competent proviral plasmids, SIVmac239 ΔVpr, SIVmac239 
ΔVpx, and SIVmac239 ΔVpr/Vpx were obtained from the NIH AIDS Research and 
Reference Reagent Program (contributed by Dr. Ronald C. Desrosiers). Restriction 
fragments containing the Vpr or Vpx inactivating mutations (ΔVpr, ΔVpx, or ΔVpr/Vpx) 
were transferred into SIVmac-GFP Δenv using the Kas I and Sph I restriction sites. In 
order to make mutations to SIVmac Vpr, Sph I and BstB I restriction sites were used to 
subclone the Vpr portion of SIVmac-GFP Δenv into pSL1180 (Stratagene). Site directed 
mutagenesis (QuikChange II, Aligent Technologies, catalog #2005235) was conducted 
using the following primers for VprHRG: 5’-
CGAGCGCTCTTCATGGCTTTCGCAGGCGCCTGCATCCACTCC-3’ and 5’-
GGAGTGGATGCAGGCGCCTGCGAAAGCCATGAAGAGCGCTCG-3’, for V21A: 
5’-GGATGAATGGGTAGCGGAGGTTCTGGAAG-3’ and 5’-
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CTTCCAGAACCTCCGCTACCCATTCATCC-3’ and for S81A: 5’-
GGATGCATCCACGCCAGAATCGGCC-3’ and 5’-
GGCCGATTCTGGCGTGGATGCATCC-3’. Mutations to ablate tat production were 
made in the same subclone using the following primers: 5’-
GACATGGAGACACCCTAGAGGGAGCAGGAGAAC-3’ and 5’-
GTTCTCCTGCTCCCTCTAGGGTGTCTCCATGTC-3’. The Sph I – BstB I fragment 
was ligated back into both SIVmac-GFP Δenv and SIVmac-GFP Δenv ΔVpr. To create 
integrase-null SIVmac-GFP Δenv -WT and -ΔVpr, the BamH I – Bcl I portion of SIVmac-
GFP Δenv was cloned into pSL1180 (Stratagene) and site directed mutagenesis 
(QuikChange II, Aligent Technologies, catalog #2005235) was conducted using the 
following primers: 5’-GGGACTTGGCAAATGAATTGTACCCATCTAGAGGG-3’ and 
5’-CCCTCTAGATGGGTACAATTCATTTGCCAAGTCCC-3’. The BamH I – Bcl I 
fragment containing the mutation in integrase was ligated back into both SIVmac-GFP 
Δenv -WT and -ΔVpr. All mutations were confirmed by sequencing (Genewiz). To create 
the wild type SIVmac Vpr and Vpr-mutant (VprHRG, -VprV21A, and -VprS81A) 
expression constructs, Vpr orf was PCR amplified using the following primers, 5’- 
AGGCAGAATTCGAAGAAAGACCTCCAG-3’ and 5’- 
AGCACTCGAGTTATAGCATGCTTCTAG-3’ were Phusion DNA Polymerase (Fisher, 
catalog #F530L). PCR-amplified fragments were spin column-purified using the 
QIAquick PCR purification kit (QIAGEN, catalog #28104), digested with EcoR I and 
Xho I restriction enzymes and ligated into pME18S-Flag eukaryotic expression plasmid 
in frame with a N-terminal Flag epitope.  
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SIV3+ Plasmids 
SIV3+ plasmid was generously provided by Dr. Andrea Cimarelli, Centre Internationale 
de Recherche en Infectiologie of Lyon (416). ΔVpr, ΔVpx, and ΔVpr/Vpx versions of 
SIV3+ were generated by ligating the Ale I – Pac I portions of SIVmac-GFP Δenv -ΔVpr, 
-ΔVpx, or -ΔVpr/Vpx into SIV3+. Corresponding Ale I – Pac I fragment of SIVmac-GFP 
Δenv (WT) was also ligated into SIV3+ to create an expression plasmid with identical 
Vpr and Vpx protein sequences. 
 
Cells and viruses 
Cells 
TZM-bl, HeLa and HEK 293T cells have been described previously (122, 327, 469). All 
were cultured in D10. TZM-Bl cells were obtained from NIH AIDS Reference Reagent 
Program (contributed by Dr. John Kappes). HeLa cells were obtained from the lab of 
Rachael Fearns (Boston University School of Medicine). HEK293T and THP-1 cells 
were obtained from ATTC and cultured in D10 and R10 media repectively. HEK293 
ISRE-luc cell line was obtained from Dr. Junzhi Wang (National Institute for the Control 
of Pharmaceutical and Biological Products, China) and Dr. Xuguang Li (University of 
Ottawa, Canada) and express luciferase under the control of an IFN-inducible promoter 
carrying the IFN-stimulated response element (369). Cells were cultured in D10 
containing 2 µg/mL puromycin (Fisher, catalog #A1113802). 
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Viral Preparations 
All replication competent viruses used in these studies were derived using calcium 
phosphate mediated transient transfection of HEK 293T cells, as described previously 
(330). HIV-1, HIV-2, SIVmac or SIVsm vectors were generated from HEK293T cells via 
co-transfection of the ∆env-viral clone with a CMV-driven VSV-G expression plasmid. 
HEK 293Ts were seeded the day before transfection at a density of 2.5-3.0x105/mL in 6-
well tissue culture plates (Fisher, catalog #08-772-1B) or 10 cm tissue culture dishes 
(Fisher, catalog #08-772E). Transfections were achieved by mixing plasmid DNA (3 µg 
total per well of a 6-well plate or 12 µg total per 10 cm tissue culture dish) with 0.25 M 
(anhydrous) calcium chloride solution. A 2x BBS solution (50 mM BES, 280 mM 
sodium chloride, 1.5 mM disodium phosphate in water, filtered through a 0.45 µM 
syringe filter (Fisher, catalog # 09-754-21) was added to the DNA-containing calcium 
chloride solution, which was then vortexed and incubated for a minimum of 15 minutes 
before addition to HEK293T cells. Cells were washed the following morning once with 
PBS to remove residual transfection reagent. Cell-free supernatant were harvested at 2 
days post transfection.  
 
Virus harvest and concentration 
Virus-containing cell supernatants were harvested 2 days post-transfection, filtered 
through a 0.45 µm filter (Fisher, catalog # 09-754-21) to clear cell debris, and stored at -
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80°C until further use. For some experiments, virus particles were concentrated by 
ultracentrifugation on a 20% sucrose cushion [24,000 rpm at 4˚C for 2 h with a SW28 
rotor (Beckman Coulter)] (470). The virus pellets were resuspended in PBS (Invitrogen, 
catalog #14190-250), aliquoted and stored at -80 °C until use.  
 
Virus Titration- p24gag ELISA 
The capsid content of HIV-1 was determined using an in-house p24Gag ELISA. 96-well, 
clear, flat-bottom, immunolon, nonsterile ELISA plates (Fisher, catalog #12-565-136) 
were coated with 100 µL HIV-Ig (50 mg/mL, NIH AIDS Research and Reference 
Reagent Program, catalog #3957) in PBS overnight at 37ºC. Standard and samples were 
diluted in assay diluent that consists of 10% normal calf serum (NCS) (Invitrogen, 
catalog #26170043), 0.5% Triton X-100 (Fisher, catalog #BP151-500) in PBS 
(Invitrogen, catalog #14190-250). Recombinant p24gag protein (Advanced BioScience 
Laboratories, Inc. Lot #B-53) standard was diluted serially (2-fold dilutions, 4 ng – 
0.0625 ng) in assay diluent. Samples or p24gag standards (100 µL volume) were added to 
HIV Ig-coated, 96-well plate for 2 hours at 37ºC. After incubation, the plate was washed 
5 times with ELISA wash buffer (250 µL). Primary anti-p24gag antibody (Clone 183-
H12-5C), grown and prepared in lab from an anti-p24 hybridoma cell line (NIH AIDS 
Research and Reference Reagent Program, catalog #1513) was diluted to the appropriate 
working concentration in assay diluent, and added to the ELISA plate for 1-3 hours at 
37ºC or overnight at 4ºC. After incubation, the plate was washed five times with 250 µL 
ELISA wash buffer. Secondary goat anti-mouse-HRP (1:70,000 dilution in assay diluent, 
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Sigma, catalog # A2554-1ML) was added to the ELISA plate for 1 hour at 37ºC. Plate 
was washed 5 times with 250 µL wash solution and 100 µL of 1:1 mixture of TMB 2-
Component Microwell Peroxidase Substrate (Seracare, catalog #KPL 50-76-00) was 
added for 30 minutes at room temperature. Reaction was stopped with 50 µL 4N sulfuric 
acid (Fisher, catalog # SA818-1) and analyzed for absorbance at 450 nm. 
 
TZM-bl Titration 
The infectious titer was determined via infecting TZM-bl cells, as described previously 
(331, 469). Briefly, 1x104 TZM-bl cells were seeded per well in a 96 well, flat bottom 
plate (Fisher) the afternoon before infection. Cells were infected in triplicate with a series 
of viral dilutions in 100 µL D10 containing polybrene (10 µg/mL final, Fisher, catalog 
#TR-1003-G) for 48 hours. Cells were fixed with a solution of 0.2% gluteraldehye 
(Fisher) and 1% formaldehyde (Calbiochem) in PBS for 5 minutes after which cells were 
washed once with PBS (Invitrogen, catalog #14190-250). Staining solution was freshly 
made and consisted of 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 2 
mM magnesium chloride, and 0.4 mg/mL X-gal (Fisher, catalog # FP2500040; stock at 
40 mg/ml in DMSO) in PBS. TZM-bl cells were stained for infection for a minimum of 1 
hour at 37 ºC. The number of blue cells per well, indicating tat-driven transcription of β-
galactosidase, were counted for an appropriate dilution (one containing 5-30 positive 
signals) and reported as infectious particles (IP) per ml.   
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Infection Readouts 
Viral replication in MDDCs and DC- T cell co-cultures was determined by measuring 
p24Gag content in cell culture supernatants at indicated days post infection by an ELISA 
(331). Infection of MDDCs using luciferase reporter virus was analyzed using Bright-Glo 
Luciferase System (Promega, catalog #E2620) (332). Cells were lysed in 50 µL Glo 
Lysis Buffer (Promega, catalog #E2661). Lysates were either stored at -20ºC or 25 µL 
was combined with 25 µL BrightGlo luciferase (Promega, catalog #E2620) and 
chemiluminescence production was measured.  
 
Isolation of primary human immune cells 
PBMC Isolation 
PBMCs were isolated from de-identified leukopacks obtained from NYBiologics. 
Briefly, leukocyte mixture was divided between 4 conical tubes and volume brought up 
to 30 mL with unsupplemented RPMI (Invitrogen, catalog #11875-119). 
Leukocyte/RPMI mixture was floated on top of 14 mL of Ficoll Paque Plus (Fisher, 
catalog #45-001-750) and centrifuged at 1400 RPM for 30 minutes. The leukocyte 
interface of Ficoll and media was harvested and washed four times with unsupplemented 
RPMI (Invitrogen, catalog #11875-119). Cells were either frozen (2x108/vial in freezing 
media) or used for monocyte/CD4+ T cell isolation. Freezing media consisted of 50% 
FBS (Invitrogen, catalog #2022-01-30), 40%  unsupplementedRPMI (Invitrogen, catalog 
#11875-119) and 10% tissue culture grade DMSO (Sigma, catalog #D2650). 
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Bead Isolation 
Monocytes or CD4+ T cells were positively isolated using antibody coated beads against 
CD4 (T cells) or CD14 (monocytes) (Miltenyi, catalog #130-045-101 and #130-050-201, 
respectively). PBMCs were washed once with PEB buffer and resuspended in 100 µL 
PEB buffer and 10 µL beads per 1x107 cells for 15 minutes at 4ºC. Magnetic isolation 
columns (Miltenyi, catalog number #130-042-401) were applied to the Miltenyi sorting 
magnet and rinsed with 3 mL PEB. Cells were washed once with 50 mL PEB. PBMCs 
were added to magnetic column(s) (2x108 PBMCs in 2.5 mL PEB per column) and 
allowed to pass through the column via gravitational flow. Flow through was collected 
for further isolation if necessary. Columns were washed 3 times with 3 mL PEB. 
Column(s) were then removed from the magnet and 5 mL PEB was plunged  through 
them to remove bound cells.  
 
Dendritic Cell Differentiation and CD4+ T cell activation 
Monocytes were cultured in 3.75 ng/mL IL-4 (Becton Dickinson, catalog # BD554605) 
and 10 ng/mL GM-CSF (Miltenyi, catalog #130-093-866) in R10 for 6 days for 
differentiation into MDDCs or in 20 ng/mL M-CSF (Peprotech, catalog #300-25B), 10% 
human AB serum, heat inactivated (Corning, MT35060CI), 1% P/S in RPMI (Invitrogen, 
catalog #11875-119) for 5 days for differentiation into macrophage differentiation.  CD4+ 
T cells were stimulated with phytohemagglutinin (PHA) (Invitrogen, catalog #10576015) 
for 2 days, washed and cultured in 50U/ml IL-2 (NIH AIDS Reference Reagent Program; 
contributed by Dr. Maurice Gately, Hoffman-Roche) containing R10 media. Purity has 
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been validated for this technique at over 90% using FACS analysis for MDDC or CD4+ T 
cell markers.  
 
HIV Inhibitors: 
In indicated experiments, cells were pretreated with the reverse transcription inhibitor 
zidovudine (AZT, 10 µM, NIH AIDS Research and Reference Reagent Program, catalog 
#3485), reverse transcription inhibitor efavirenz (1 µM in DMSO, NIH AIDS Research 
and Reference Reagent Program, catalog #4624), integrase inhibitor raltegravir (30 µM 
or 60 µM in DMSO, NIH AIDS Research and Reference Reagent Program, catalog 
#11680 or Selleckchem, catalog #50-615-1) or reverse transcription inhibitor tenofovir 
(10µM or 40µM, NIH AIDS Research and Reference Reagent Program, catalog #10198) 
for 30 minutes at 37°C prior to infection and maintained for the duration of the cultures. 
Cells were treated with the protease inhibitor indinavir (1 µM, NIH AIDS Research and 
Reference Reagent Program, catalog #8145) post-virus exposure.  
 
Signaling Pathway Inhibitors 
In indicated experiments, cells were pretreated with the TAK1 inhibitor (5Z)-7-
Oxozeaenol (1 µM, Calbiochem, catalog #499610), the NLRP3 inhibitor Glybenclamide 
(50 µM, InvivoGen, catalog #tlrl-gly), the IκBα inhibitor BAY11-7082 (1 µM, 
InvivoGen, catalog #11B14-MM), or the TBK1 inhibitor BX795 (0.1 µM, Sigma, catalog 
#SML0694). 
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Quantitative Western blotting  
Cell Processing 
To detect Gag, Env, and Vpr in cell and virus particle lysates, 2-5x106 cells were lysed in 
50-100 µL Triton X lysis buffer. Lysates were mixed with 6x loading dye and heated at 
100 ºC for 5 minutes to denature the proteins. Input was normalized to equivalent 
amounts of cell-associated Gag content or 100-150 ng p24Gag concentrated virus 
equivalents (as determined by quantitative ELISA).  Concentrated virus was lysed 
directly in 6x loading dye and heated at 100 ºC for 5 minutes to lyse and denature the 
proteins.  
 
SDS PAGE Gel 
SDS-PAGE gels were poured by hand and composed of 10% (Gag and Env detection) or 
12.5% (Gag and Vpr detection) acrylamide (acrylamide 40% solution, bis-acrylamide 
37.5:1, Fisher, catalog #BP1410-1). The separating gel consisted of 10% or 12.5% 
acrylamide (acrylamide 40% solution, bis-acrylamide 37.5:1, Fisher, catalog #BP1410-
1), 0.375 M Tris hydrochloride, pH 8.8, 0.012% ammonium persulfate (Fisher, catalog 
#A682-500), 0.1% TEMED (Fisher, catalog #17919) in water. Stacking gel consisted of 
4.5% acrylamide (acrylamide 40% solution, bis-acrylamide 37.5:1, Fisher, catalog 
#BP1410-1), 0.125 M Tris hydrochloride, pH 6.8, 0.012% ammonium persulfate (Fisher, 
catalog #A682-500), 0.1% TEMED (Fisher, catalog #17919) in water. Gels were run at 
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100 V until the loading dye approached the bottom of the gel (~2-4 hours). SDS-PAGE 
running buffer is described above.  
 
Transfer 
Resolved proteins were transferred to Whatman Nitrocellulose Membrane (0.45 µm 
paper, Fisher, catalog #45-004-002). using a semi-dry transfer apparatus run at 70 mA for 
a single gel or 150 mA to transfer two gels at once for 1 hour. Transfer buffer is 
described above.  
 
Antibodies and Detection 
Blots were blocked with a 1:1 mix of PBS/Li-Cor Odyssey Blocking Buffer (Fisher, 
catalog #NC9877369) in PBS (Invitrogen, catalog #14190-250) for 1-2 hours at room 
temperature or overnight at 4ºC. Blots were probed with rabbit anti-gp120 (a gift from 
Dr. Nancy Haigwood, Oregon National Primate Research Institute) and mouse anti-
p24Gag (clone p24-2, NIH AIDS Research and Reference Reagent Program, catalog 
#6457), followed by goat anti-mouse IgG DyLight 680 (Pierce, catalog #35518) and goat 
anti-rabbit IgG DyLight 800 (Pierce, catalog #SA5-10036). To determine Vpr 
incorporation, a polyclonal rabbit anti-Vpr antibody (clone 1-50, NIH AIDS Research 
and Reference Reagent Program, catalog #11836) was used followed by goat anti-rabbit 
IgG DyLight 700. To quantify SIVmac Gag, monoclonal rabbit anti-p17Gag was used 
(clone KK59, NIH AIDS Research and Reference Reagent Program, catalog #2320). To 
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detect Flag-SIVmac Vpr and Vpr mutants, monoclonal mouse anti-Flag was used (Sigma, 
catalog #F3165). Primary antibody was incubated 2 hours at room temperature or 
overnight at 4ºC and secondary antibody was incubated for 1-3 hours at room 
temperature. All antibodies were prepared in a 1:1 mixture of PBS/Li-Cor Odyssey 
Blocking Buffer in PBS (Fisher, catalog #NC9877369). Blots were washed 3 times for 5 
minutes with PBS-T (0.05% tween-20 in PBS). The membranes were scanned with an 
Odyssey scanner (Li-Cor). 
 
Quantitative RT-PCR  
For the quantitation of IFNβ and IP-10 mRNA, MDDCs (2-4x106 cells) were mock 
infected or infected with Lai-YU2 or Lai-YU2ΔVpr (MOI = 2). At 48 h post infection, 
cells were harvested for RNA isolation using RNAeasy (QIAGEN, catalog # 74104) 
RNA isolation kits and cDNA was synthesized using oligo dT primers and Superscript III 
RT (Invitrogen, catalog #18080-051). cDNA corresponding to 200 ng of RNA was 
analyzed by qRT-PCR using SYBR green (Fisher, catalog # FERK0241) to quantify 
mRNA levels for IFNβ (forward primer: 5’-ATTCTAACTGCAACCTTTCG-3’ and 
reverse primer: 5’-GTTGTAGCTCATGGAAAGAG-3’), IP-10 (forward primer: 5’-
TCATTGGTCACCTTTTAGTG-3’ and reverse primer: 5’-
AAAGCAGTTAGCAAGGAAAG-3’) and GAPDH (forward primer: 5’-
AGGGATGATGTTCTGGAGAG-3’ and reverse primer: 5’-
CAAGATCATCAGCAATGCCT-3’). The ΔΔCT value relative to GAPDH in the mock-
infected cultures was set to 1, and the data from the infected cultures reported as fold 
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enhancements.  To determine the extent of de novo viral transcription, the number of tat-
rev-nef multiply spliced transcripts was determined by qRT-PCR using SYBR green 
(Fisher, catalog # FERK0241) as described previously (363), with the following primer 
set: forward primer, 5’-GCGACGAAGACCTCCTCAG-3’ and reverse primer, 5’-
GAGGTGGGTTGCTTTGATAGAGA-3’. The data were normalized to GAPDH levels. 
As a control, MDDCs were treated with AZT (10µM, NIH AIDS Research and Reference 
Reagent Program) for 30 min prior to infection and drug levels were maintained during 
the course of infection.   
 
Quantification of viral RT-products and 2-LTR circles 
In order to quantify viral RT-products or 2-LTR circles, MDDCs were spinoculated at 
indicated MOI at 2300 RPM for 1 h and then incubated 2 h at 37ºC. Cells were washed 
twice with PBS (Invitrogen, catalog #14190-250) and cultured for indicated amount of 
time before lysis and DNA extraction using the DNeasy kit (QIAGEN, catalog #51304). 
For HIV-1: MDDCs were infected with either Lai-YU2 or Lai-YU2 ΔVpr. For RT-
products, the following primers: 5’-TGTGTGCCCGTCTGTTGTGT-3’ and 5’-
GAGTCCTGCGTCGAGAGAGC-3’ and probe: 5′-(FAM)-
CAGTGGCGCCCGAACAGGGA-(TAMRA)-3′ was used. For 2-LTR circles, the 
following primers: 5’-AACTAGGGAACCCACTGCTTAAG-3’ and 5’-
TCCACAGATCAAGGATATCTTGTC-3’ and probe: 5′-(FAM)-
ACACTACTTGAAGCACTCAAGGCAAGCTTT-(TAMRA)-3′ were used. 
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For SIVmac: MDDCs were infected at MOI = 3 with SIVmac-GFP Δenv/GFP -WT, -ΔVpr, 
-ΔVpx, or -ΔVpr/Vpr. To quantify RT-products, the following primers: 5’-
TTGGGAAACCGAAGCAGG-3’ and 5’-TCTCTCACTCTCCTTCAAGTCCCT-3’ and 
probe: 5'-(FAM)-AAATCCCTAGCAGATTGGCGCCTGAA-(TAMRA)-3' was used. 
Maxima Probe 2X qPCR master mix (Fisher, catalog #K0261) was used with 
primer/probes to quantify DNA products. Cycle conditions were as follows: 95ºC, 10 min 
initial denaturation, followed by 40 cycles as follows: denature at 95ºC, 15 sec; anneal at 
60ºC, 30 sec; extension at 72ºC, 30 sec. 
 
Quantification of viral integration  
To determine the number of proviral integrants, MDDCs (3x106 cells) were infected with 
virus (MOI = 3) for 2 h at 37˚C, washed with PBS (Invitrogen, catalog #14190-250) 
twice and cultured for 72 h before cells were lysed for DNA extraction with a DNeasy kit 
(QIAGEN, catalog #51304). As a background control, MDDCs were treated with 10 µM 
AZT (NIH AIDS Research and Reference Reagent Program) for at least 30 min prior to 
infection. Quantitative Alu-PCR was performed using 20 ng of DNA with the following 
primer sets, as described previously (371). For the first step, the following primers were 
used: Alu-forward 5′-GCCTCCCAAACTGCTGGGATTACAG-3′ and Gag-reverse 5’-
GCTCTCGCACCCATCTCTCTCC-3’. For the second step, the following primers were 
used: R-U5-F: 5′-GCCTCAATAAAGCTTGCCTTGA-3′ and R-U5-R: 5′-
TCCACACTGACTAAAAGGGTCTGA-3′ with the following probe: R-U5-Probe: 5′-
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FAM-CCAGAGTCACACAACAGACG-TAMRA-3′. The data were normalized to a 
standard curve generated from infected HEK293 cell DNA (370, 371).  
 
Splicing Assay   
The assay for spliced viral RNAs has been described in detail and was preformed in 
conjunction with Ann Emery in the Swanstrom Lab at University of North Carolina, 
Chapel Hill (374). Briefly, cDNA primers with an internal random sequence block 
(Primer ID; (373)) were designed to be within the env intron, to measure the 4 kb size 
class of spliced viral RNAs, or spanning the D4/A7 splice junction to measure the 1.8 kb 
size class. The reverse primer for the 4-kb size class was: 5’-
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNGTAC
GCTAATACTTGTAAAGATTGCAGTACATGTACTACTT-3’ and the reverse primer 
for the 1.8 kb size class was: 5’- 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNCAGT
CTGAGCTGGGAGGTGGGTTGC-3’. Whole cell RNA from infected cells was purified 
and used in a cDNA reaction. After removal of the cDNA primers, PCR was carried out 
using a downstream primer encoded in the cDNA primer tail and a forward primer placed 
just upstream of the D1 major donor site in the 5' noncoding region, 5’-
GCCTCCCTCGCGCCATCAGAGATGTGTATAAGAGACAGNNNNTGCTGAAGCG
CGCACGGCAAG-3’. PCR products were sequenced using the MiSeq platform, and 
sequence reads with the same Primer ID were collapsed into a single read (to correct for 
skewing during PCR since each unique Primer ID tag represents a separate viral mRNA 
  
168 
template). Data were processed using customized scripts that are available on request. 
The number of unique Primer IDs for each spliced product was used to determine the 
relative level of splicing from each splice donor to each splice acceptor in the viral 
genome with the exception of splicing events to the nef splice acceptor A7. 
 
IP-10 measurements  
Secreted IP-10 in MDDC culture supernatants was measured using a commercially 
available ELISA kit (Becton Dickinson, catalog # 550926), according to directions 
provided. Briefly, 96-well, clear, flat-bottom, immunolon, nonsterile plates (Fisher, 
catalog #12-565-136) were coated overnight at 4ºC with 100 µL of Capture Antibody in 
0.1 Sodium Carbonate, pH 9.5. Wash buffer (0.05% Tween-20 in PBS) was prepared 
fresh each use. Plate(s) were washed 3 times with 250 µL wash buffer before application 
of samples/standards. Standards ranged from 500-7.81 pg/mL and were made fresh from 
frozen stocks for each application in assay diluent. Assay diluent, composed of 10% 
normal calf serum (NCS) (Invitrogen, catalog #26170043), 0.25% Triton X-100 (Fisher, 
catalog #BP151-500) in PBS (Invitrogen, catalog #14190-250), for the dilution of 
samples and standards was made in bulk and stored at 4°C for up to 6 months. Plates 
were incubated at room temperature with 100 µL of samples and standard for 2 hours and 
then washed five times with 250 µL wash buffer. Detection antibody was mixed with 
secondary anti-detection-HRP in 10% FBS/PBS and added in 100 µL for 1 hour at room 
temperature. Plate was washed 7 times with 250 µL wash solution and 100 µL 1:1 
mixture of TMB 2-Component Microwell Peroxidase Substrate (Seracare, catalog #KPL 
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50-76-00) was added for 30 minutes at room temperature. Reaction was stopped with 50 
µL 4N sulfuric acid (Fisher, catalog # SA818-1) and analyzed for absorbance at 450 nm. 
 
IFN Bioassay 
Secreted levels of bioactive type I IFN in infected MDDC supernatants was measured 
using a HEK293 ISRE-luc cell line which expresses luciferase under the control of an 
IFN-inducible promoter carrying the IFN-stimulated response element (369). Briefly, 
HEK293 ISRE-luc cells (8x104) were incubated with 20 µL or 50 µL MDDC culture 
supernatants for 21 hours. Cells were lysed in 50 µL BrightGlo lysis buffer (Promega, 
catalog #E2661). Luciferase activity in the cell lysates analyzed with Bright-Glo 
Luciferase System (Promega, catalog #E2620), as described above by combining 25 µL 
and 25 µL BrightGlo luciferse. Serial dilutions of recombinant interferon alpha ranging 
from 200-0.39 units/ml (PBL Interferon Source, catalog #11100-1) were added to cells in 
50 µL in each experiment for generating a standard curve.  
 
FACS 
Cells were analyzed using either LSRII or FACSCalibur (Becton Dickinson) instruments 
with the help of Boston University Flow Cytometry Core who provided instrumentation 
and technical support. 
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Extracellular FACS staining 
Cells were pre-chilled at 4ºC for 30 minutes prior to staining. Antibody solution was 
added at indicated dilution in 2% NCS (Invitrogen, catalog #26170043) in PBS (catalog 
#14190-250) for 30 minutes at 4ºC. Cells were washed once with 2% NCS/PBS and fixed 
in 4% PFA (Boston bioproducts, catalog #BM-155) for at least 30 minutes at 4ºC. 
 
Intracellular FACS staining 
Intracellular FACS staining was performed for cell-internal proteins post-fixation. 
Briefly, cells were permeabilized using Perm/Wash Buffer (1x in water, Becton 
Dickinson, catalog #554723) for at least 15 minutes at room temperature. Cells were 
stained at indicated dilution of antibody in Perm/Wash buffer for 30 minutes at 4ºC. Cells 
were washed once with Perm/Wash and resuspended in 2% NCS/PBS. 
 
Antibodies 
Intracellular fluorescence-activated cell sorter (FACS) analysis for p24Gag was done using 
FITC-conjugated anti-p24Gag monoclonal antibody (KC57; Beckman Coulter, catalog # 
6604665) at a 1:25 dilution in 25 µL. Surface staining for CD11c was done using APC-
conjugated anti-CD11c (Clone B-ly6, Becton Dickinson, catalog # 559877) using 3 
µL/sample in 50 µL staining buffer. Surface staining for DC-SIGN (CD209) was 
conducted using FITC-conjugated anti-CD209 (Clone DCN46, Becton Dickinson, 
catalog # BD551264) using 3 µL/sample in 50 µL staining buffer. 
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